ID
DB00186|APRD00116||
名称
Lorazepam
描述
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic.[A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095]
cas号
846-49-1
唯一标识码
O26FZP769L
状态
solid
一般参考文献
Kemper N, Poser W, Poser S: [Benzodiazepine dependence: addiction potential of the benzodiazepines is greater than previously assumed (author's transl)]. Dtsch Med Wochenschr. 1980 Dec 5;105(49):1707-12.
Lader M: Short-term versus long-term benzodiazepine therapy. Curr Med Res Opin. 1984;8 Suppl 4:120-6.
Maltais F, Laberge F, Laviolette M: A randomized, double-blind, placebo-controlled study of lorazepam as premedication for bronchoscopy. Chest. 1996 May;109(5):1195-8.
Heisterkamp DV, Cohen PJ: The effect of intravenous premedication with lorazepam (ativan), pentobarbitone or diazepam on recall. Br J Anaesth. 1975 Jan;47(1):79-81.
Milligan DW, Howard MR, Judd A: Premedication with lorazepam before bone marrow biopsy. J Clin Pathol. 1987 Jun;40(6):696-8.
Authors unspecified: Systematic review of the benzodiazepines. Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Committee on the Review of Medicines. Br Med J. 1980 Mar 29;280(6218):910-2.
Li C, Liu T, Cui X, Uss AS, Cheng KC: Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans. J Biomol Screen. 2007 Dec;12(8):1084-91. doi: 10.1177/1087057107308892. Epub 2007 Nov 7.
Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31.
McLean MJ, Macdonald RL: Benzodiazepines, but not beta carbolines, limit high frequency repetitive firing of action potentials of spinal cord neurons in cell culture. J Pharmacol Exp Ther. 1988 Feb;244(2):789-95.
Kamal MA, Smith DE, Cook J, Feltner D, Moton A, Ouellet D: Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measure. J Pharm Sci. 2010 Aug;99(8):3628-41. doi: 10.1002/jps.22093.
Ghiasi N. and Marwaha R. (2018). Lorazepam.. Treasure Island, FL.
Pagliaro L. and Pagliaro A. (1999). Psychologists' psychotropic drug reference. Taylor and Francis.
Volpe J. (2008). Neurology of the Newborn (5th ed.). Saunders Elsevier.
T385Ghiasi N. and Marwaha R. (2018). Lorazepam.. Treasure Island, FL.T388Pagliaro L. and Pagliaro A. (1999). Psychologists' psychotropic drug reference. Taylor and Francis.T391Volpe J. (2008). Neurology of the Newborn (5th ed.). Saunders Elsevier.
FDA approvals
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=070472
Lorazepam monograph
https://pdf.hres.ca/dpd_pm/00026294.PDF

approved,
指示
Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.[T385] Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.[T385]
药效学
The effect of lorazepam in GABA-A receptors produces an increase in the frequency of opening of the chloride ion channel. However, for its effect to generate, the neurotransmitter is required.[A5415] The anticonvulsant properties of lorazepam are thought to be related to the binding to voltage-dependent sodium channels in which the sustained repetitive firing gets limited by the slow recovery of sodium channels due to the benzodiazepine effect.[A1240] The effect of lorazepam seems to be very compartmental which was observed with a different generation of sleepiness and a dizziness effect.[A173920]
作用机制
Lorazepam allosterically binds on the benzodiazepine receptors in the post-synaptic GABA-A ligand-gated chloride channel in different sites of the central nervous system (CNS). This binding will result in an increase on the GABA inhibitory effects which is translated as an increase in the flow of chloride ions into the cell causing hyperpolarization and stabilization of the cellular plasma membrane.[T385] According to the binding site of lorazepam, we can observe different activities as the binding in the amygdala is known to help mainly in anxiety disorders while the binding in the cerebral cortex helps in seizure disorders.[T385]
毒性
The LD50 observed by oral administration in a mouse is of 1850 mg/kg.[L6403] When an overdose administration is registered, signs of CNS and respiratory depression are rapidly observed. An overdose stage can result in profound sedation, deep respiratory depression, coma, and death.[T385] When overdose is observed, it is recommended to administer emergency symptomatic medical support with attention to produce an increase in lorazepam elimination.[T388] There is no evidence of carcinogenicity nor mutagenicity. At doses higher than 40 mg/kg there is evidence of fetal resorption and increase in fetal loss.[FDA label]
代谢
Lorazepam is hepatically metabolized by CYP450 isoenzymes and extensively conjugated to the 3-0-phenolic glucuronide.[T385] This is an inactive metabolite and is eliminated mainly by the kidneys.
吸收
Readily absorbed with an absolute bioavailability of 90% when given orally. When intramuscularly administered a dose of 4 mg, lorazepam is completely and rapidly absorbed and achieves a maximal serum concentration of 48 ng/ml in 15-30 minutes. When administered orally, the time to attained maximum concentration is observed to be of 2 hours.[T385]
半衰期
When administered parentally, the registered half-life of lorazepam is of 14 hours.[T385]
分类
description:This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
direct-parent:1,4-benzodiazepines
kingdom:Organic compounds
superclass:Organoheterocyclic compounds
class:Benzodiazepines
subclass:1,4-benzodiazepines
alternative-parent:Alkanolamines
alternative-parent:Alpha amino acids and derivatives
alternative-parent:Aryl chlorides
alternative-parent:Azacyclic compounds
alternative-parent:Carbonyl compounds
alternative-parent:Chlorobenzenes
alternative-parent:Hydrocarbon derivatives
alternative-parent:Ketimines
alternative-parent:Lactams
alternative-parent:Organic oxides
alternative-parent:Organochlorides
alternative-parent:Organopnictogen compounds
alternative-parent:Propargyl-type 1,3-dipolar organic compounds
alternative-parent:Secondary carboxylic acid amides
substituent:1,4-benzodiazepine
substituent:Alkanolamine
substituent:Alpha-amino acid or derivatives
substituent:Aromatic heteropolycyclic compound
substituent:Aryl chloride
substituent:Aryl halide
substituent:Azacycle
substituent:Benzenoid
substituent:Carbonyl group
substituent:Carboxamide group
substituent:Carboxylic acid derivative
substituent:Chlorobenzene
substituent:Halobenzene
substituent:Hydrocarbon derivative
substituent:Imine
substituent:Ketimine
substituent:Lactam
substituent:Monocyclic benzene moiety
substituent:Organic 1,3-dipolar compound
substituent:Organic nitrogen compound
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organochloride
substituent:Organohalogen compound
substituent:Organonitrogen compound
substituent:Organooxygen compound
substituent:Organopnictogen compound
substituent:Propargyl-type 1,3-dipolar organic compound
substituent:Secondary carboxylic acid amide
消除途径
When a single 2 mg oral dose is given to healthy subjects, 88% of the administered dose is recovered in urine and 7% was recovered in feces. From the excreted dose in urine, the major form is the glucuronide version that represents 74% while only 0.3% of the dose is recovered as unchanged lorazepam.[T388]
种类
Anti-Anxiety Agents
D014151
Anticonvulsants
D000927
Antiemetics
D000932
Autonomic Agents
D001337
Benzazepines
D001552
Benzodiazepine hypnotics and sedatives

Benzodiazepines and benzodiazepine derivatives
D001569
Benzodiazepinones
D001570
Central Nervous System Agents
D002491
Central Nervous System Depressants
D002492
Cytochrome P-450 CYP3A Substrates

Cytochrome P-450 CYP3A4 Substrates

Cytochrome P-450 CYP3A4 Substrates (strength unknown)

Cytochrome P-450 Substrates

Drugs that are Mainly Renally Excreted

GABA Agents
D018682
GABA Modulators
D018757
Gastrointestinal Agents
D005765
Heterocyclic Compounds, Fused-Ring
D000072471
Hypnotics and Sedatives
D006993
Muscle Relaxants

Muscle Relaxants, Centrally Acting Agents
D009125
Nervous System
D009420
Neurotransmitter Agents
D018377
Peripheral Nervous System Agents
D018373
Psycholeptics

Psychotropic Drugs
D011619
Tranquilizing Agents
D014149
盐类
蛋白质结合
Reports indicate that 85% of lorazepam administered dose is protein bound.[T388]
清除
_In vivo_ studies with lorazepam have shown a clearance rate of 5.8 ml.min/kg.[A173914]
同义词
language:spanish; code:; name;Loracepam
language:english; code:inn/usan; name;Lorazepam
language:english; code:; name;o-Chlorooxazepam
language:english; code:; name;o-Chloroxazepam
国际品牌
AlmazinePsyco RemediesAnxiedinU-LiangIdalpremNovartisLorabenzLorsilanBelupoSomagerolTemestaWyethWypaxWyeth KK
配送量
The reported volume of distribution of lorazepam is 1.3 L/kg.[T388] It is important to mention that due to the lipophilicity of lorazepam, it does not redistribute as fast in the brain.[T391]
产品
name:Apo-lorazepam Tab 0.5mg
labeller:Apotex Corporation
ndc-id:
ndc-product-code:
dpd-id:00655740
ema-product-code:
ema-ma-number:
started-marketing-on:1985-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Apo-lorazepam Tab 1mg
labeller:Apotex Corporation
ndc-id:
ndc-product-code:
dpd-id:00655759
ema-product-code:
ema-ma-number:
started-marketing-on:1985-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Apo-lorazepam Tab 2mg
labeller:Apotex Corporation
ndc-id:
ndc-product-code:
dpd-id:00655767
ema-product-code:
ema-ma-number:
started-marketing-on:1985-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ativan
labeller:Stat Rx USA
ndc-id:
ndc-product-code:16590-813
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-16
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:NDA017794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:Stat Rx USA
ndc-id:
ndc-product-code:16590-937
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-16
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:NDA017794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-2407
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-10-19
ended-marketing-on:2001-06-30
dosage-form:Injection, solution
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-2144
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-16
ended-marketing-on:2012-06-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:NDA017794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-1339
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-16
ended-marketing-on:2012-06-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:NDA017794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:A S Medication Solutions
ndc-id:
ndc-product-code:54569-0927
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-16
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:NDA017794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:BTA Pharmaceuticals Inc.
ndc-id:
ndc-product-code:64455-063
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-16
ended-marketing-on:2015-01-31
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:NDA017794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:BTA Pharmaceuticals Inc.
ndc-id:
ndc-product-code:64455-064
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-16
ended-marketing-on:2015-01-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:NDA017794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:BTA Pharmaceuticals Inc.
ndc-id:
ndc-product-code:64455-065
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-16
ended-marketing-on:2015-01-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:NDA017794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:Baxter Laboratories
ndc-id:
ndc-product-code:60977-112
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-09-24
ended-marketing-on:2014-02-28
dosage-form:Injection, solution
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:Baxter Laboratories
ndc-id:
ndc-product-code:60977-116
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-09-24
ended-marketing-on:2013-06-30
dosage-form:Injection, solution
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:Baxter Laboratories
ndc-id:
ndc-product-code:60977-113
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-09-24
ended-marketing-on:2014-01-31
dosage-form:Injection, solution
strength:4 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-4209
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-16
ended-marketing-on:2011-10-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:NDA017794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-0192
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-05-01
ended-marketing-on:2017-09-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:NDA017794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:West-Ward Pharmaceuticals Corp.
ndc-id:
ndc-product-code:0641-6001
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1980-07-25
ended-marketing-on:
dosage-form:Injection
strength:2.0 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:West-Ward Pharmaceuticals Corp.
ndc-id:
ndc-product-code:0641-6000
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1980-07-25
ended-marketing-on:
dosage-form:Injection
strength:2.0 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:West-Ward Pharmaceuticals Corp.
ndc-id:
ndc-product-code:0641-6003
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1980-07-25
ended-marketing-on:
dosage-form:Injection
strength:4.0 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:West-Ward Pharmaceuticals Corp.
ndc-id:
ndc-product-code:0641-6002
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1980-07-25
ended-marketing-on:
dosage-form:Injection
strength:4.0 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:Bausch Health US LLC
ndc-id:
ndc-product-code:0187-0063
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-05-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:NDA017794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:Bausch Health US LLC
ndc-id:
ndc-product-code:0187-0064
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-05-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:NDA017794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:Bausch Health US LLC
ndc-id:
ndc-product-code:0187-0065
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-05-01
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:NDA017794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:McKesson Corporation dba RX Pak
ndc-id:
ndc-product-code:65084-463
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-05-01
ended-marketing-on:2019-09-01
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:NDA017794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ativan
labeller:Pfizer Canada Ulc
ndc-id:
ndc-product-code:
dpd-id:02041464
ema-product-code:
ema-ma-number:
started-marketing-on:1994-12-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg
route:Sublingual
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ativan
labeller:Pfizer Canada Ulc
ndc-id:
ndc-product-code:
dpd-id:02041472
ema-product-code:
ema-ma-number:
started-marketing-on:1994-12-31
ended-marketing-on:
dosage-form:Tablet
strength:2 mg
route:Sublingual
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ativan
labeller:Pfizer Canada Ulc
ndc-id:
ndc-product-code:
dpd-id:02041448
ema-product-code:
ema-ma-number:
started-marketing-on:1994-12-31
ended-marketing-on:
dosage-form:Tablet
strength:2 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ativan
labeller:Pfizer Canada Ulc
ndc-id:
ndc-product-code:
dpd-id:02041421
ema-product-code:
ema-ma-number:
started-marketing-on:1994-12-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ativan
labeller:Pfizer Canada Ulc
ndc-id:
ndc-product-code:
dpd-id:02041413
ema-product-code:
ema-ma-number:
started-marketing-on:1994-12-31
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ativan
labeller:Pfizer Canada Ulc
ndc-id:
ndc-product-code:
dpd-id:02041456
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-31
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg
route:Sublingual
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ativan Inj 4mg/ml
labeller:Wyeth Ltd.
ndc-id:
ndc-product-code:
dpd-id:00557773
ema-product-code:
ema-ma-number:
started-marketing-on:1982-12-31
ended-marketing-on:1996-09-10
dosage-form:Liquid
strength:
route:Intramuscular; Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ativan Injection Liq 4mg/ml
labeller:Wyeth Ltd.
ndc-id:
ndc-product-code:
dpd-id:02041405
ema-product-code:
ema-ma-number:
started-marketing-on:1994-12-31
ended-marketing-on:2005-01-19
dosage-form:Solution
strength:
route:Intramuscular; Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ativan Subl Tab 0.5mg
labeller:Wyeth Ltd.
ndc-id:
ndc-product-code:
dpd-id:00722138
ema-product-code:
ema-ma-number:
started-marketing-on:1987-12-31
ended-marketing-on:1996-09-10
dosage-form:Tablet
strength:
route:Sublingual
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ativan Subl Tab 1mg
labeller:Wyeth Ltd.
ndc-id:
ndc-product-code:
dpd-id:00557757
ema-product-code:
ema-ma-number:
started-marketing-on:1982-12-31
ended-marketing-on:1996-09-10
dosage-form:Tablet
strength:
route:Sublingual
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ativan Tab 0.5mg
labeller:Wyeth Ltd.
ndc-id:
ndc-product-code:
dpd-id:00399124
ema-product-code:
ema-ma-number:
started-marketing-on:1983-12-31
ended-marketing-on:1996-09-10
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ativan Tab 1mg
labeller:Wyeth Ltd.
ndc-id:
ndc-product-code:
dpd-id:00348325
ema-product-code:
ema-ma-number:
started-marketing-on:1977-12-31
ended-marketing-on:1996-09-10
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ativan Tab 2mg
labeller:Wyeth Ltd.
ndc-id:
ndc-product-code:
dpd-id:00348333
ema-product-code:
ema-ma-number:
started-marketing-on:1977-12-31
ended-marketing-on:1996-09-10
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Dom-lorazepam
labeller:Dominion Pharmacal
ndc-id:
ndc-product-code:
dpd-id:02245784
ema-product-code:
ema-ma-number:
started-marketing-on:2002-04-25
ended-marketing-on:2019-02-20
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Dom-lorazepam
labeller:Dominion Pharmacal
ndc-id:
ndc-product-code:
dpd-id:02245785
ema-product-code:
ema-ma-number:
started-marketing-on:2002-04-25
ended-marketing-on:2019-02-20
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Dom-lorazepam
labeller:Dominion Pharmacal
ndc-id:
ndc-product-code:
dpd-id:02245786
ema-product-code:
ema-ma-number:
started-marketing-on:2002-04-25
ended-marketing-on:2019-02-20
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lorazepam
labeller:Watson Pharmaceuticals
ndc-id:
ndc-product-code:0591-3365
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-06-14
ended-marketing-on:
dosage-form:Injection
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Stat Rx USA
ndc-id:
ndc-product-code:16590-584
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Stat Rx USA
ndc-id:
ndc-product-code:16590-143
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-6010
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-03-31
ended-marketing-on:
dosage-form:Solution, concentrate
strength:2 mg/1mL
route:Oral
fda-application-number:ANDA073079
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-3566
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-10
ended-marketing-on:
dosage-form:Injection, solution
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA074300
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Caremark L.L.C.
ndc-id:
ndc-product-code:0339-4153
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-10-18
ended-marketing-on:2011-09-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Caremark L.L.C.
ndc-id:
ndc-product-code:0339-4152
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-09-27
ended-marketing-on:2011-06-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Caremark L.L.C.
ndc-id:
ndc-product-code:0339-4154
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-10-18
ended-marketing-on:2010-12-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Goldline Laboratories, Inc.
ndc-id:
ndc-product-code:0182-8237
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-01-21
ended-marketing-on:2010-11-01
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071193
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Goldline Laboratories, Inc.
ndc-id:
ndc-product-code:0182-8238
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-01-21
ended-marketing-on:2010-11-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071193
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Goldline Laboratories, Inc.
ndc-id:
ndc-product-code:0182-8239
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-01-21
ended-marketing-on:2010-11-30
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071193
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-2145
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-06-29
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-1338
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1993-07-23
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-0061
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1995-12-20
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072928
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Rebel Distributors
ndc-id:
ndc-product-code:21695-238
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1988-04-15
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071193
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Rebel Distributors
ndc-id:
ndc-product-code:21695-239
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1988-04-15
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071194
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Rebel Distributors
ndc-id:
ndc-product-code:21695-240
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1988-04-15
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071195
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Red Pharm Drug, Inc.
ndc-id:
ndc-product-code:67296-0306
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Red Pharm
ndc-id:
ndc-product-code:67296-0726
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-05-18
ended-marketing-on:
dosage-form:Tablet
strength:.5 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Contract Pharmacy Services Pa
ndc-id:
ndc-product-code:67046-980
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-03-29
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Contract Pharmacy Services Pa
ndc-id:
ndc-product-code:67046-981
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-03-29
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Contract Pharmacy Services Pa
ndc-id:
ndc-product-code:67046-982
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-03-29
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Red Pharm Drug, Inc.
ndc-id:
ndc-product-code:67296-0042
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1988-04-15
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071194
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Life Line Home Care Services
ndc-id:
ndc-product-code:75921-241
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Stat Rx USA
ndc-id:
ndc-product-code:42549-655
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Stat Rx USA
ndc-id:
ndc-product-code:42549-558
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072928
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Amneal Pharmaceuticals
ndc-id:
ndc-product-code:65162-015
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-06-23
ended-marketing-on:2012-11-26
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078826
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Amneal Pharmaceuticals
ndc-id:
ndc-product-code:65162-018
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-06-23
ended-marketing-on:2012-11-26
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078826
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Amneal Pharmaceuticals
ndc-id:
ndc-product-code:65162-017
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-06-23
ended-marketing-on:2012-11-26
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078826
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mutual Pharmaceutical
ndc-id:
ndc-product-code:53489-357
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-03-29
ended-marketing-on:2010-04-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072555
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mutual Pharmaceutical
ndc-id:
ndc-product-code:53489-358
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-03-29
ended-marketing-on:2010-04-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072555
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mutual Pharmaceutical
ndc-id:
ndc-product-code:53489-359
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-03-29
ended-marketing-on:2010-04-30
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072555
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Preferreed Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-9174
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:2013-07-19
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Ranbaxy Inc.
ndc-id:
ndc-product-code:63304-772
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-12-11
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Ranbaxy Inc.
ndc-id:
ndc-product-code:63304-773
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-12-11
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Ranbaxy Inc.
ndc-id:
ndc-product-code:63304-774
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-12-11
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Dispensing Solutions, Inc.
ndc-id:
ndc-product-code:66336-363
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A S Medication Solutions
ndc-id:
ndc-product-code:54569-2687
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A S Medication Solutions
ndc-id:
ndc-product-code:54569-1585
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A S Medication Solutions
ndc-id:
ndc-product-code:54569-2173
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072928
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A S Medication Solutions
ndc-id:
ndc-product-code:54569-5401
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Dispensing Solutions, Inc.
ndc-id:
ndc-product-code:66336-047
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Dispensing Solutions, Inc.
ndc-id:
ndc-product-code:66336-800
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-08
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Rebel Distributors
ndc-id:
ndc-product-code:42254-254
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Rebel Distributors
ndc-id:
ndc-product-code:42254-113
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-10-09
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Rebel Distributors
ndc-id:
ndc-product-code:42254-096
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-10-09
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Rebel Distributors
ndc-id:
ndc-product-code:42254-111
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-10-09
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Sandoz
ndc-id:
ndc-product-code:0781-1403
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1988-04-15
ended-marketing-on:2011-12-31
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071193
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Sandoz
ndc-id:
ndc-product-code:0781-1404
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1988-04-15
ended-marketing-on:2011-12-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071194
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Sandoz
ndc-id:
ndc-product-code:0781-1405
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1988-04-15
ended-marketing-on:2011-12-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071195
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:TYA Pharmaceuticals
ndc-id:
ndc-product-code:64725-6044
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1980-07-25
ended-marketing-on:
dosage-form:Injection
strength:2.0 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:TYA Pharmaceuticals
ndc-id:
ndc-product-code:64725-0242
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072928
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Excellium Pharmaceutical, Inc.
ndc-id:
ndc-product-code:64125-904
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Excellium Pharmaceutical, Inc.
ndc-id:
ndc-product-code:64125-905
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Excellium Pharmaceutical, Inc.
ndc-id:
ndc-product-code:64125-906
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:TYA Pharmaceuticals
ndc-id:
ndc-product-code:64725-0772
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-12-11
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:TYA Pharmaceuticals
ndc-id:
ndc-product-code:64725-0773
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-12-11
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Blenheim Pharmacal, Inc.
ndc-id:
ndc-product-code:10544-269
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-11-18
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Rxchange Co
ndc-id:
ndc-product-code:33358-221
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-11-12
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Apotheca, Inc.
ndc-id:
ndc-product-code:12634-867
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-12-11
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Northwind Pharmaceuticals
ndc-id:
ndc-product-code:51655-822
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-06-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions Tennessee, Inc.
ndc-id:
ndc-product-code:67544-870
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-03-05
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions Tennessee, Inc.
ndc-id:
ndc-product-code:67544-879
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-03-05
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions Tennessee, Inc.
ndc-id:
ndc-product-code:67544-982
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-03-05
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Bedford Pharmaceuticals
ndc-id:
ndc-product-code:55390-168
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-09-14
ended-marketing-on:2009-05-31
dosage-form:Injection
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA077074
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Bedford Pharmaceuticals
ndc-id:
ndc-product-code:55390-170
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-09-14
ended-marketing-on:2009-05-31
dosage-form:Injection
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA077076
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Bedford Pharmaceuticals
ndc-id:
ndc-product-code:55390-169
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-09-14
ended-marketing-on:2009-05-31
dosage-form:Injection
strength:4 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA077074
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Bedford Pharmaceuticals
ndc-id:
ndc-product-code:55390-171
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-09-14
ended-marketing-on:2009-05-31
dosage-form:Injection
strength:4 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA077076
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aidarex Pharmaceuticals LLC
ndc-id:
ndc-product-code:33261-364
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aidarex Pharmaceuticals LLC
ndc-id:
ndc-product-code:33261-068
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aidarex Pharmaceuticals LLC
ndc-id:
ndc-product-code:33261-069
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Directrx
ndc-id:
ndc-product-code:61919-584
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Amerincan Health Packaging
ndc-id:
ndc-product-code:68084-414
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-06-13
ended-marketing-on:2015-08-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Amerincan Health Packaging
ndc-id:
ndc-product-code:68084-412
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-06-19
ended-marketing-on:2015-04-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Amerincan Health Packaging
ndc-id:
ndc-product-code:68084-413
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-10-09
ended-marketing-on:2014-11-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Amerincan Health Packaging
ndc-id:
ndc-product-code:68084-088
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-05-01
ended-marketing-on:2014-04-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Amerincan Health Packaging
ndc-id:
ndc-product-code:68084-089
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-05-01
ended-marketing-on:2014-07-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Amerincan Health Packaging
ndc-id:
ndc-product-code:68084-090
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-05-01
ended-marketing-on:2014-07-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Baxter Laboratories
ndc-id:
ndc-product-code:10019-102
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-12-02
ended-marketing-on:2014-02-28
dosage-form:Injection, solution
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018840
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Baxter Laboratories
ndc-id:
ndc-product-code:10019-103
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-12-02
ended-marketing-on:2014-01-31
dosage-form:Injection, solution
strength:4 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018840
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Baxter Laboratories
ndc-id:
ndc-product-code:10019-105
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-09-23
ended-marketing-on:2014-01-31
dosage-form:Injection, solution
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Baxter Laboratories
ndc-id:
ndc-product-code:10019-106
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-09-23
ended-marketing-on:2014-01-31
dosage-form:Injection, solution
strength:4 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Ncs Health Care Of Ky, Inc Dba Vangard Labs
ndc-id:
ndc-product-code:0615-7805
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-27
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Av Pak
ndc-id:
ndc-product-code:50268-507
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-06-02
ended-marketing-on:2015-02-25
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Av Pak
ndc-id:
ndc-product-code:50268-508
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-06-02
ended-marketing-on:2015-02-25
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Av Pak
ndc-id:
ndc-product-code:50268-509
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-06-02
ended-marketing-on:2015-04-14
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Blenheim Pharmacal, Inc.
ndc-id:
ndc-product-code:10544-085
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-09-04
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Blenheim Pharmacal, Inc.
ndc-id:
ndc-product-code:10544-244
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-12
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Teva
ndc-id:
ndc-product-code:0093-4820
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-02-01
ended-marketing-on:2011-08-31
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077396
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Teva
ndc-id:
ndc-product-code:0093-4821
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-02-01
ended-marketing-on:2011-08-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077396
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Teva
ndc-id:
ndc-product-code:0093-4822
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-02-01
ended-marketing-on:2012-09-17
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA077396
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Actavis Pharma Company
ndc-id:
ndc-product-code:0228-2057
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:2014-04-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Actavis Pharma Company
ndc-id:
ndc-product-code:0228-2059
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:2014-04-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Actavis Pharma Company
ndc-id:
ndc-product-code:0228-2063
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-08
ended-marketing-on:2014-08-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-329
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-05-08
ended-marketing-on:2013-05-09
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072928
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Ncs Health Care Of Ky, Inc Dba Vangard Labs
ndc-id:
ndc-product-code:0615-8003
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-10
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Ncs Health Care Of Ky, Inc Dba Vangard Labs
ndc-id:
ndc-product-code:0615-8004
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-10
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Ncs Health Care Of Ky, Inc Dba Vangard Labs
ndc-id:
ndc-product-code:0615-8050
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-10
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Directrx
ndc-id:
ndc-product-code:61919-143
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-06-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Paddock Laboratories, Inc.
ndc-id:
ndc-product-code:0574-0163
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-04-01
ended-marketing-on:2017-02-28
dosage-form:Solution, concentrate
strength:2 mg/1mL
route:Oral
fda-application-number:ANDA079244
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-025
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-02-25
ended-marketing-on:2013-02-26
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Remedy Repack
ndc-id:
ndc-product-code:24236-516
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-12-31
ended-marketing-on:2014-12-31
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Upsher Smith Laboratories
ndc-id:
ndc-product-code:0832-0910
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:2016-07-01
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Upsher Smith Laboratories
ndc-id:
ndc-product-code:0832-0911
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:2016-07-01
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Upsher Smith Laboratories
ndc-id:
ndc-product-code:0832-0912
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-08
ended-marketing-on:2016-07-01
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aidarex Pharmaceuticals LLC
ndc-id:
ndc-product-code:53217-208
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-316
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-05-13
ended-marketing-on:2013-05-14
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aidarex Pharmaceuticals LLC
ndc-id:
ndc-product-code:53217-216
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-867
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-10
ended-marketing-on:2015-03-10
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072928
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-030
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-07-22
ended-marketing-on:2014-03-06
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-031
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-07-21
ended-marketing-on:2013-07-22
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Avera McKennan Hospital
ndc-id:
ndc-product-code:69189-4246
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-05-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Lake Erie Medical Dba Quality Care Produts Llc
ndc-id:
ndc-product-code:35356-882
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-12-11
ended-marketing-on:2015-10-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Unit Dose Services
ndc-id:
ndc-product-code:50436-3961
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-08
ended-marketing-on:2014-08-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Hi-Tech Pharmacal Co., Inc.
ndc-id:
ndc-product-code:50383-705
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-01-30
ended-marketing-on:
dosage-form:Concentrate
strength:2 mg/1mL
route:Oral
fda-application-number:ANDA200169
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-2748
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-2841
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Unit Dose Services
ndc-id:
ndc-product-code:50436-3959
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:2014-12-31
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-3534
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:2013-07-31
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-3535
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:2013-08-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Remedy Repack
ndc-id:
ndc-product-code:61786-578
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-03-31
ended-marketing-on:2017-01-17
dosage-form:Injection
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Red Pharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1277
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions Tennessee, Inc.
ndc-id:
ndc-product-code:43353-581
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-10
ended-marketing-on:2018-07-19
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Pharmaceutical Associates, Inc.
ndc-id:
ndc-product-code:0121-0770
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-01
ended-marketing-on:
dosage-form:Liquid
strength:2 mg/1mL
route:Oral
fda-application-number:ANDA090260
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Remedy Repack
ndc-id:
ndc-product-code:70518-0303
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-03-12
ended-marketing-on:2018-03-20
dosage-form:Injection
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mc Kesson Contract Packaging
ndc-id:
ndc-product-code:76237-289
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-08-28
ended-marketing-on:2017-09-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mc Kesson Contract Packaging
ndc-id:
ndc-product-code:76237-290
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-27
ended-marketing-on:2017-09-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mc Kesson Contract Packaging
ndc-id:
ndc-product-code:76237-291
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-10-18
ended-marketing-on:2017-09-30
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-2954
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:2018-02-28
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072928
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mc Kesson
ndc-id:
ndc-product-code:63739-154
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-07-28
ended-marketing-on:2010-09-01
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071193
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mc Kesson
ndc-id:
ndc-product-code:63739-155
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-07-28
ended-marketing-on:2010-09-01
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071194
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mc Kesson
ndc-id:
ndc-product-code:63739-156
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-07-28
ended-marketing-on:2010-09-01
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071195
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Rpk Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:53002-7720
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-27
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Rpk Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:53002-5290
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Oceanside Pharmaceuticals
ndc-id:
ndc-product-code:68682-303
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-05-01
ended-marketing-on:2017-12-29
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:NDA017794
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Oceanside Pharmaceuticals
ndc-id:
ndc-product-code:68682-304
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-05-01
ended-marketing-on:2017-12-29
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:NDA017794
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Oceanside Pharmaceuticals
ndc-id:
ndc-product-code:68682-305
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-05-01
ended-marketing-on:2017-12-29
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:NDA017794
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-3825
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:2013-12-31
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-3826
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:2014-08-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-0844
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-10
ended-marketing-on:2015-12-31
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-0845
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-10
ended-marketing-on:2015-12-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-7229
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-10
ended-marketing-on:2015-12-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc
ndc-id:
ndc-product-code:35356-747
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-08
ended-marketing-on:2014-12-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Lake Erie Medical Dba Quality Care Produts Llc
ndc-id:
ndc-product-code:35356-694
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:2014-06-01
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Remedy Repack
ndc-id:
ndc-product-code:70518-1045
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-03-01
ended-marketing-on:
dosage-form:Injection, solution
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA074282
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mesource Pharmaceuticals
ndc-id:
ndc-product-code:45865-499
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-3510
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mesource Pharmaceuticals
ndc-id:
ndc-product-code:45865-422
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-08
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mesource Pharmaceuticals
ndc-id:
ndc-product-code:45865-470
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Hospira, Inc.
ndc-id:
ndc-product-code:0409-6776
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-07-03
ended-marketing-on:2006-07-03
dosage-form:Injection, solution
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Hospira, Inc.
ndc-id:
ndc-product-code:0409-6777
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-07-03
ended-marketing-on:2006-07-03
dosage-form:Injection, solution
strength:4 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Vintage Pharmaceuticals, LLC
ndc-id:
ndc-product-code:0254-4007
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-09-05
ended-marketing-on:2007-09-05
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Vintage Pharmaceuticals, LLC
ndc-id:
ndc-product-code:0254-4008
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-09-05
ended-marketing-on:2007-09-05
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Vintage Pharmaceuticals, LLC
ndc-id:
ndc-product-code:0254-4009
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-09-05
ended-marketing-on:2007-09-05
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:International Medication Systems, Limited
ndc-id:
ndc-product-code:76329-8251
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-12-01
ended-marketing-on:2012-09-04
dosage-form:Injection
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA076150
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Contract Pharmacy Services-PA
ndc-id:
ndc-product-code:67046-924
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-5371
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:2021-09-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-5377
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:2021-09-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-5379
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-08
ended-marketing-on:2021-09-30
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-3093
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-27
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-3146
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-27
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:H.J. Harkins Company, Inc.
ndc-id:
ndc-product-code:52959-365
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1995-11-10
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:H.J. Harkins Company, Inc.
ndc-id:
ndc-product-code:52959-331
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1996-02-12
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:H.J. Harkins Company, Inc.
ndc-id:
ndc-product-code:52959-538
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-01-18
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:71610-122
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-10-09
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:71610-148
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:2021-09-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:71610-149
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-08
ended-marketing-on:2021-09-30
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:67544-191
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:67544-261
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:67544-142
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072928
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:American Health Packaging
ndc-id:
ndc-product-code:68084-736
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-17
ended-marketing-on:2019-06-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:American Health Packaging
ndc-id:
ndc-product-code:68084-742
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-17
ended-marketing-on:2019-08-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:American Health Packaging
ndc-id:
ndc-product-code:68084-754
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-17
ended-marketing-on:2019-08-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Rpk Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:53002-5291
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Rpk Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:53002-6290
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:43353-255
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-10-09
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:71610-178
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:St. Mary’s Medical Park Pharmacy
ndc-id:
ndc-product-code:60760-457
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-05-06
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:West-Ward Pharmaceuticals Corp.
ndc-id:
ndc-product-code:0641-6044
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1980-07-25
ended-marketing-on:
dosage-form:Injection
strength:2.0 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:West-Ward Pharmaceuticals Corp.
ndc-id:
ndc-product-code:0641-6046
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1980-07-25
ended-marketing-on:
dosage-form:Injection
strength:2.0 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:West-Ward Pharmaceuticals Corp.
ndc-id:
ndc-product-code:0641-6045
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1980-07-25
ended-marketing-on:
dosage-form:Injection
strength:4.0 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:West-Ward Pharmaceuticals Corp.
ndc-id:
ndc-product-code:0641-6047
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1980-07-25
ended-marketing-on:
dosage-form:Injection
strength:4.0 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:West-Ward Pharmaceuticals Corp.
ndc-id:
ndc-product-code:0641-6048
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1980-07-25
ended-marketing-on:
dosage-form:Injection
strength:2.0 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:West-Ward Pharmaceuticals Corp.
ndc-id:
ndc-product-code:0641-6050
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1980-07-25
ended-marketing-on:
dosage-form:Injection
strength:2.0 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:West-Ward Pharmaceuticals Corp.
ndc-id:
ndc-product-code:0641-6049
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1980-07-25
ended-marketing-on:
dosage-form:Injection
strength:4.0 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:West-Ward Pharmaceuticals Corp.
ndc-id:
ndc-product-code:0641-6051
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1980-07-25
ended-marketing-on:
dosage-form:Injection
strength:4.0 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Qualitest Pharmaceuticals
ndc-id:
ndc-product-code:0603-4246
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-10
ended-marketing-on:2020-05-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Qualitest Pharmaceuticals
ndc-id:
ndc-product-code:0603-4247
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-10
ended-marketing-on:2018-07-19
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Qualitest Pharmaceuticals
ndc-id:
ndc-product-code:0603-4248
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-10
ended-marketing-on:2018-05-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:West-Ward Pharmaceuticals Corp.
ndc-id:
ndc-product-code:0641-6207
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1980-07-25
ended-marketing-on:
dosage-form:Injection
strength:2.0 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:NCS HealthCare of KY, Inc dba Vangard Labs
ndc-id:
ndc-product-code:0615-8075
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:NCS HealthCare of KY, Inc dba Vangard Labs
ndc-id:
ndc-product-code:0615-8076
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:NCS HealthCare of KY, Inc dba Vangard Labs
ndc-id:
ndc-product-code:0615-8077
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-1233
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:71610-199
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:63187-576
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-4001
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:71610-225
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-3462
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:71610-229
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:International Medication Systems, Limited
ndc-id:
ndc-product-code:76329-8261
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-12-01
ended-marketing-on:
dosage-form:Injection
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA076150
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Preferred Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-7355
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-02-27
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68071-3227
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:St. Mary's Medical Park Pharmacy
ndc-id:
ndc-product-code:60760-516
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-01-14
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68071-3242
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:71610-255
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68071-3121
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-0387
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:2016-09-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:71610-008
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-10-09
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:63187-536
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-2321
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-27
ended-marketing-on:2020-02-29
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-2457
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-27
ended-marketing-on:2020-03-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-2777
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-27
ended-marketing-on:2020-03-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Atlantic Biologicals Corp.
ndc-id:
ndc-product-code:17856-3532
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-04-05
ended-marketing-on:
dosage-form:Solution, concentrate
strength:2 mg/1mL
route:Oral
fda-application-number:ANDA072755
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-4157
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072928
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-4882
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Quality Care Products, LLC
ndc-id:
ndc-product-code:55700-745
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-04-26
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:American Health Packaging
ndc-id:
ndc-product-code:60687-401
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-06-17
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:American Health Packaging
ndc-id:
ndc-product-code:60687-355
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-02-17
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:American Health Packaging
ndc-id:
ndc-product-code:60687-367
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-11-28
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072928
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:RedPharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1629
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-01-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-4916
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-4918
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-4191
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-1482
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-09-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Clinical Solutions Wholesale, LLC
ndc-id:
ndc-product-code:58118-0904
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-02-15
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Clinical Solutions Wholesale, LLC
ndc-id:
ndc-product-code:58118-1095
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-02-15
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Clinical Solutions Wholesale, LLC
ndc-id:
ndc-product-code:58118-1096
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-02-15
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-2239
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-07-30
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Quality Care Products, LLC
ndc-id:
ndc-product-code:55700-778
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-07-26
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:PharmPak, Inc.
ndc-id:
ndc-product-code:54348-028
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-07-11
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-5022
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:PharmPak, Inc.
ndc-id:
ndc-product-code:54348-049
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-07-11
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-2268
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-08-15
ended-marketing-on:
dosage-form:Injection
strength:2 mg/1mL
route:Intramuscular
fda-application-number:ANDA075025
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-5048
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Leading Pharma, Llc
ndc-id:
ndc-product-code:69315-904
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Leading Pharma, Llc
ndc-id:
ndc-product-code:69315-905
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Leading Pharma, Llc
ndc-id:
ndc-product-code:69315-906
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aurolife Pharma, LLC
ndc-id:
ndc-product-code:13107-083
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aurolife Pharma, LLC
ndc-id:
ndc-product-code:13107-084
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Aurolife Pharma, LLC
ndc-id:
ndc-product-code:13107-085
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:McKesson Corporation dba SKY Packaging
ndc-id:
ndc-product-code:63739-499
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:McKesson Corporation dba SKY Packaging
ndc-id:
ndc-product-code:63739-500
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:McKesson Corporation dba SKY Packaging
ndc-id:
ndc-product-code:63739-501
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072928
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-8185
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-8223
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-5061
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-1431
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-09-21
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:McKesson Corporation dba RX Pak
ndc-id:
ndc-product-code:65084-441
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:McKesson Corporation dba RX Pak
ndc-id:
ndc-product-code:65084-442
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:McKesson Corporation dba RX Pak
ndc-id:
ndc-product-code:65084-443
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-5068
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:McKesson Corporation dba SKY Packaging
ndc-id:
ndc-product-code:63739-802
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:McKesson Corporation dba SKY Packaging
ndc-id:
ndc-product-code:63739-803
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:McKesson Corporation dba SKY Packaging
ndc-id:
ndc-product-code:63739-804
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-1520
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-10-11
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-6007
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-10-09
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-6008
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-10-09
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-6009
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-10-09
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:71205-200
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-08
ended-marketing-on:2021-09-30
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-7428
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-7533
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-5084
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:71205-228
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:71205-166
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Atlantic Biologicals Corp.
ndc-id:
ndc-product-code:17856-2059
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Preferred Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-7411
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-06-07
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Amneal Pharmaceuticals LLC
ndc-id:
ndc-product-code:65162-687
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-02-01
ended-marketing-on:
dosage-form:Concentrate
strength:2 mg/1mL
route:Oral
fda-application-number:ANDA091383
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-1679
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-11-20
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Akorn, Inc.
ndc-id:
ndc-product-code:17478-040
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1980-07-01
ended-marketing-on:
dosage-form:Injection
strength:2 mg/1mL
route:Intramuscular
fda-application-number:ANDA075025
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Lohxa
ndc-id:
ndc-product-code:70166-260
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-02-01
ended-marketing-on:
dosage-form:Concentrate
strength:2 mg/1mL
route:Oral
fda-application-number:ANDA091383
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-2186
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-07-02
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-2194
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-07-09
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:West-Ward Pharmaceuticals Corp.
ndc-id:
ndc-product-code:0054-3532
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-06-28
ended-marketing-on:
dosage-form:Solution, concentrate
strength:2 mg/1mL
route:Oral
fda-application-number:ANDA072755
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-2442
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-11-21
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Actavis Pharma, Inc.
ndc-id:
ndc-product-code:0591-0240
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Actavis Pharma, Inc.
ndc-id:
ndc-product-code:0591-0241
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Actavis Pharma, Inc.
ndc-id:
ndc-product-code:0591-0242
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072928
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-2953
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:2019-06-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-8174
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-5137
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:RedPharm Drug, Inc.
ndc-id:
ndc-product-code:67296-0143
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2000-01-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:RedPharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1622
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-01-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:RedPharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1539
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-1138
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-1311
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-1455
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-0329
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-0655
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-1467
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Direct Rx
ndc-id:
ndc-product-code:61919-062
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-02-10
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:RedPharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1540
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-0272
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:66267-835
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:55289-487
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:RedPharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1228
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:RedPharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1332
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:66267-133
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:RedPharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1060
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-10
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:55289-594
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072928
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:43063-048
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:43063-057
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-7975
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-10-09
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-7976
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-10-09
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:55289-402
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Contract Pharmacy Services-PA
ndc-id:
ndc-product-code:67046-888
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-12-15
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:71205-235
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Hospira, Inc.
ndc-id:
ndc-product-code:0409-1539
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-12-28
ended-marketing-on:
dosage-form:Injection, solution
strength:4 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA074243
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Hospira, Inc.
ndc-id:
ndc-product-code:0409-1985
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-06-06
ended-marketing-on:
dosage-form:Injection, solution
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA074243
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-0275
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-02
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68071-3096
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-0445
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-04-20
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-7480
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-03-02
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-0486
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-05-08
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-5250
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-1313
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-19
ended-marketing-on:2020-05-19
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Hospira, Inc.
ndc-id:
ndc-product-code:0409-6779
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-01-04
ended-marketing-on:
dosage-form:Injection, solution
strength:4 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA074282
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Hospira, Inc.
ndc-id:
ndc-product-code:0409-6780
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-01-03
ended-marketing-on:
dosage-form:Injection, solution
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA074282
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Hospira, Inc.
ndc-id:
ndc-product-code:0409-6781
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-01-30
ended-marketing-on:2018-04-01
dosage-form:Injection, solution
strength:4 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA074282
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Hospira, Inc.
ndc-id:
ndc-product-code:0409-6778
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-03-06
ended-marketing-on:
dosage-form:Injection, solution
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA074282
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Directrx
ndc-id:
ndc-product-code:61919-607
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-04-18
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-0274
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-10
ended-marketing-on:2018-04-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-2913
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-10
ended-marketing-on:2017-07-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68071-3010
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:2019-12-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-0155
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-01-19
ended-marketing-on:2017-01-23
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:66267-608
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-08
ended-marketing-on:2017-12-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:63187-208
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-27
ended-marketing-on:2020-03-31
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:63187-417
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-27
ended-marketing-on:2020-03-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-5550
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-12-17
ended-marketing-on:2020-03-31
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-5590
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-12-17
ended-marketing-on:2020-03-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-5655
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-12-17
ended-marketing-on:2020-03-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:61786-902
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-09-29
ended-marketing-on:2018-09-12
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:52125-913
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-04-18
ended-marketing-on:2018-03-14
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-3141
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-08
ended-marketing-on:2018-06-30
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Avera McKennan Hospital
ndc-id:
ndc-product-code:69189-5371
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-03-27
ended-marketing-on:2017-05-24
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:KAISER FOUNDATION HOSPITALS
ndc-id:
ndc-product-code:0179-0163
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-11-07
ended-marketing-on:2017-03-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:55700-614
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-05-04
ended-marketing-on:2019-12-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:35356-844
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-03-05
ended-marketing-on:2019-10-11
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:61786-918
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-10-10
ended-marketing-on:2018-09-21
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:66267-427
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:2019-12-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mylan Institutional Inc.
ndc-id:
ndc-product-code:51079-417
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-27
ended-marketing-on:2019-07-31
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mylan Institutional Inc.
ndc-id:
ndc-product-code:51079-386
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-29
ended-marketing-on:2019-07-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Mylan Institutional Inc.
ndc-id:
ndc-product-code:51079-387
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-28
ended-marketing-on:2019-04-30
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-9982
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-04-16
ended-marketing-on:2019-10-23
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:52125-950
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-05-27
ended-marketing-on:2016-07-28
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:61786-726
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-06-01
ended-marketing-on:2018-08-27
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-5886
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-24
ended-marketing-on:2015-09-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-5878
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-24
ended-marketing-on:2014-12-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:49999-122
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-31
ended-marketing-on:2019-10-11
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:61786-316
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-05-19
ended-marketing-on:2017-01-20
dosage-form:Injection
strength:2 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:61786-919
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-10-05
ended-marketing-on:2017-10-10
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:61786-428
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-02
ended-marketing-on:2018-11-09
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-0241
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-08-27
ended-marketing-on:2019-10-23
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-5980
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-24
ended-marketing-on:2015-09-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-5981
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-24
ended-marketing-on:2015-09-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-5982
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-24
ended-marketing-on:2015-09-30
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:KAISER FOUNDATION HOSPITALS
ndc-id:
ndc-product-code:0179-0131
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-03-11
ended-marketing-on:2015-02-28
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-5404
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:2015-11-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-5406
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:2015-11-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-5408
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-08
ended-marketing-on:2015-11-30
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Preferred Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-9258
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-08-27
ended-marketing-on:2019-10-23
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:61786-310
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-05-12
ended-marketing-on:2018-05-23
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:63187-868
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-27
ended-marketing-on:2020-03-31
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:KAISER FOUNDATION HOSPITALS
ndc-id:
ndc-product-code:0179-0186
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-11-23
ended-marketing-on:2017-04-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:KAISER FOUNDATION HOSPITALS
ndc-id:
ndc-product-code:0179-0185
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-09-15
ended-marketing-on:2017-04-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-0204
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-04
ended-marketing-on:2019-06-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-0277
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-08
ended-marketing-on:2019-04-30
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA071141
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-0806
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:2019-06-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-0156
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-01-19
ended-marketing-on:2019-03-05
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA077657
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:66267-798
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-01-03
ended-marketing-on:2019-12-31
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-0275
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-10
ended-marketing-on:2018-04-30
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-2576
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:2018-03-31
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:49999-805
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-11-17
ended-marketing-on:2019-06-30
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA072926
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-1255
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-06-13
ended-marketing-on:2020-04-16
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Preferred Pharmaceuticals, Inc
ndc-id:
ndc-product-code:68788-9840
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-29
ended-marketing-on:2019-10-23
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Preferred Pharmaceuticals, Inc
ndc-id:
ndc-product-code:68788-9839
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-29
ended-marketing-on:2019-10-23
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA076045
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:61786-616
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-03-07
ended-marketing-on:2017-05-26
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-9511
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-02-05
ended-marketing-on:2019-10-23
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Unit Dose Services
ndc-id:
ndc-product-code:50436-3960
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:2017-12-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:KAISER FOUNDATION HOSPITALS
ndc-id:
ndc-product-code:0179-0148
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-04-28
ended-marketing-on:2017-03-31
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA071403
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-0273
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1991-10-31
ended-marketing-on:2019-07-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA072927
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:52125-931
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-05-07
ended-marketing-on:2018-08-08
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA077754
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:61786-358
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-06-23
ended-marketing-on:2017-02-17
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA071404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-2810
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:2018-05-31
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Denton Pharma, Inc. Dba Northwind Pharmaceuticals
ndc-id:
ndc-product-code:70934-782
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-07-15
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-2799
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-06-25
ended-marketing-on:
dosage-form:Tablet
strength:2 mg/1
route:Oral
fda-application-number:ANDA072928
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-1694
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-24
ended-marketing-on:
dosage-form:Tablet
strength:1 mg/1
route:Oral
fda-application-number:ANDA203572
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Civica, Inc.
ndc-id:
ndc-product-code:72572-380
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-12-07
ended-marketing-on:
dosage-form:Injection
strength:2.0 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA018140
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Rpk Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:53002-7721
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-01
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg/1
route:Oral
fda-application-number:ANDA078203
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Lorazepam
labeller:Sanis Health Inc
ndc-id:
ndc-product-code:
dpd-id:02351080
ema-product-code:
ema-ma-number:
started-marketing-on:2010-06-15
ended-marketing-on:
dosage-form:Tablet
strength:1.0 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lorazepam
labeller:Sanis Health Inc
ndc-id:
ndc-product-code:
dpd-id:02351099
ema-product-code:
ema-ma-number:
started-marketing-on:2010-06-15
ended-marketing-on:
dosage-form:Tablet
strength:2.0 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lorazepam
labeller:Sivem Pharmaceuticals Ulc
ndc-id:
ndc-product-code:
dpd-id:02429802
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lorazepam
labeller:Sivem Pharmaceuticals Ulc
ndc-id:
ndc-product-code:
dpd-id:02429810
ema-product-code:
ema-ma-number:
started-marketing-on:2015-03-12
ended-marketing-on:2016-02-06
dosage-form:Tablet
strength:1 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lorazepam
labeller:Sivem Pharmaceuticals Ulc
ndc-id:
ndc-product-code:
dpd-id:02429829
ema-product-code:
ema-ma-number:
started-marketing-on:2015-03-12
ended-marketing-on:2016-09-08
dosage-form:Tablet
strength:2 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lorazepam
labeller:Sanis Health Inc
ndc-id:
ndc-product-code:
dpd-id:02351072
ema-product-code:
ema-ma-number:
started-marketing-on:2010-06-15
ended-marketing-on:
dosage-form:Tablet
strength:0.5 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lorazepam Injection USP
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02243278
ema-product-code:
ema-ma-number:
started-marketing-on:2001-06-06
ended-marketing-on:
dosage-form:Liquid
strength:
route:Intramuscular; Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lorazepam Injection USP
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02438704
ema-product-code:
ema-ma-number:
started-marketing-on:2015-11-12
ended-marketing-on:
dosage-form:Solution
strength:
route:Intramuscular; Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lorazepam Injection USP
labeller:Pfizer Canada Ulc
ndc-id:
ndc-product-code:
dpd-id:02388669
ema-product-code:
ema-ma-number:
started-marketing-on:2014-06-10
ended-marketing-on:
dosage-form:Solution
strength:
route:Intramuscular; Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lorazepam Sublingual
labeller:Aa Pharma Inc
ndc-id:
ndc-product-code:
dpd-id:02410745
ema-product-code:
ema-ma-number:
started-marketing-on:2013-10-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Sublingual
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lorazepam Sublingual
labeller:Aa Pharma Inc
ndc-id:
ndc-product-code:
dpd-id:02410753
ema-product-code:
ema-ma-number:
started-marketing-on:2013-10-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Sublingual
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lorazepam Sublingual
labeller:Aa Pharma Inc
ndc-id:
ndc-product-code:
dpd-id:02410761
ema-product-code:
ema-ma-number:
started-marketing-on:2013-10-16
ended-marketing-on:
dosage-form:Tablet
strength:
route:Sublingual
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ntp-lorazepam
labeller:TEVA Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02347733
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ntp-lorazepam
labeller:TEVA Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02347741
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ntp-lorazepam
labeller:TEVA Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02347768
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Nu-loraz Tab 0.5mg
labeller:Nu Pharm Inc
ndc-id:
ndc-product-code:
dpd-id:00865672
ema-product-code:
ema-ma-number:
started-marketing-on:1990-12-31
ended-marketing-on:2012-09-04
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Nu-loraz Tab 1mg
labeller:Nu Pharm Inc
ndc-id:
ndc-product-code:
dpd-id:00865680
ema-product-code:
ema-ma-number:
started-marketing-on:1990-12-31
ended-marketing-on:2012-09-04
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Nu-loraz Tab 2mg
labeller:Nu Pharm Inc
ndc-id:
ndc-product-code:
dpd-id:00865699
ema-product-code:
ema-ma-number:
started-marketing-on:1990-12-31
ended-marketing-on:2012-09-04
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:PHL-lorazepam
labeller:Pharmel Inc
ndc-id:
ndc-product-code:
dpd-id:02298201
ema-product-code:
ema-ma-number:
started-marketing-on:2007-07-30
ended-marketing-on:2007-07-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:PHL-lorazepam
labeller:Pharmel Inc
ndc-id:
ndc-product-code:
dpd-id:02298228
ema-product-code:
ema-ma-number:
started-marketing-on:2007-07-30
ended-marketing-on:2007-07-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:PHL-lorazepam
labeller:Pharmel Inc
ndc-id:
ndc-product-code:
dpd-id:02298236
ema-product-code:
ema-ma-number:
started-marketing-on:2007-07-30
ended-marketing-on:2007-07-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:PMS-lorazepam Tab 0.5mg
labeller:Pharmascience Inc
ndc-id:
ndc-product-code:
dpd-id:00728187
ema-product-code:
ema-ma-number:
started-marketing-on:1988-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:PMS-lorazepam Tab 1mg
labeller:Pharmascience Inc
ndc-id:
ndc-product-code:
dpd-id:00728195
ema-product-code:
ema-ma-number:
started-marketing-on:1988-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:PMS-lorazepam Tab 2mg
labeller:Pharmascience Inc
ndc-id:
ndc-product-code:
dpd-id:00728209
ema-product-code:
ema-ma-number:
started-marketing-on:1988-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Pro-lorazepam
labeller:Pro Doc Limitee
ndc-id:
ndc-product-code:
dpd-id:00655643
ema-product-code:
ema-ma-number:
started-marketing-on:1986-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Pro-lorazepam Tab 1.0mg
labeller:Pro Doc Limitee
ndc-id:
ndc-product-code:
dpd-id:00655651
ema-product-code:
ema-ma-number:
started-marketing-on:1986-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Pro-lorazepam Tab 2mg
labeller:Pro Doc Limitee
ndc-id:
ndc-product-code:
dpd-id:00655678
ema-product-code:
ema-ma-number:
started-marketing-on:1986-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Riva-lorazepam 0.5 Mg Tablets
labeller:Laboratoire Riva Inc
ndc-id:
ndc-product-code:
dpd-id:02240725
ema-product-code:
ema-ma-number:
started-marketing-on:1999-08-26
ended-marketing-on:2003-07-28
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Riva-lorazepam 1 Mg Tablets
labeller:Laboratoire Riva Inc
ndc-id:
ndc-product-code:
dpd-id:02240726
ema-product-code:
ema-ma-number:
started-marketing-on:1999-08-26
ended-marketing-on:2003-07-28
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Riva-lorazepam 2mg Tablets
labeller:Laboratoire Riva Inc
ndc-id:
ndc-product-code:
dpd-id:02240727
ema-product-code:
ema-ma-number:
started-marketing-on:1999-08-26
ended-marketing-on:2003-07-28
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Teva-lorazepam
labeller:TEVA Canada Limited
ndc-id:
ndc-product-code:
dpd-id:00637742
ema-product-code:
ema-ma-number:
started-marketing-on:1985-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Teva-lorazepam
labeller:TEVA Canada Limited
ndc-id:
ndc-product-code:
dpd-id:00637750
ema-product-code:
ema-ma-number:
started-marketing-on:1985-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Teva-lorazepam
labeller:TEVA Canada Limited
ndc-id:
ndc-product-code:
dpd-id:00711101
ema-product-code:
ema-ma-number:
started-marketing-on:1987-12-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
混合物
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Ativan
ingredients:Lorazepam
name:Teva-lorazepam
ingredients:Lorazepam
name:Teva-lorazepam
ingredients:Lorazepam
name:Apo-lorazepam Tab 0.5mg
ingredients:Lorazepam
name:Apo-lorazepam Tab 1mg
ingredients:Lorazepam
name:Apo-lorazepam Tab 2mg
ingredients:Lorazepam
name:Pro-lorazepam Tab 1.0mg
ingredients:Lorazepam
name:Pro-lorazepam Tab 2mg
ingredients:Lorazepam
name:Teva-lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:PMS-lorazepam Tab 0.5mg
ingredients:Lorazepam
name:PMS-lorazepam Tab 1mg
ingredients:Lorazepam
name:PMS-lorazepam Tab 2mg
ingredients:Lorazepam
name:Nu-loraz Tab 1mg
ingredients:Lorazepam
name:Nu-loraz Tab 2mg
ingredients:Lorazepam
name:Nu-loraz Tab 0.5mg
ingredients:Lorazepam
name:Ativan Injection Liq 4mg/ml
ingredients:Lorazepam
name:Ativan Tab 1mg
ingredients:Lorazepam
name:Ativan Tab 2mg
ingredients:Lorazepam
name:Ativan Subl Tab 1mg
ingredients:Lorazepam
name:Ativan Inj 4mg/ml
ingredients:Lorazepam
name:Ativan Tab 0.5mg
ingredients:Lorazepam
name:Riva-lorazepam 0.5 Mg Tablets
ingredients:Lorazepam
name:Riva-lorazepam 1 Mg Tablets
ingredients:Lorazepam
name:Riva-lorazepam 2mg Tablets
ingredients:Lorazepam
name:Ativan Subl Tab 0.5mg
ingredients:Lorazepam
name:Ntp-lorazepam
ingredients:Lorazepam
name:Ntp-lorazepam
ingredients:Lorazepam
name:Ntp-lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
name:Lorazepam Injection USP
ingredients:Lorazepam
name:Lorazepam Injection USP
ingredients:Lorazepam
name:Dom-lorazepam
ingredients:Lorazepam
name:Dom-lorazepam
ingredients:Lorazepam
name:Dom-lorazepam
ingredients:Lorazepam
name:Lorazepam Injection USP
ingredients:Lorazepam
name:PHL-lorazepam
ingredients:Lorazepam
name:PHL-lorazepam
ingredients:Lorazepam
name:PHL-lorazepam
ingredients:Lorazepam
name:Pro-lorazepam
ingredients:Lorazepam
name:Lorazepam Sublingual
ingredients:Lorazepam
name:Lorazepam Sublingual
ingredients:Lorazepam
name:Lorazepam Sublingual
ingredients:Lorazepam
name:Lorazepam
ingredients:Lorazepam
包装者
name:Actavis Group
url:http://www.actavis.com
name:Aidarex Pharmacuticals LLC
url:http://www.aidarex.com
name:Akorn Inc.
url:http://www.akorn.com
name:Amerisource Health Services Corp.
url:http://www.amerisourcebergen.com
name:Amneal Pharmaceuticals
url:http://www.amneal.com
name:Apotheca Inc.
url:
name:A-S Medication Solutions LLC
url:http://orders.a-smeds.com
name:Baxter International Inc.
url:http://www.baxter.com
name:Bedford Labs
url:http://www.bedfordlabs.com
name:Ben Venue Laboratories Inc.
url:http://www.benvenue.com
name:Bryant Ranch Prepack
url:http://bryantranchprepack.com
name:BTA Pharmaceuticals
url:
name:Cardinal Health
url:http://www.cardinal.com
name:Caremark LLC
url:http://www.caremark.com
name:Centaur Pharmaceuticals Pvt Ltd.
url:http://www.centaurpharma.com
name:Cipla Ltd.
url:http://www.cipla.com
name:Comprehensive Consultant Services Inc.
url:
name:Corepharma LLC
url:http://www.corepharma.com
name:Direct Dispensing Inc.
url:
name:DispenseXpress Inc.
url:
name:Dispensing Solutions
url:http://www.drxdispensing.com
name:Diversified Healthcare Services Inc.
url:http://www.dhscorp.com
name:Excellium Pharmaceutical Inc.
url:http://www.excellium.com
name:Goldline Laboratories Inc.
url:
name:H.J. Harkins Co. Inc.
url:http://hjharkinscompanyinc.com
name:Heartland Repack Services LLC
url:
name:Hospira Inc.
url:http://www.hospira.com
name:Innoviant Pharmacy Inc.
url:http://www.innoviantpharmacy.com
name:Kaiser Foundation Hospital
url:
name:Lake Erie Medical and Surgical Supply
url:
name:Liberty Pharmaceuticals
url:
name:Major Pharmaceuticals
url:http://www.majorpharmaceuticals.com
name:Mckesson Corp.
url:http://www.mckesson.com
name:Meda AB
url:http://www.meda.se
name:Medisca Inc.
url:http://www.medisca.com
name:Murfreesboro Pharmaceutical Nursing Supply
url:http://www.unitdosesupply.com
name:Mutual Pharmaceutical Co.
url:
name:Mylan
url:http://www.mylan.com
name:Nucare Pharmaceuticals Inc.
url:http://www.nucarerx.com
name:Ohm Laboratories Inc.
url:http://www.ohmlabs.com
name:Paddock Labs
url:http://www.paddocklabs.com
name:Palmetto Pharmaceuticals Inc.
url:http://www.palmettopharm.com
name:PCA LLC
url:
name:PD-Rx Pharmaceuticals Inc.
url:http://www.pdrx.com
name:Pharmedium
url:http://www.pharmedium.com
name:Physicians Total Care Inc.
url:http://www.physicianstotalcare.com
name:Preferred Pharmaceuticals Inc.
url:http://www.preferredpharmaceuticals.com
name:Prepackage Specialists
url:
name:Prepak Systems Inc.
url:http://www.prepaksys.com
name:Ranbaxy Laboratories
url:http://www.ranbaxy.com
name:Rebel Distributors Corp.
url:http://www.rebelrx.com
name:Redpharm Drug
url:
name:Remedy Repack
url:http://www.remedyrepack.com
name:Roxane Labs
url:http://www.roxane.com
name:Sandhills Packaging Inc.
url:http://www.sandhillspackaging.com
name:Sandoz
url:http://www.sandoz.ca
name:Southwood Pharmaceuticals
url:http://www.southwoodhealthcare.com
name:St Mary's Medical Park Pharmacy
url:
name:Stat Rx Usa
url:http://statrxusa.exporterus.com
name:Talbert Medical Management Corp.
url:
name:Taylor Pharmaceuticals
url:
name:Teva Pharmaceutical Industries Ltd.
url:http://www.tevapharm.com
name:UDL Laboratories
url:http://www.udllabs.com
name:United Research Laboratories Inc.
url:http://www.urlpharma.com
name:Va Cmop Dallas
url:
name:Watson Pharmaceuticals
url:http://www.watson.com
生产者
generic:是; url:; name;Amneal pharmaceuticals
generic:是; url:; name;Paddock laboratories inc
generic:是; url:; name;Pharmaceutical assoc inc
generic:否; url:; name;Roxane laboratories inc
generic:否; url:; name;Baxter healthcare corp anesthesia critical care
generic:是; url:; name;Akorn inc
generic:是; url:; name;Baxter healthcare corp anesthesia and critical care
generic:是; url:; name;Bedford laboratories div ben venue laboratories inc
generic:是; url:; name;Dava pharmaceuticals inc
generic:是; url:; name;Hospira inc
generic:是; url:; name;International medication systems ltd
generic:是; url:; name;Marsam pharmaceuticals llc
generic:是; url:; name;Taylor pharmaceuticals
generic:是; url:; name;Watson laboratories inc
generic:否; url:; name;Bedford laboratories
generic:否; url:; name;Biovail laboratories inc
generic:否; url:; name;Quantum pharmics ltd
generic:是; url:; name;Actavis elizabeth llc
generic:是; url:; name;American therapeutics inc
generic:是; url:; name;Excellium pharmaceutical inc
generic:是; url:; name;Halsey drug co inc
generic:是; url:; name;Ivax pharmaceuticals inc sub teva pharmaceuticals usa
generic:是; url:; name;Mutual pharmaceutical co inc
generic:是; url:; name;Mylan pharmaceuticals inc
generic:是; url:; name;Par pharmaceutical inc
generic:是; url:; name;Ranbaxy laboratories ltd
generic:是; url:; name;Sandoz inc
generic:是; url:; name;Superpharm corp
generic:是; url:; name;Usl pharma inc
generic:是; url:; name;Vintage pharmaceuticals inc
generic:是; url:; name;Warner chilcott div warner lambert co
价格
Lorazepam 2 mg tablet
1.01(单位:USD)
tablet
Lorazepam-d5w 100 mg/100 ml
1.16(单位:USD)
ml
Lorazepam-ns 100 mg/100 ml bag
1.16(单位:USD)
ml
Ativan 0.5 mg tablet
1.37(单位:USD)
tablet
Lorazepam-ns 60 mg/60 ml bag
1.53(单位:USD)
ml
Lorazepam intensol 2 mg/ml
1.6(单位:USD)
ml
Ativan 1 mg tablet
1.96(单位:USD)
tablet
Ativan 4 mg/ml vial
2.16(单位:USD)
ml
Ativan 2 mg tablet
2.3(单位:USD)
tablet
Lorazepam 2 mg/ml vial
2.5(单位:USD)
ml
Lorazepam 4 mg/ml vial
9.59(单位:USD)
ml
Lorazepam powder
20.81(单位:USD)
g
LORazepam Intensol 2 mg/ml Concentrate 30ml Bottle
44.99(单位:USD)
bottle
Apo-Lorazepam 0.5 mg Tablet
0.04(单位:USD)
tablet
Novo-Lorazem 0.5 mg Tablet
0.04(单位:USD)
tablet
Pms-Lorazepam 0.5 mg Tablet
0.04(单位:USD)
tablet
Apo-Lorazepam 1 mg Tablet
0.05(单位:USD)
tablet
Novo-Lorazem 1 mg Tablet
0.05(单位:USD)
tablet
Pms-Lorazepam 1 mg Tablet
0.05(单位:USD)
tablet
Apo-Lorazepam 2 mg Tablet
0.07(单位:USD)
tablet
Novo-Lorazem 2 mg Tablet
0.07(单位:USD)
tablet
Pms-Lorazepam 2 mg Tablet
0.07(单位:USD)
tablet
Ativan 0.5 mg Sublingual Tablet
0.12(单位:USD)
tablet
Ativan 1 mg Sublingual Tablet
0.15(单位:USD)
tablet
Ativan 2 mg Sublingual Tablet
0.24(单位:USD)
tablet
Lorazepam 0.5 mg tablet
0.55(单位:USD)
tablet
Lorazepam 1 mg tablet
0.69(单位:USD)
tablet
Ativan 2 mg/ml vial
0.9(单位:USD)
ml
受影响的生物体
Humans and other mammals
剂量
form:Tablet
route:
strength:500 mcg
form:Injection
route:Intramuscular; Intravenous
strength:4.0 mg/1mL
form:Tablet
route:Sublingual
strength:0.5 mg
form:Tablet
route:Sublingual
strength:1 mg
form:Tablet
route:Sublingual
strength:2 mg
form:Liquid
route:Intramuscular; Intravenous
strength:
form:Solution
route:Intramuscular; Intravenous
strength:
form:Tablet
route:Sublingual
strength:
form:Tablet
route:
strength:125 MICROGRAMMI
form:Tablet
route:
strength:250 MICROGRAMMI
form:Concentrate
route:Oral
strength:2 mg/1mL
form:Injection
route:Intramuscular
strength:2 mg/1mL
form:Injection
route:Intramuscular; Intravenous
strength:2 mg/1mL
form:Injection
route:Intramuscular; Intravenous
strength:2.0 mg/1mL
form:Injection
route:Intramuscular; Intravenous
strength:4 mg/1mL
form:Injection, solution
route:Intramuscular; Intravenous
strength:2 mg/1mL
form:Injection, solution
route:Intramuscular; Intravenous
strength:4 mg/1mL
form:Liquid
route:Oral
strength:2 mg/1mL
form:Solution, concentrate
route:Oral
strength:2 mg/1mL
form:Tablet
route:Oral
strength:.5 mg/1
form:Tablet
route:Oral
strength:0.5 mg/1
form:Tablet
route:Oral
strength:1 mg/1
form:Tablet
route:Oral
strength:1.0 mg
form:Tablet
route:Oral
strength:2 mg/1
form:Tablet
route:Oral
strength:2.0 mg
form:Tablet
route:Oral
strength:500 mcg
form:Tablet, film coated
route:Oral
strength:2 MG
form:Tablet
route:Oral
strength:2.099 mg
form:Tablet, orally disintegrating
route:Oral
strength:
form:Tablet
route:
strength:1 MG
form:Tablet
route:
strength:2.5 MG
form:Tablet, orally disintegrating
route:Oral
strength:1 mg
form:Tablet, orally disintegrating
route:Oral
strength:2.5 mg
form:Solution / drops
route:Oral
strength:20 MG/10ML
form:Tablet
route:
strength:
form:Solution / drops
route:Oral
strength:0.2 %
form:Tablet, film coated
route:Oral
strength:1 MG
form:Tablet, film coated
route:Oral
strength:2.5 MG
form:Tablet
route:Oral
strength:2 mg
form:Injection, solution
route:Parenteral
strength:4 MG/ML
form:Solution / drops
route:Oral
strength:2 MG/ML
form:Tablet
route:
strength:0.5 mg
form:Tablet
route:Oral
strength:1 mg
form:Tablet
route:Oral
strength:2.5 mg
form:Tablet
route:
strength:2 mg
form:Tablet
route:
strength:1.0 mg
form:Injection, solution
route:Intramuscular; Intravenous
strength:2 mg/ml
form:Tablet
route:Oral
strength:
form:Tablet
route:Oral
strength:0.5 MG
atc代码
Benzodiazepine derivatives
ANXIOLYTICS
PSYCHOLEPTICS
NERVOUS SYSTEM
Benzodiazepine derivatives
ANXIOLYTICS
PSYCHOLEPTICS
NERVOUS SYSTEM
fda标签
//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00186.pdf?1265922808
化学品安全技术说明书
//s3-us-west-2.amazonaws.com/drugbank/msds/DB00186.pdf?1373674180
专利
食物相互作用
Avoid alcohol.Limit caffeine intake.Take with food.
药物相互作用
DB00252
The metabolism of Lorazepam can be increased when combined with Phenytoin.
DB01320
The metabolism of Lorazepam can be increased when combined with Fosphenytoin.
DB00921
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.
DB00470
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.
DB00450
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
DB00956
Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.
DB00557
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.
DB00653
The therapeutic efficacy of Lorazepam can be increased when used in combination with Magnesium sulfate.
DB01403
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
DB00765
Lorazepam may increase the sedative activities of Metyrosine.
DB01017
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.
DB00370
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DB00486
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.
DB01173
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DB09117
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
DB08883
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.
DB00413
Lorazepam may increase the sedative activities of Pramipexole.
DB00268
Lorazepam may increase the sedative activities of Ropinirole.
DB05271
Lorazepam may increase the sedative activities of Rotigotine.
DB06201
The risk or severity of adverse effects can be increased when Rufinamide is combined with Lorazepam.
DB09034
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
DB06204
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.
DB01041
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DB00425
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DB00363
The risk or severity of adverse effects can be increased when Lorazepam is combined with Clozapine.
DB00408
The risk or severity of adverse effects can be increased when Loxapine is combined with Lorazepam.
DB00333
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
DB00334
The risk or severity of adverse effects can be increased when Lorazepam is combined with Olanzapine.
DB01032
The serum concentration of Lorazepam can be increased when it is combined with Probenecid.
DB09072
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
DB08900
The serum concentration of Lorazepam can be increased when it is combined with Teduglutide.
DB01392
The therapeutic efficacy of Lorazepam can be increased when used in combination with Yohimbine.
DB00358
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Mefloquine.
DB06148
The therapeutic efficacy of Mianserin can be decreased when used in combination with Lorazepam.
DB01083
Orlistat can cause a decrease in the absorption of Lorazepam resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01030
Lorazepam may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
DB00313
The serum concentration of Lorazepam can be increased when it is combined with Valproic acid.
DB01205
Flumazenil may decrease the sedative activities of Lorazepam.
DB01284
The risk or severity of liver damage can be increased when Tetracosactide is combined with Lorazepam.
DB00898
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
DB00972
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DB00484
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.
DB04832
The risk or severity of adverse effects can be increased when Lorazepam is combined with Zimelidine.
DB04884
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dapoxetine.
DB06731
The risk or severity of adverse effects can be increased when Lorazepam is combined with Seproxetine.
DB00176
The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Lorazepam.
DB00215
The risk or severity of adverse effects can be increased when Lorazepam is combined with Citalopram.
DB00476
The risk or severity of adverse effects can be increased when Lorazepam is combined with Duloxetine.
DB00656
The risk or severity of adverse effects can be increased when Lorazepam is combined with Trazodone.
DB00715
The risk or severity of adverse effects can be increased when Lorazepam is combined with Paroxetine.
DB01104
The risk or severity of adverse effects can be increased when Lorazepam is combined with Sertraline.
DB01105
The risk or severity of adverse effects can be increased when Lorazepam is combined with Sibutramine.
DB01175
The risk or severity of adverse effects can be increased when Lorazepam is combined with Escitalopram.
DB04896
The risk or severity of adverse effects can be increased when Lorazepam is combined with Milnacipran.
DB06700
The risk or severity of adverse effects can be increased when Lorazepam is combined with Desvenlafaxine.
DB08918
The risk or severity of adverse effects can be increased when Lorazepam is combined with Levomilnacipran.
DB08953
The risk or severity of adverse effects can be increased when Lorazepam is combined with Indalpine.
DB12693
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ritanserin.
DB13233
The risk or severity of adverse effects can be increased when Lorazepam is combined with Alaproclate.
DB00209
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Trospium.
DB00219
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.
DB00245
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.
DB00280
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
DB00332
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.
DB00340
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Metixene.
DB00354
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Buclizine.
DB00376
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
DB00383
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.
DB00387
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.
DB00392
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Profenamine.
DB00424
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
DB00434
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
DB00462
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine bromide.
DB00505
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.
DB00517
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Anisotropine methylbromide.
DB00572
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Atropine.
DB00670
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.
DB00725
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.
DB00767
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Benzquinamide.
DB00777
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.
DB00782
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
DB00804
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
DB00810
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Biperiden.
DB00907
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Cocaine.
DB00940
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Methantheline.
DB00942
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Cycrimine.
DB00986
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
DB01036
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
DB01148
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
DB01231
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Diphenidol.
DB01409
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Tiotropium.
DB01591
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
DB01625
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.
DB04843
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.
DB06702
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
DB06787
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.
DB08801
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.
DB08897
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
DB08997
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.
DB09076
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Umeclidinium.
DB09089
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.
DB09262
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Imidafenacin.
DB09300
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.
DB11235
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.
DB11315
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.
DB11855
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.
DB12086
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Oxitropium.
DB12278
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Propiverine.
DB12526
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Batefenterol.
DB12554
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.
DB13252
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.
DB13254
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Prifinium.
DB13351
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.
DB13369
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Benzilone.
DB13380
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Difemerine.
DB13413
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Phenglutarimide.
DB13448
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Mazaticol.
DB13468
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Etybenzatropine.
DB13500
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Otilonium.
DB13507
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Poldine.
DB13542
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Bevonium.
DB13581
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Rociverine.
DB13619
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.
DB13636
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Etanautine.
DB13666
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Tiemonium iodide.
DB13678
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.
DB13695
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Penthienate.
DB13720
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.
DB13738
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Camylofin.
DB13759
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Fenpiverinium.
DB13769
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Emetonium iodide.
DB13844
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.
DB13850
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Timepidium.
DB00321
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
DB00458
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
DB01142
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
DB00496
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
DB09007
Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.
DB01198
The risk or severity of adverse effects can be increased when Lorazepam is combined with Zopiclone.
DB00201
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Caffeine.
DB00651
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Dyphylline.
DB00806
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Pentoxifylline.
DB01033
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Mercaptopurine.
DB01303
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Oxtriphylline.
DB01412
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Theobromine.
DB01482
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Fenethylline.
DB01667
The therapeutic efficacy of Lorazepam can be decreased when used in combination with 8-azaguanine.
DB01978
The therapeutic efficacy of Lorazepam can be decreased when used in combination with 7,9-Dimethylguanine.
DB02134
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Xanthine.
DB02245
The therapeutic efficacy of Lorazepam can be decreased when used in combination with 7-Deazaguanine.
DB02377
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Guanine.
DB02489
The therapeutic efficacy of Lorazepam can be decreased when used in combination with 9-Methylguanine.
DB02568
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Peldesine.
DB04076
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Hypoxanthine.
DB04356
The therapeutic efficacy of Lorazepam can be decreased when used in combination with 9-Deazaguanine.
DB06479
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Propentofylline.
DB06575
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Valomaciclovir.
DB07954
The therapeutic efficacy of Lorazepam can be decreased when used in combination with 3-isobutyl-1-methyl-7H-xanthine.
DB08844
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Uric acid.
DB09273
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Doxofylline.
DB11919
The therapeutic efficacy of Lorazepam can be decreased when used in combination with 6-O-benzylguanine.
DB12406
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Lisofylline.
DB12531
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Lobucavir.
DB12926
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Cafedrine.
DB12927
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Theodrenaline.
DB13203
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Bamifylline.
DB13449
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Proxyphylline.
DB13573
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Acefylline.
DB13592
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Etamiphylline.
DB13634
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Pentifylline.
DB13812
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Bufylline.
DB14018
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Bromotheophylline.
DB14029
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Furafylline.
DB14132
The therapeutic efficacy of Lorazepam can be decreased when used in combination with 8-chlorotheophylline.
DB15122
The therapeutic efficacy of Lorazepam can be decreased when used in combination with PCS-499.
DB00307
The metabolism of Lorazepam can be increased when combined with Bexarotene.
DB00559
The metabolism of Lorazepam can be increased when combined with Bosentan.
DB00607
The metabolism of Lorazepam can be increased when combined with Nafcillin.
DB00745
The metabolism of Lorazepam can be increased when combined with Modafinil.
DB06414
The metabolism of Lorazepam can be increased when combined with Etravirine.
DB06442
The metabolism of Lorazepam can be increased when combined with Avasimibe.
DB14240
The metabolism of Lorazepam can be increased when combined with Echinacea.
DB00312
The metabolism of Lorazepam can be increased when combined with Pentobarbital.
DB00648
The metabolism of Lorazepam can be increased when combined with Mitotane.
DB00794
The metabolism of Lorazepam can be increased when combined with Primidone.
DB01174
The metabolism of Lorazepam can be increased when combined with Phenobarbital.
DB01220
The metabolism of Lorazepam can be increased when combined with Rifaximin.
DB01234
The metabolism of Lorazepam can be increased when combined with Dexamethasone.
DB01323
The metabolism of Lorazepam can be increased when combined with St. John's Wort.
DB06595
The metabolism of Lorazepam can be increased when combined with Midostaurin.
DB08899
The metabolism of Lorazepam can be increased when combined with Enzalutamide.
DB09280
The metabolism of Lorazepam can be increased when combined with Lumacaftor.
DB11753
The metabolism of Lorazepam can be increased when combined with Rifamycin.
DB11901
The metabolism of Lorazepam can be increased when combined with Apalutamide.
DB01045
The metabolism of Rifampicin can be increased when combined with Lorazepam.
DB00196
The metabolism of Fluconazole can be decreased when combined with Lorazepam.
DB00270
The metabolism of Isradipine can be decreased when combined with Lorazepam.
DB00537
The metabolism of Ciprofloxacin can be decreased when combined with Lorazepam.
DB00661
The metabolism of Verapamil can be decreased when combined with Lorazepam.
DB00199
The metabolism of Lorazepam can be decreased when combined with Erythromycin.
DB00343
The metabolism of Lorazepam can be decreased when combined with Diltiazem.
DB00622
The metabolism of Lorazepam can be decreased when combined with Nicardipine.
DB01087
The metabolism of Lorazepam can be decreased when combined with Primaquine.
DB01110
The metabolism of Lorazepam can be decreased when combined with Miconazole.
DB01406
The metabolism of Lorazepam can be decreased when combined with Danazol.
DB02703
The metabolism of Lorazepam can be decreased when combined with Fusidic acid.
DB06290
The metabolism of Lorazepam can be decreased when combined with Simeprevir.
DB06712
The metabolism of Lorazepam can be decreased when combined with Nilvadipine.
DB08882
The metabolism of Lorazepam can be decreased when combined with Linagliptin.
DB09048
The metabolism of Lorazepam can be decreased when combined with Netupitant.
DB09227
The metabolism of Lorazepam can be decreased when combined with Barnidipine.
DB09231
The metabolism of Lorazepam can be decreased when combined with Benidipine.
DB14019
The metabolism of Lorazepam can be decreased when combined with Fosnetupitant.
DB00227
The metabolism of Lorazepam can be decreased when combined with Lovastatin.
DB00673
The metabolism of Lorazepam can be decreased when combined with Aprepitant.
DB11633
The metabolism of Lorazepam can be decreased when combined with Isavuconazole.
DB15982
The metabolism of Lorazepam can be decreased when combined with Berotralstat.
DB01149
The metabolism of Nefazodone can be decreased when combined with Lorazepam.
DB01183
The metabolism of Lorazepam can be decreased when combined with Naloxone.
DB00763
The metabolism of Methimazole can be decreased when combined with Lorazepam.
DB00582
The metabolism of Lorazepam can be decreased when combined with Voriconazole.
DB00625
The metabolism of Lorazepam can be decreased when combined with Efavirenz.
DB00705
The metabolism of Lorazepam can be decreased when combined with Delavirdine.
DB00836
The metabolism of Lorazepam can be decreased when combined with Loperamide.
DB00976
The metabolism of Lorazepam can be decreased when combined with Telithromycin.
DB01026
The metabolism of Lorazepam can be decreased when combined with Ketoconazole.
DB01072
The metabolism of Lorazepam can be decreased when combined with Atazanavir.
DB01167
The metabolism of Lorazepam can be decreased when combined with Itraconazole.
DB01211
The metabolism of Lorazepam can be decreased when combined with Clarithromycin.
DB01263
The metabolism of Lorazepam can be decreased when combined with Posaconazole.
DB02520
The metabolism of Lorazepam can be decreased when combined with Ditiocarb.
DB04868
The metabolism of Lorazepam can be decreased when combined with Nilotinib.
DB05521
The metabolism of Lorazepam can be decreased when combined with Telaprevir.
DB09065
The metabolism of Lorazepam can be decreased when combined with Cobicistat.
DB09101
The metabolism of Lorazepam can be decreased when combined with Elvitegravir.
DB09118
The metabolism of Lorazepam can be decreased when combined with Stiripentol.
DB11730
The metabolism of Lorazepam can be decreased when combined with Ribociclib.
DB11779
The metabolism of Lorazepam can be decreased when combined with Danoprevir.
DB13179
The metabolism of Lorazepam can be decreased when combined with Troleandomycin.
DB00342
The metabolism of Terfenadine can be decreased when combined with Lorazepam.
DB00696
The metabolism of Ergotamine can be decreased when combined with Lorazepam.
DB00872
The metabolism of Conivaptan can be decreased when combined with Lorazepam.
DB00932
The metabolism of Tipranavir can be decreased when combined with Lorazepam.
DB01601
The metabolism of Lopinavir can be decreased when combined with Lorazepam.
DB08873
The metabolism of Boceprevir can be decreased when combined with Lorazepam.
DB01232
The metabolism of Lorazepam can be decreased when combined with Saquinavir.
DB06448
The metabolism of Lorazepam can be decreased when combined with Lonafarnib.
DB00042
The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lorazepam.
DB00083
The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lorazepam.
DB00181
The risk or severity of adverse effects can be increased when Baclofen is combined with Lorazepam.
DB00189
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ethchlorvynol.
DB00202
The risk or severity of adverse effects can be increased when Lorazepam is combined with Succinylcholine.
DB00228
The risk or severity of adverse effects can be increased when Lorazepam is combined with Enflurane.
DB00237
The risk or severity of adverse effects can be increased when Lorazepam is combined with Butabarbital.
DB00241
The risk or severity of adverse effects can be increased when Lorazepam is combined with Butalbital.
DB00273
The risk or severity of adverse effects can be increased when Lorazepam is combined with Topiramate.
DB00283
The risk or severity of adverse effects can be increased when Lorazepam is combined with Clemastine.
DB00289
The risk or severity of adverse effects can be increased when Lorazepam is combined with Atomoxetine.
DB00292
The risk or severity of adverse effects can be increased when Lorazepam is combined with Etomidate.
DB00306
The risk or severity of adverse effects can be increased when Lorazepam is combined with Talbutal.
DB00315
The risk or severity of adverse effects can be increased when Lorazepam is combined with Zolmitriptan.
DB00323
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tolcapone.
DB00341
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cetirizine.
DB00347
The risk or severity of adverse effects can be increased when Lorazepam is combined with Trimethadione.
DB00356
The risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorzoxazone.
DB00372
The risk or severity of adverse effects can be increased when Lorazepam is combined with Thiethylperazine.
DB00405
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dexbrompheniramine.
DB00416
The risk or severity of adverse effects can be increased when Lorazepam is combined with Metocurine iodide.
DB00418
The risk or severity of adverse effects can be increased when Lorazepam is combined with Secobarbital.
DB00423
The risk or severity of adverse effects can be increased when Lorazepam is combined with Methocarbamol.
DB00427
The risk or severity of adverse effects can be increased when Lorazepam is combined with Triprolidine.
DB00463
The risk or severity of adverse effects can be increased when Lorazepam is combined with Metharbital.
DB00468
The risk or severity of adverse effects can be increased when Lorazepam is combined with Quinine.
DB00474
The risk or severity of adverse effects can be increased when Lorazepam is combined with Methohexital.
DB00483
The risk or severity of adverse effects can be increased when Lorazepam is combined with Gallamine triethiodide.
DB00494
The risk or severity of adverse effects can be increased when Lorazepam is combined with Entacapone.
DB00514
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dextromethorphan.
DB00532
The risk or severity of adverse effects can be increased when Lorazepam is combined with Mephenytoin.
DB00565
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cisatracurium.
DB00574
The risk or severity of adverse effects can be increased when Lorazepam is combined with Fenfluramine.
DB00579
The risk or severity of adverse effects can be increased when Lorazepam is combined with Mazindol.
DB00588
The risk or severity of adverse effects can be increased when Lorazepam is combined with Fluticasone propionate.
DB00589
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lisuride.
DB00599
The risk or severity of adverse effects can be increased when Lorazepam is combined with Thiopental.
DB00601
The risk or severity of adverse effects can be increased when Lorazepam is combined with Linezolid.
DB00614
The risk or severity of adverse effects can be increased when Lorazepam is combined with Furazolidone.
DB00617
The risk or severity of adverse effects can be increased when Lorazepam is combined with Paramethadione.
DB00633
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dexmedetomidine.
DB00645
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dyclonine.
DB00660
The risk or severity of adverse effects can be increased when Lorazepam is combined with Metaxalone.
DB00662
The risk or severity of adverse effects can be increased when Lorazepam is combined with Trimethobenzamide.
DB00680
The risk or severity of adverse effects can be increased when Lorazepam is combined with Moricizine.
DB00697
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tizanidine.
DB00714
The risk or severity of adverse effects can be increased when Lorazepam is combined with Apomorphine.
DB00721
The risk or severity of adverse effects can be increased when Lorazepam is combined with Procaine.
DB00728
The risk or severity of adverse effects can be increased when Lorazepam is combined with Rocuronium.
DB00732
The risk or severity of adverse effects can be increased when Lorazepam is combined with Atracurium besylate.
DB00737
The risk or severity of adverse effects can be increased when Lorazepam is combined with Meclizine.
DB00740
The risk or severity of adverse effects can be increased when Lorazepam is combined with Riluzole.
DB00747
The risk or severity of adverse effects can be increased when Lorazepam is combined with Scopolamine.
DB00748
The risk or severity of adverse effects can be increased when Lorazepam is combined with Carbinoxamine.
DB00753
The risk or severity of adverse effects can be increased when Lorazepam is combined with Isoflurane.
DB00754
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ethotoin.
DB00757
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dolasetron.
DB00771
The risk or severity of adverse effects can be increased when Lorazepam is combined with Clidinium.
DB00818
The risk or severity of adverse effects can be increased when Lorazepam is combined with Propofol.
DB00819
The risk or severity of adverse effects can be increased when Lorazepam is combined with Acetazolamide.
DB00832
The risk or severity of adverse effects can be increased when Lorazepam is combined with Phensuximide.
DB00835
The risk or severity of adverse effects can be increased when Lorazepam is combined with Brompheniramine.
DB00843
The risk or severity of adverse effects can be increased when Lorazepam is combined with Donepezil.
DB00849
The risk or severity of adverse effects can be increased when Lorazepam is combined with Methylphenobarbital.
DB00865
The risk or severity of adverse effects can be increased when Lorazepam is combined with Benzphetamine.
DB00866
The risk or severity of adverse effects can be increased when Lorazepam is combined with Alprenolol.
DB00889
The risk or severity of adverse effects can be increased when Lorazepam is combined with Granisetron.
DB00906
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tiagabine.
DB00909
The risk or severity of adverse effects can be increased when Lorazepam is combined with Zonisamide.
DB00937
The risk or severity of adverse effects can be increased when Lorazepam is combined with Diethylpropion.
DB00941
The risk or severity of adverse effects can be increased when Lorazepam is combined with Hexafluronium.
DB00949
The risk or severity of adverse effects can be increased when Lorazepam is combined with Felbamate.
DB00952
The risk or severity of adverse effects can be increased when Lorazepam is combined with Naratriptan.
DB00962
The risk or severity of adverse effects can be increased when Lorazepam is combined with Zaleplon.
DB00967
The risk or severity of adverse effects can be increased when Lorazepam is combined with Desloratadine.
DB00969
The risk or severity of adverse effects can be increased when Lorazepam is combined with Alosetron.
DB00980
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ramelteon.
DB00985
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dimenhydrinate.
DB00998
The risk or severity of adverse effects can be increased when Lorazepam is combined with Frovatriptan.
DB01018
The risk or severity of adverse effects can be increased when Lorazepam is combined with Guanfacine.
DB01028
The risk or severity of adverse effects can be increased when Lorazepam is combined with Methoxyflurane.
DB01049
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ergoloid mesylate.
DB01063
The risk or severity of adverse effects can be increased when Lorazepam is combined with Acetophenazine.
DB01065
The risk or severity of adverse effects can be increased when Lorazepam is combined with Melatonin.
DB01068
The risk or severity of adverse effects can be increased when Lorazepam is combined with Clonazepam.
DB01069
The risk or severity of adverse effects can be increased when Lorazepam is combined with Promethazine.
DB01075
The risk or severity of adverse effects can be increased when Lorazepam is combined with Diphenhydramine.
DB01080
The risk or severity of adverse effects can be increased when Lorazepam is combined with Vigabatrin.
DB01107
The risk or severity of adverse effects can be increased when Lorazepam is combined with Methyprylon.
DB01114
The risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorpheniramine.
DB01121
The risk or severity of adverse effects can be increased when Lorazepam is combined with Phenacemide.
DB01135
The risk or severity of adverse effects can be increased when Lorazepam is combined with Doxacurium.
DB01154
The risk or severity of adverse effects can be increased when Lorazepam is combined with Thiamylal.
DB01159
The risk or severity of adverse effects can be increased when Lorazepam is combined with Halothane.
DB01168
The risk or severity of adverse effects can be increased when Lorazepam is combined with Procarbazine.
DB01176
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cyclizine.
DB01186
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pergolide.
DB01189
The risk or severity of adverse effects can be increased when Lorazepam is combined with Desflurane.
DB01199
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tubocurarine.
DB01202
The risk or severity of adverse effects can be increased when Lorazepam is combined with Levetiracetam.
DB01219
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dantrolene.
DB01221
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ketamine.
DB01226
The risk or severity of adverse effects can be increased when Lorazepam is combined with Mivacurium.
DB01235
The risk or severity of adverse effects can be increased when Lorazepam is combined with Levodopa.
DB01236
The risk or severity of adverse effects can be increased when Lorazepam is combined with Sevoflurane.
DB01245
The risk or severity of adverse effects can be increased when Lorazepam is combined with Decamethonium.
DB01246
The risk or severity of adverse effects can be increased when Lorazepam is combined with Alimemazine.
DB01253
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ergometrine.
DB01336
The risk or severity of adverse effects can be increased when Lorazepam is combined with Metocurine.
DB01337
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pancuronium.
DB01338
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pipecuronium.
DB01339
The risk or severity of adverse effects can be increased when Lorazepam is combined with Vecuronium.
DB01351
The risk or severity of adverse effects can be increased when Lorazepam is combined with Amobarbital.
DB01352
The risk or severity of adverse effects can be increased when Lorazepam is combined with Aprobarbital.
DB01353
The risk or severity of adverse effects can be increased when Lorazepam is combined with Butobarbital.
DB01354
The risk or severity of adverse effects can be increased when Lorazepam is combined with Heptabarbital.
DB01355
The risk or severity of adverse effects can be increased when Lorazepam is combined with Hexobarbital.
DB01437
The risk or severity of adverse effects can be increased when Lorazepam is combined with Glutethimide.
DB01440
The risk or severity of adverse effects can be increased when Lorazepam is combined with gamma-Hydroxybutyric acid.
DB01442
The risk or severity of adverse effects can be increased when Lorazepam is combined with MMDA.
DB01483
The risk or severity of adverse effects can be increased when Lorazepam is combined with Barbital.
DB01489
The risk or severity of adverse effects can be increased when Lorazepam is combined with Camazepam.
DB01495
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dichloralphenazone.
DB01501
The risk or severity of adverse effects can be increased when Lorazepam is combined with Difenoxin.
DB01511
The risk or severity of adverse effects can be increased when Lorazepam is combined with Delorazepam.
DB01534
The risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorhexadol.
DB01547
The risk or severity of adverse effects can be increased when Lorazepam is combined with Drotebanol.
DB01553
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cloxazolam.
DB01559
The risk or severity of adverse effects can be increased when Lorazepam is combined with Clotiazepam.
DB01563
The risk or severity of adverse effects can be increased when Lorazepam is combined with Chloral hydrate.
DB01580
The risk or severity of adverse effects can be increased when Lorazepam is combined with Oxprenolol.
DB01589
The risk or severity of adverse effects can be increased when Lorazepam is combined with Quazepam.
DB01594
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cinolazepam.
DB01608
The risk or severity of adverse effects can be increased when Lorazepam is combined with Periciazine.
DB01616
The risk or severity of adverse effects can be increased when Lorazepam is combined with Alverine.
DB01621
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pipotiazine.
DB01622
The risk or severity of adverse effects can be increased when Lorazepam is combined with Thioproperazine.
DB01626
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pargyline.
DB02234
The risk or severity of adverse effects can be increased when Lorazepam is combined with S-Ethylisothiourea.
DB02852
The risk or severity of adverse effects can be increased when Lorazepam is combined with Domoic Acid.
DB04165
The risk or severity of adverse effects can be increased when Lorazepam is combined with Valpromide.
DB04819
The risk or severity of adverse effects can be increased when Lorazepam is combined with Methapyrilene.
DB04821
The risk or severity of adverse effects can be increased when Lorazepam is combined with Nomifensine.
DB04827
The risk or severity of adverse effects can be increased when Lorazepam is combined with Urethane.
DB04833
The risk or severity of adverse effects can be increased when Lorazepam is combined with Methaqualone.
DB04834
The risk or severity of adverse effects can be increased when Lorazepam is combined with Rapacuronium.
DB04841
The risk or severity of adverse effects can be increased when Lorazepam is combined with Flunarizine.
DB04885
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cilansetron.
DB04888
The risk or severity of adverse effects can be increased when Lorazepam is combined with Bifeprunox.
DB04903
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pagoclone.
DB04908
The risk or severity of adverse effects can be increased when Lorazepam is combined with Flibanserin.
DB04917
The risk or severity of adverse effects can be increased when Lorazepam is combined with Renzapride.
DB04953
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ezogabine.
DB05227
The risk or severity of adverse effects can be increased when Lorazepam is combined with APD791.
DB05232
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tetrodotoxin.
DB05246
The risk or severity of adverse effects can be increased when Lorazepam is combined with Methsuximide.
DB05541
The risk or severity of adverse effects can be increased when Lorazepam is combined with Brivaracetam.
DB05542
The risk or severity of adverse effects can be increased when Lorazepam is combined with Naronapride.
DB05562
The risk or severity of adverse effects can be increased when Lorazepam is combined with Naluzotan.
DB05607
The risk or severity of adverse effects can be increased when Lorazepam is combined with PRX-08066.
DB05687
The risk or severity of adverse effects can be increased when Lorazepam is combined with BL-1020.
DB05710
The risk or severity of adverse effects can be increased when Lorazepam is combined with Gantacurium.
DB06077
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lumateperone.
DB06109
The risk or severity of adverse effects can be increased when Lorazepam is combined with YKP-1358.
DB06218
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lacosamide.
DB06264
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tolperisone.
DB06282
The risk or severity of adverse effects can be increased when Lorazepam is combined with Levocetirizine.
DB06446
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dotarizine.
DB06458
The risk or severity of adverse effects can be increased when Lorazepam is combined with Remacemide.
DB06470
The risk or severity of adverse effects can be increased when Lorazepam is combined with Clomethiazole.
DB06527
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tramiprosate.
DB06529
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ocinaplon.
DB06554
The risk or severity of adverse effects can be increased when Lorazepam is combined with Gaboxadol.
DB06594
The risk or severity of adverse effects can be increased when Lorazepam is combined with Agomelatine.
DB06654
The risk or severity of adverse effects can be increased when Lorazepam is combined with Safinamide.
DB06660
The risk or severity of adverse effects can be increased when Lorazepam is combined with Saredutant.
DB06690
The risk or severity of adverse effects can be increased when Lorazepam is combined with Nitrous oxide.
DB06691
The risk or severity of adverse effects can be increased when Lorazepam is combined with Mepyramine.
DB06701
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dexmethylphenidate.
DB06716
The risk or severity of adverse effects can be increased when Lorazepam is combined with Fospropofol.
DB06753
The risk or severity of adverse effects can be increased when Lorazepam is combined with Triclofos.
DB06770
The risk or severity of adverse effects can be increased when Lorazepam is combined with Benzyl alcohol.
DB06797
The risk or severity of adverse effects can be increased when Lorazepam is combined with Mebutamate.
DB08059
The risk or severity of adverse effects can be increased when Lorazepam is combined with Wortmannin.
DB08329
The risk or severity of adverse effects can be increased when Lorazepam is combined with Sulthiame.
DB08550
The risk or severity of adverse effects can be increased when Lorazepam is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
DB08810
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cinitapride.
DB08839
The risk or severity of adverse effects can be increased when Lorazepam is combined with Serotonin.
DB08872
The risk or severity of adverse effects can be increased when Lorazepam is combined with Gabapentin enacarbil.
DB08892
The risk or severity of adverse effects can be increased when Lorazepam is combined with Arbaclofen Placarbil.
DB08954
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ifenprodil.
DB08960
The risk or severity of adverse effects can be increased when Lorazepam is combined with Hexamethonium.
DB08992
The risk or severity of adverse effects can be increased when Lorazepam is combined with Eperisone.
DB09000
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cyamemazine.
DB09001
The risk or severity of adverse effects can be increased when Lorazepam is combined with Barbexaclone.
DB09011
The risk or severity of adverse effects can be increased when Lorazepam is combined with Beclamide.
DB09014
The risk or severity of adverse effects can be increased when Lorazepam is combined with Captodiame.
DB09017
The risk or severity of adverse effects can be increased when Lorazepam is combined with Brotizolam.
DB09021
The risk or severity of adverse effects can be increased when Lorazepam is combined with Benzoctamine.
DB09071
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tasimelteon.
DB09119
The risk or severity of adverse effects can be increased when Lorazepam is combined with Eslicarbazepine acetate.
DB09128
The risk or severity of adverse effects can be increased when Lorazepam is combined with Brexpiprazole.
DB09184
The risk or severity of adverse effects can be increased when Lorazepam is combined with Edivoxetine.
DB09186
The risk or severity of adverse effects can be increased when Lorazepam is combined with Nisoxetine.
DB09187
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lortalamine.
DB09190
The risk or severity of adverse effects can be increased when Lorazepam is combined with Talopram.
DB09223
The risk or severity of adverse effects can be increased when Lorazepam is combined with Blonanserin.
DB09241
The risk or severity of adverse effects can be increased when Lorazepam is combined with Methylene blue.
DB09243
The risk or severity of adverse effects can be increased when Lorazepam is combined with Hydracarbazine.
DB09246
The risk or severity of adverse effects can be increased when Lorazepam is combined with Benmoxin.
DB09247
The risk or severity of adverse effects can be increased when Lorazepam is combined with Iproclozide.
DB09248
The risk or severity of adverse effects can be increased when Lorazepam is combined with Mebanazine.
DB09249
The risk or severity of adverse effects can be increased when Lorazepam is combined with Octamoxin.
DB09250
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pheniprazine.
DB09251
The risk or severity of adverse effects can be increased when Lorazepam is combined with Phenoxypropazine.
DB09252
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pivhydrazine.
DB09253
The risk or severity of adverse effects can be increased when Lorazepam is combined with Safrazine.
DB09254
The risk or severity of adverse effects can be increased when Lorazepam is combined with Caroxazone.
DB09290
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ramosetron.
DB11156
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pyrantel.
DB11371
The risk or severity of adverse effects can be increased when Lorazepam is combined with Alfaxalone.
DB11400
The risk or severity of adverse effects can be increased when Lorazepam is combined with Doramectin.
DB11428
The risk or severity of adverse effects can be increased when Lorazepam is combined with Medetomidine.
DB11477
The risk or severity of adverse effects can be increased when Lorazepam is combined with Xylazine.
DB11540
The risk or severity of adverse effects can be increased when Lorazepam is combined with Propiopromazine.
DB11543
The risk or severity of adverse effects can be increased when Lorazepam is combined with Romifidine.
DB11549
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tiletamine.
DB11552
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tricaine.
DB11556
The risk or severity of adverse effects can be increased when Lorazepam is combined with Detomidine.
DB11582
The risk or severity of adverse effects can be increased when Lorazepam is combined with Thiocolchicoside.
DB11675
The risk or severity of adverse effects can be increased when Lorazepam is combined with Mosapride.
DB11686
The risk or severity of adverse effects can be increased when Lorazepam is combined with Iferanserin.
DB11755
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tetrahydrocannabivarin.
DB11859
The risk or severity of adverse effects can be increased when Lorazepam is combined with Brexanolone.
DB11868
The risk or severity of adverse effects can be increased when Lorazepam is combined with Etiracetam.
DB11889
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lanicemine.
DB11957
The risk or severity of adverse effects can be increased when Lorazepam is combined with Idalopirdine.
DB12071
The risk or severity of adverse effects can be increased when Lorazepam is combined with Vabicaserin.
DB12105
The risk or severity of adverse effects can be increased when Lorazepam is combined with Imagabalin.
DB12110
The risk or severity of adverse effects can be increased when Lorazepam is combined with m-Chlorophenylpiperazine.
DB12111
The risk or severity of adverse effects can be increased when Lorazepam is combined with MK-212.
DB12131
The risk or severity of adverse effects can be increased when Lorazepam is combined with Vinpocetine.
DB12163
The risk or severity of adverse effects can be increased when Lorazepam is combined with Sarpogrelate.
DB12177
The risk or severity of adverse effects can be increased when Lorazepam is combined with Eplivanserin.
DB12229
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cerlapirdine.
DB12308
The risk or severity of adverse effects can be increased when Lorazepam is combined with Eltanolone.
DB12338
The risk or severity of adverse effects can be increased when Lorazepam is combined with Carisbamate.
DB12361
The risk or severity of adverse effects can be increased when Lorazepam is combined with Piclozotan.
DB12395
The risk or severity of adverse effects can be increased when Lorazepam is combined with Esreboxetine.
DB12427
The risk or severity of adverse effects can be increased when Lorazepam is combined with Orvepitant.
DB12465
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ketanserin.
DB12537
The risk or severity of adverse effects can be increased when Lorazepam is combined with Benzodiazepine.
DB12576
The risk or severity of adverse effects can be increased when Lorazepam is combined with AZD-3043.
DB12590
The risk or severity of adverse effects can be increased when Lorazepam is combined with Indiplon.
DB12661
The risk or severity of adverse effects can be increased when Lorazepam is combined with Urapidil.
DB12725
The risk or severity of adverse effects can be increased when Lorazepam is combined with TD-8954.
DB12883
The risk or severity of adverse effects can be increased when Lorazepam is combined with Eltoprazine.
DB12951
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pivagabine.
DB12958
The risk or severity of adverse effects can be increased when Lorazepam is combined with Prothipendyl.
DB12989
The risk or severity of adverse effects can be increased when Lorazepam is combined with Neosaxitoxin.
DB13099
The risk or severity of adverse effects can be increased when Lorazepam is combined with Valnoctamide.
DB13114
The risk or severity of adverse effects can be increased when Lorazepam is combined with Amitriptylinoxide.
DB13213
The risk or severity of adverse effects can be increased when Lorazepam is combined with Butaperazine.
DB13219
The risk or severity of adverse effects can be increased when Lorazepam is combined with Medifoxamine.
DB13221
The risk or severity of adverse effects can be increased when Lorazepam is combined with Apronalide.
DB13234
The risk or severity of adverse effects can be increased when Lorazepam is combined with Propanidid.
DB13246
The risk or severity of adverse effects can be increased when Lorazepam is combined with Quinupramine.
DB13253
The risk or severity of adverse effects can be increased when Lorazepam is combined with Proxibarbal.
DB13295
The risk or severity of adverse effects can be increased when Lorazepam is combined with Atracurium.
DB13303
The risk or severity of adverse effects can be increased when Lorazepam is combined with Febarbamate.
DB13323
The risk or severity of adverse effects can be increased when Lorazepam is combined with Trichloroethylene.
DB13324
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tetrazepam.
DB13331
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pyrithyldione.
DB13354
The risk or severity of adverse effects can be increased when Lorazepam is combined with Phenprobamate.
DB13357
The risk or severity of adverse effects can be increased when Lorazepam is combined with Styramate.
DB13362
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pheneturide.
DB13370
The risk or severity of adverse effects can be increased when Lorazepam is combined with Bromisoval.
DB13377
The risk or severity of adverse effects can be increased when Lorazepam is combined with Vinbarbital.
DB13382
The risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorproethazine.
DB13384
The risk or severity of adverse effects can be increased when Lorazepam is combined with Melitracen.
DB13396
The risk or severity of adverse effects can be increased when Lorazepam is combined with Neocitrullamon.
DB13402
The risk or severity of adverse effects can be increased when Lorazepam is combined with Acetylglycinamide chloral hydrate.
DB13403
The risk or severity of adverse effects can be increased when Lorazepam is combined with Oxypertine.
DB13414
The risk or severity of adverse effects can be increased when Lorazepam is combined with Fenyramidol.
DB13420
The risk or severity of adverse effects can be increased when Lorazepam is combined with Thiazinam.
DB13457
The risk or severity of adverse effects can be increased when Lorazepam is combined with Oxaflozane.
DB13505
The risk or severity of adverse effects can be increased when Lorazepam is combined with Emepronium.
DB13520
The risk or severity of adverse effects can be increased when Lorazepam is combined with Metergoline.
DB13534
The risk or severity of adverse effects can be increased when Lorazepam is combined with Gedocarnil.
DB13541
The risk or severity of adverse effects can be increased when Lorazepam is combined with Iprazochrome.
DB13554
The risk or severity of adverse effects can be increased when Lorazepam is combined with Moperone.
DB13557
The risk or severity of adverse effects can be increased when Lorazepam is combined with Thiopropazate.
DB13572
The risk or severity of adverse effects can be increased when Lorazepam is combined with Emylcamate.
DB13577
The risk or severity of adverse effects can be increased when Lorazepam is combined with Allobarbital.
DB13584
The risk or severity of adverse effects can be increased when Lorazepam is combined with Gallamine.
DB13588
The risk or severity of adverse effects can be increased when Lorazepam is combined with Naftidrofuryl.
DB13598
The risk or severity of adverse effects can be increased when Lorazepam is combined with Diethyl ether.
DB13623
The risk or severity of adverse effects can be increased when Lorazepam is combined with Fabomotizole.
DB13642
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pridinol.
DB13648
The risk or severity of adverse effects can be increased when Lorazepam is combined with Alcuronium.
DB13662
The risk or severity of adverse effects can be increased when Lorazepam is combined with Hexapropymate.
DB13676
The risk or severity of adverse effects can be increased when Lorazepam is combined with Mosapramine.
DB13687
The risk or severity of adverse effects can be increased when Lorazepam is combined with Niaprazine.
DB13690
The risk or severity of adverse effects can be increased when Lorazepam is combined with Vinyl ether.
DB13733
The risk or severity of adverse effects can be increased when Lorazepam is combined with Methylpentynol.
DB13737
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cyclobarbital.
DB13745
The risk or severity of adverse effects can be increased when Lorazepam is combined with Fazadinium bromide.
DB13754
The risk or severity of adverse effects can be increased when Lorazepam is combined with Mephenoxalone.
DB13770
The risk or severity of adverse effects can be increased when Lorazepam is combined with Vinylbital.
DB13782
The risk or severity of adverse effects can be increased when Lorazepam is combined with Imipramine oxide.
DB13799
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ethadione.
DB13805
The risk or severity of adverse effects can be increased when Lorazepam is combined with Reposal.
DB13817
The risk or severity of adverse effects can be increased when Lorazepam is combined with Carbromal.
DB13837
The risk or severity of adverse effects can be increased when Lorazepam is combined with Doxefazepam.
DB13872
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lormetazepam.
DB13875
The risk or severity of adverse effects can be increased when Lorazepam is combined with Harmaline.
DB13876
The risk or severity of adverse effects can be increased when Lorazepam is combined with Brofaromine.
DB13940
The risk or severity of adverse effects can be increased when Lorazepam is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
DB13948
The risk or severity of adverse effects can be increased when Lorazepam is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.
DB13984
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cyclopropane.
DB13993
The risk or severity of adverse effects can be increased when Lorazepam is combined with MRK-409.
DB14010
The risk or severity of adverse effects can be increased when Lorazepam is combined with 5-methoxy-N,N-dimethyltryptamine.
DB14050
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cannabidivarin.
DB14575
The risk or severity of adverse effects can be increased when Lorazepam is combined with Eslicarbazepine.
DB14651
The risk or severity of adverse effects can be increased when Lorazepam is combined with Perphenazine enanthate.
DB14672
The risk or severity of adverse effects can be increased when Lorazepam is combined with Oxazepam acetate.
DB14715
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cinazepam.
DB14718
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pyrazolam.
DB14719
The risk or severity of adverse effects can be increased when Lorazepam is combined with Bentazepam.
DB14754
The risk or severity of adverse effects can be increased when Lorazepam is combined with Solriamfetol.
DB15203
The risk or severity of adverse effects can be increased when Lorazepam is combined with JNJ-26489112.
DB00377
The risk or severity of adverse effects can be increased when Lorazepam is combined with Palonosetron.
DB00669
The risk or severity of adverse effects can be increased when Lorazepam is combined with Sumatriptan.
DB00918
The risk or severity of adverse effects can be increased when Lorazepam is combined with Almotriptan.
DB00953
The risk or severity of adverse effects can be increased when Lorazepam is combined with Rizatriptan.
DB00960
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pindolol.
DB01359
The risk or severity of adverse effects can be increased when Lorazepam is combined with Penbutolol.
DB01577
The risk or severity of adverse effects can be increased when Lorazepam is combined with Metamfetamine.
DB04871
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lorcaserin.
DB09194
The risk or severity of adverse effects can be increased when Lorazepam is combined with Etoperidone.
DB11699
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tropisetron.
DB11951
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lemborexant.
DB00216
The risk or severity of adverse effects can be increased when Lorazepam is combined with Eletriptan.
DB00404
The risk or severity of adverse effects can be increased when Lorazepam is combined with Alprazolam.
DB00593
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ethosuximide.
DB00683
The risk or severity of adverse effects can be increased when Lorazepam is combined with Midazolam.
DB00897
The risk or severity of adverse effects can be increased when Lorazepam is combined with Triazolam.
DB01200
The risk or severity of adverse effects can be increased when Lorazepam is combined with Bromocriptine.
DB01356
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lithium cation.
DB08815
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lurasidone.
DB08996
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dimetacrine.
DB00751
The risk or severity of adverse effects can be increased when Lorazepam is combined with Epinastine.
DB00604
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cisapride.
DB00070
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Hyaluronidase (ovine).
DB06205
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Hyaluronidase (human recombinant).
DB14740
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Hyaluronidase.
DB09195
The risk or severity of sedation can be increased when Lorpiprazole is combined with Lorazepam.
DB00150
The risk or severity of adverse effects can be increased when Tryptophan is combined with Lorazepam.
DB00206
The risk or severity of adverse effects can be increased when Lorazepam is combined with Reserpine.
DB00231
The risk or severity of adverse effects can be increased when Lorazepam is combined with Temazepam.
DB00234
The risk or severity of adverse effects can be increased when Lorazepam is combined with Reboxetine.
DB00285
The risk or severity of adverse effects can be increased when Lorazepam is combined with Venlafaxine.
DB00344
The risk or severity of adverse effects can be increased when Lorazepam is combined with Protriptyline.
DB00349
The risk or severity of adverse effects can be increased when Lorazepam is combined with Clobazam.
DB00371
The risk or severity of adverse effects can be increased when Lorazepam is combined with Meprobamate.
DB00391
The risk or severity of adverse effects can be increased when Lorazepam is combined with Sulpiride.
DB00409
The risk or severity of adverse effects can be increased when Lorazepam is combined with Remoxipride.
DB00420
The risk or severity of adverse effects can be increased when Lorazepam is combined with Promazine.
DB00433
The risk or severity of adverse effects can be increased when Lorazepam is combined with Prochlorperazine.
DB00475
The risk or severity of adverse effects can be increased when Lorazepam is combined with Chlordiazepoxide.
DB00477
The risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorpromazine.
DB00508
The risk or severity of adverse effects can be increased when Lorazepam is combined with Triflupromazine.
DB00543
The risk or severity of adverse effects can be increased when Lorazepam is combined with Amoxapine.
DB00546
The risk or severity of adverse effects can be increased when Lorazepam is combined with Adinazolam.
DB00555
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lamotrigine.
DB00623
The risk or severity of adverse effects can be increased when Lorazepam is combined with Fluphenazine.
DB00628
The risk or severity of adverse effects can be increased when Lorazepam is combined with Clorazepic acid.
DB00679
The risk or severity of adverse effects can be increased when Lorazepam is combined with Thioridazine.
DB00690
The risk or severity of adverse effects can be increased when Lorazepam is combined with Flurazepam.
DB00726
The risk or severity of adverse effects can be increased when Lorazepam is combined with Trimipramine.
DB00734
The risk or severity of adverse effects can be increased when Lorazepam is combined with Risperidone.
DB00752
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tranylcypromine.
DB00780
The risk or severity of adverse effects can be increased when Lorazepam is combined with Phenelzine.
DB00801
The risk or severity of adverse effects can be increased when Lorazepam is combined with Halazepam.
DB00805
The risk or severity of adverse effects can be increased when Lorazepam is combined with Minaprine.
DB00829
The risk or severity of adverse effects can be increased when Lorazepam is combined with Diazepam.
DB00831
The risk or severity of adverse effects can be increased when Lorazepam is combined with Trifluoperazine.
DB00837
The risk or severity of adverse effects can be increased when Lorazepam is combined with Progabide.
DB00842
The risk or severity of adverse effects can be increased when Lorazepam is combined with Oxazepam.
DB00850
The risk or severity of adverse effects can be increased when Lorazepam is combined with Perphenazine.
DB00875
The risk or severity of adverse effects can be increased when Lorazepam is combined with Flupentixol.
DB00904
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ondansetron.
DB00933
The risk or severity of adverse effects can be increased when Lorazepam is combined with Mesoridazine.
DB00934
The risk or severity of adverse effects can be increased when Lorazepam is combined with Maprotiline.
DB00996
The risk or severity of adverse effects can be increased when Lorazepam is combined with Gabapentin.
DB01037
The risk or severity of adverse effects can be increased when Lorazepam is combined with Selegiline.
DB01156
The risk or severity of adverse effects can be increased when Lorazepam is combined with Bupropion.
DB01171
The risk or severity of adverse effects can be increased when Lorazepam is combined with Moclobemide.
DB01178
The risk or severity of adverse effects can be increased when Lorazepam is combined with Chlormezanone.
DB01215
The risk or severity of adverse effects can be increased when Lorazepam is combined with Estazolam.
DB01238
The risk or severity of adverse effects can be increased when Lorazepam is combined with Aripiprazole.
DB01239
The risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorprothixene.
DB01247
The risk or severity of adverse effects can be increased when Lorazepam is combined with Isocarboxazid.
DB01267
The risk or severity of adverse effects can be increased when Lorazepam is combined with Paliperidone.
DB01445
The risk or severity of adverse effects can be increased when Lorazepam is combined with Bufotenine.
DB01454
The risk or severity of adverse effects can be increased when Lorazepam is combined with Midomafetamine.
DB01463
The risk or severity of adverse effects can be increased when Lorazepam is combined with Fencamfamin.
DB01472
The risk or severity of adverse effects can be increased when Lorazepam is combined with 4-Methoxyamphetamine.
DB01484
The risk or severity of adverse effects can be increased when Lorazepam is combined with 4-Bromo-2,5-dimethoxyamphetamine.
DB01488
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dimethyltryptamine.
DB01509
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tenamfetamine.
DB01544
The risk or severity of adverse effects can be increased when Lorazepam is combined with Flunitrazepam.
DB01545
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ethyl loflazepate.
DB01558
The risk or severity of adverse effects can be increased when Lorazepam is combined with Bromazepam.
DB01560
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cathinone.
DB01567
The risk or severity of adverse effects can be increased when Lorazepam is combined with Fludiazepam.
DB01587
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ketazolam.
DB01588
The risk or severity of adverse effects can be increased when Lorazepam is combined with Prazepam.
DB01595
The risk or severity of adverse effects can be increased when Lorazepam is combined with Nitrazepam.
DB01614
The risk or severity of adverse effects can be increased when Lorazepam is combined with Acepromazine.
DB01615
The risk or severity of adverse effects can be increased when Lorazepam is combined with Aceprometazine.
DB01618
The risk or severity of adverse effects can be increased when Lorazepam is combined with Molindone.
DB01623
The risk or severity of adverse effects can be increased when Lorazepam is combined with Thiothixene.
DB01624
The risk or severity of adverse effects can be increased when Lorazepam is combined with Zuclopenthixol.
DB01954
The risk or severity of adverse effects can be increased when Lorazepam is combined with Rolipram.
DB02207
The risk or severity of adverse effects can be increased when Lorazepam is combined with 7-Nitroindazole.
DB02959
The risk or severity of adverse effects can be increased when Lorazepam is combined with Oxitriptan.
DB03575
The risk or severity of adverse effects can be increased when Lorazepam is combined with Phencyclidine.
DB04017
The risk or severity of adverse effects can be increased when Lorazepam is combined with Clorgiline.
DB04325
The risk or severity of adverse effects can be increased when Lorazepam is combined with Phenethylamine.
DB04599
The risk or severity of adverse effects can be increased when Lorazepam is combined with Aniracetam.
DB04818
The risk or severity of adverse effects can be increased when Lorazepam is combined with Iproniazid.
DB04820
The risk or severity of adverse effects can be increased when Lorazepam is combined with Nialamide.
DB04829
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lysergic acid diethylamide.
DB04836
The risk or severity of adverse effects can be increased when Lorazepam is combined with Amineptine.
DB04842
The risk or severity of adverse effects can be increased when Lorazepam is combined with Fluspirilene.
DB04872
The risk or severity of adverse effects can be increased when Lorazepam is combined with Osanetant.
DB04946
The risk or severity of adverse effects can be increased when Lorazepam is combined with Iloperidone.
DB05316
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pimavanserin.
DB06016
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cariprazine.
DB06144
The risk or severity of adverse effects can be increased when Lorazepam is combined with Sertindole.
DB06153
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pizotifen.
DB06216
The risk or severity of adverse effects can be increased when Lorazepam is combined with Asenapine.
DB06288
The risk or severity of adverse effects can be increased when Lorazepam is combined with Amisulpride.
DB06512
The risk or severity of adverse effects can be increased when Lorazepam is combined with Deramciclane.
DB06579
The risk or severity of adverse effects can be increased when Lorazepam is combined with Adipiplon.
DB06582
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dextofisopam.
DB06678
The risk or severity of adverse effects can be increased when Lorazepam is combined with Esmirtazapine.
DB06684
The risk or severity of adverse effects can be increased when Lorazepam is combined with Vilazodone.
DB08811
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tofisopam.
DB08922
The risk or severity of adverse effects can be increased when Lorazepam is combined with Perospirone.
DB08927
The risk or severity of adverse effects can be increased when Lorazepam is combined with Amperozide.
DB08986
The risk or severity of adverse effects can be increased when Lorazepam is combined with Etifoxine.
DB09016
The risk or severity of adverse effects can be increased when Lorazepam is combined with Butriptyline.
DB09023
The risk or severity of adverse effects can be increased when Lorazepam is combined with Benactyzine.
DB09068
The risk or severity of adverse effects can be increased when Lorazepam is combined with Vortioxetine.
DB09166
The risk or severity of adverse effects can be increased when Lorazepam is combined with Etizolam.
DB09167
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dosulepin.
DB09185
The risk or severity of adverse effects can be increased when Lorazepam is combined with Viloxazine.
DB09224
The risk or severity of adverse effects can be increased when Lorazepam is combined with Melperone.
DB09225
The risk or severity of adverse effects can be increased when Lorazepam is combined with Zotepine.
DB09226
The risk or severity of adverse effects can be increased when Lorazepam is combined with Brilaroxazine.
DB09244
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pirlindole.
DB09245
The risk or severity of adverse effects can be increased when Lorazepam is combined with Toloxatone.
DB09286
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pipamperone.
DB09307
The risk or severity of adverse effects can be increased when Lorazepam is combined with Oxaprotiline.
DB11376
The risk or severity of adverse effects can be increased when Lorazepam is combined with Azaperone.
DB11555
The risk or severity of adverse effects can be increased when Lorazepam is combined with Zolazepam.
DB11664
The risk or severity of adverse effects can be increased when Lorazepam is combined with Psilocybin.
DB12093
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tetrahydropalmatine.
DB12184
The risk or severity of adverse effects can be increased when Lorazepam is combined with Gepirone.
DB12273
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ecopipam.
DB12327
The risk or severity of adverse effects can be increased when Lorazepam is combined with Salvinorin A.
DB12401
The risk or severity of adverse effects can be increased when Lorazepam is combined with Bromperidol.
DB12518
The risk or severity of adverse effects can be increased when Lorazepam is combined with Raclopride.
DB12710
The risk or severity of adverse effects can be increased when Lorazepam is combined with Perazine.
DB12833
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tandospirone.
DB12867
The risk or severity of adverse effects can be increased when Lorazepam is combined with Benperidol.
DB12930
The risk or severity of adverse effects can be increased when Lorazepam is combined with Opipramol.
DB13014
The risk or severity of adverse effects can be increased when Lorazepam is combined with Hypericin.
DB13025
The risk or severity of adverse effects can be increased when Lorazepam is combined with Tiapride.
DB13082
The risk or severity of adverse effects can be increased when Lorazepam is combined with Nefiracetam.
DB13225
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dibenzepin.
DB13256
The risk or severity of adverse effects can be increased when Lorazepam is combined with Clothiapine.
DB13273
The risk or severity of adverse effects can be increased when Lorazepam is combined with Sultopride.
DB13335
The risk or severity of adverse effects can be increased when Lorazepam is combined with Pinazepam.
DB13352
The risk or severity of adverse effects can be increased when Lorazepam is combined with Deanol.
DB13411
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lofepramine.
DB13437
The risk or severity of adverse effects can be increased when Lorazepam is combined with Medazepam.
DB13455
The risk or severity of adverse effects can be increased when Lorazepam is combined with Phenibut.
DB13496
The risk or severity of adverse effects can be increased when Lorazepam is combined with Iprindole.
DB13522
The risk or severity of adverse effects can be increased when Lorazepam is combined with Mebicar.
DB13523
The risk or severity of adverse effects can be increased when Lorazepam is combined with Veralipride.
DB13550
The risk or severity of adverse effects can be increased when Lorazepam is combined with Bifemelane.
DB13552
The risk or severity of adverse effects can be increased when Lorazepam is combined with Trifluperidol.
DB13601
The risk or severity of adverse effects can be increased when Lorazepam is combined with Oxiracetam.
DB13643
The risk or severity of adverse effects can be increased when Lorazepam is combined with Loprazolam.
DB13665
The risk or severity of adverse effects can be increased when Lorazepam is combined with Fluanisone.
DB13784
The risk or severity of adverse effects can be increased when Lorazepam is combined with Dixyrazine.
DB13791
The risk or severity of adverse effects can be increased when Lorazepam is combined with Penfluridol.
DB13841
The risk or severity of adverse effects can be increased when Lorazepam is combined with Clopenthixol.
DB14028
The risk or severity of adverse effects can be increased when Lorazepam is combined with Nordazepam.
DB14185
The risk or severity of adverse effects can be increased when Lorazepam is combined with Aripiprazole lauroxil.
DB11642
The serum concentration of Lorazepam can be decreased when it is combined with Pitolisant.
DB04844
The risk or severity of sedation and somnolence can be increased when Lorazepam is combined with Tetrabenazine.
DB12161
The risk or severity of sedation and somnolence can be increased when Lorazepam is combined with Deutetrabenazine.
DB04948
The therapeutic efficacy of Lorazepam can be increased when used in combination with Lofexidine.
DB00159
Icosapent may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00229
Cefotiam may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00244
Mesalazine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00267
Cefmenoxime may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00274
Cefmetazole may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00282
Pamidronic acid may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00300
Tenofovir disoproxil may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00328
Indomethacin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00369
Cidofovir may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00384
Triamterene may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00430
Cefpiramide may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00438
Ceftazidime may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00447
Loracarbef may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00456
Cefalotin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00461
Nabumetone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00465
Ketorolac may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00469
Tenoxicam may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00482
Celecoxib may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00493
Cefotaxime may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00500
Tolmetin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00529
Foscarnet may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00533
Rofecoxib may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00554
Piroxicam may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00567
Cephalexin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00573
Fenoprofen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00577
Valaciclovir may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00580
Valdecoxib may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00586
Diclofenac may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00605
Sulindac may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00626
Bacitracin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00681
Amphotericin B may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00689
Cephaloglycin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00712
Flurbiprofen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00718
Adefovir dipivoxil may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00738
Pentamidine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00742
Mannitol may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00749
Etodolac may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00784
Mefenamic acid may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00787
Acyclovir may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00788
Naproxen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00795
Sulfasalazine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00812
Phenylbutazone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00814
Meloxicam may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00821
Carprofen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00833
Cefaclor may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00861
Diflunisal may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00903
Etacrynic acid may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00923
Ceforanide may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00936
Salicylic acid may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00939
Meclofenamic acid may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00945
Acetylsalicylic acid may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00958
Carboplatin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00991
Oxaprozin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00999
Hydrochlorothiazide may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01009
Ketoprofen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01014
Balsalazide may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01066
Cefditoren may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01111
Colistimethate may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01112
Cefuroxime may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01139
Cefapirin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01140
Cefadroxil may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01150
Cefprozil may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01212
Ceftriaxone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01250
Olsalazine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01283
Lumiracoxib may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01326
Cefamandole may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01327
Cefazolin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01328
Cefonicid may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01329
Cefoperazone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01330
Cefotetan may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01331
Cefoxitin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01332
Ceftizoxime may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01333
Cefradine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01397
Magnesium salicylate may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01399
Salsalate may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01401
Choline magnesium trisalicylate may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01413
Cefepime may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01414
Cefacetrile may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01415
Ceftibuten may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01416
Cefpodoxime may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01419
Antrafenine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01424
Aminophenazone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01435
Antipyrine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01600
Tiaprofenic acid may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01628
Etoricoxib may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB02247
Hydrolyzed Cephalothin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB03450
Cephalothin Group may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB03585
Oxyphenbutazone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB04570
Latamoxef may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB04743
Nimesulide may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB04812
Benoxaprofen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB04817
Metamizole may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB04828
Zomepirac may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB04918
Ceftobiprole may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB05095
Cimicoxib may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB06590
Ceftaroline fosamil may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB06725
Lornoxicam may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB06736
Aceclofenac may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB06737
Zaltoprofen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB07402
Azapropazone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB08439
Parecoxib may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB08797
Salicylamide may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB08940
Kebuzone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB08942
Isoxicam may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB08951
Indoprofen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB08955
Ibuproxam may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB08976
Floctafenine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB08981
Fenbufen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB08984
Etofenamate may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB08991
Epirizole may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB09008
Cefaloridine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB09062
Cefminox may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB09084
Benzydamine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB09213
Dexibuprofen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB09215
Droxicam may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB09216
Tolfenamic acid may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB09217
Firocoxib may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB09218
Clonixin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB09285
Morniflumate may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB09288
Propacetamol may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB09295
Talniflumate may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB09299
Tenofovir alafenamide may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB11367
Cefroxadine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB11455
Robenacoxib may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB11466
Tepoxalin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB11518
Flunixin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB11935
Flomoxef may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB12151
Brincidofovir may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB12445
Nitroaspirin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB12545
Indobufen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13001
Tinoridine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13167
Alclofenac may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13217
Fentiazac may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13232
Suxibuzone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13266
Cefatrizine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13286
Bumadizone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13314
Alminoprofen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13371
Difenpiramide may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13407
Nifenazone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13432
Lonazolac may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13461
Cefcapene may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13470
Cefodizime may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13481
Tenidap may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13499
Cefsulodin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13504
Cefetamet may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13524
Propyphenazone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13527
Proglumetacin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13538
Guacetisal may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13544
Ethenzamide may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13612
Carbaspirin calcium may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13629
Mofebutazone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13638
Cefbuperazone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13649
Proquazone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13657
Benorilate may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13667
Cefozopran may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13682
Cefpirome may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13722
Pirprofen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13778
Cefazedone may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13783
Acemetacin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13821
Ceftezole may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13860
Imidazole salicylate may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13868
Adefovir may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB14059
SC-236 may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB14060
NS-398 may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB14126
Tenofovir may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB14713
Inotersen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01438
Phenazopyridine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01050
Ibuprofen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB09214
Dexketoprofen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB15066
Givosiran may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB14507
Lithium citrate may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB09212
Loxoprofen may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00452
Framycetin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01421
Paromomycin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB04263
Geneticin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB04626
Apramycin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB04808
Neamine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB08437
Puromycin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB11512
Dihydrostreptomycin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB11520
Hygromycin B may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00007
Leuprolide may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00014
Goserelin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00017
Salmon calcitonin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00035
Desmopressin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00080
Daptomycin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00081
Tositumomab may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00115
Cyanocobalamin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00158
Folic acid may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00165
Pyridoxine may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00185
Cevimeline may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00190
Lorazepam may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00198
Lorazepam may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
DB00200
Lorazepam may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
DB00213
Lorazepam may decrease the excretion rate of Pantoprazole which could result in a higher serum level.
DB00225
Lorazepam may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
DB00235
Lorazepam may decrease the excretion rate of Milrinone which could result in a higher serum level.
DB00243
Lorazepam may decrease the excretion rate of Ranolazine which could result in a higher serum level.
DB00262
Lorazepam may decrease the excretion rate of Carmustine which could result in a higher serum level.
DB00271
Lorazepam may decrease the excretion rate of Diatrizoate which could result in a higher serum level.
DB00279
Lorazepam may decrease the excretion rate of Liothyronine which could result in a higher serum level.
DB00284
Lorazepam may decrease the excretion rate of Acarbose which could result in a higher serum level.
DB00286
Lorazepam may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
DB00290
Lorazepam may decrease the excretion rate of Bleomycin which could result in a higher serum level.
DB00296
Lorazepam may decrease the excretion rate of Ropivacaine which could result in a higher serum level.
DB00303
Lorazepam may decrease the excretion rate of Ertapenem which could result in a higher serum level.
DB00308
Lorazepam may decrease the excretion rate of Ibutilide which could result in a higher serum level.
DB00319
Lorazepam may decrease the excretion rate of Piperacillin which could result in a higher serum level.
DB00322
Lorazepam may decrease the excretion rate of Floxuridine which could result in a higher serum level.
DB00325
Lorazepam may decrease the excretion rate of Nitroprusside which could result in a higher serum level.
DB00330
Lorazepam may decrease the excretion rate of Ethambutol which could result in a higher serum level.
DB00331
Lorazepam may decrease the excretion rate of Metformin which could result in a higher serum level.
DB00339
Lorazepam may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
DB00355
Lorazepam may decrease the excretion rate of Aztreonam which could result in a higher serum level.
DB00359
Lorazepam may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.
DB00364
Lorazepam may decrease the excretion rate of Sucralfate which could result in a higher serum level.
DB00373
Lorazepam may decrease the excretion rate of Timolol which could result in a higher serum level.
DB00380
Lorazepam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
DB00412
Lorazepam may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.
DB00415
Lorazepam may decrease the excretion rate of Ampicillin which could result in a higher serum level.
DB00432
Lorazepam may decrease the excretion rate of Trifluridine which could result in a higher serum level.
DB00437
Lorazepam may decrease the excretion rate of Allopurinol which could result in a higher serum level.
DB00440
Lorazepam may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
DB00441
Lorazepam may decrease the excretion rate of Gemcitabine which could result in a higher serum level.
DB00480
Lorazepam may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
DB00492
Lorazepam may decrease the excretion rate of Fosinopril which could result in a higher serum level.
DB00499
Lorazepam may decrease the excretion rate of Flutamide which could result in a higher serum level.
DB00535
Lorazepam may decrease the excretion rate of Cefdinir which could result in a higher serum level.
DB00548
Lorazepam may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
DB00553
Lorazepam may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
DB00558
Lorazepam may decrease the excretion rate of Zanamivir which could result in a higher serum level.
DB00569
Lorazepam may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
DB00583
Lorazepam may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
DB00597
Lorazepam may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
DB00598
Lorazepam may decrease the excretion rate of Labetalol which could result in a higher serum level.
DB00612
Lorazepam may decrease the excretion rate of Bisoprolol which could result in a higher serum level.
DB00631
Lorazepam may decrease the excretion rate of Clofarabine which could result in a higher serum level.
DB00635
Lorazepam may decrease the excretion rate of Prednisone which could result in a higher serum level.
DB00657
Lorazepam may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
DB00665
Lorazepam may decrease the excretion rate of Nilutamide which could result in a higher serum level.
DB00672
Lorazepam may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
DB00688
Lorazepam may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.
DB00692
Lorazepam may decrease the excretion rate of Phentolamine which could result in a higher serum level.
DB00698
Lorazepam may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
DB00706
Lorazepam may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
DB00709
Lorazepam may decrease the excretion rate of Lamivudine which could result in a higher serum level.
DB00713
Lorazepam may decrease the excretion rate of Oxacillin which could result in a higher serum level.
DB00716
Lorazepam may decrease the excretion rate of Nedocromil which could result in a higher serum level.
DB00722
Lorazepam may decrease the excretion rate of Lisinopril which could result in a higher serum level.
DB00730
Lorazepam may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
DB00731
Lorazepam may decrease the excretion rate of Nateglinide which could result in a higher serum level.
DB00733
Lorazepam may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
DB00743
Lorazepam may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
DB00760
Lorazepam may decrease the excretion rate of Meropenem which could result in a higher serum level.
DB00761
Lorazepam may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
DB00775
Lorazepam may decrease the excretion rate of Tirofiban which could result in a higher serum level.
DB00789
Lorazepam may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
DB00790
Lorazepam may decrease the excretion rate of Perindopril which could result in a higher serum level.
DB00800
Lorazepam may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
DB00811
Lorazepam may decrease the excretion rate of Ribavirin which could result in a higher serum level.
DB00828
Lorazepam may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
DB00839
Lorazepam may decrease the excretion rate of Tolazamide which could result in a higher serum level.
DB00841
Lorazepam may decrease the excretion rate of Dobutamine which could result in a higher serum level.
DB00851
Lorazepam may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
DB00853
Lorazepam may decrease the excretion rate of Temozolomide which could result in a higher serum level.
DB00871
Lorazepam may decrease the excretion rate of Terbutaline which could result in a higher serum level.
DB00894
Lorazepam may decrease the excretion rate of Testolactone which could result in a higher serum level.
DB00900
Lorazepam may decrease the excretion rate of Didanosine which could result in a higher serum level.
DB00911
Lorazepam may decrease the excretion rate of Tinidazole which could result in a higher serum level.
DB00915
Lorazepam may decrease the excretion rate of Amantadine which could result in a higher serum level.
DB00928
Lorazepam may decrease the excretion rate of Azacitidine which could result in a higher serum level.
DB00961
Lorazepam may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
DB00968
Lorazepam may decrease the excretion rate of Methyldopa which could result in a higher serum level.
DB00988
Lorazepam may decrease the excretion rate of Dopamine which could result in a higher serum level.
DB00993
Lorazepam may decrease the excretion rate of Azathioprine which could result in a higher serum level.
DB00995
Lorazepam may decrease the excretion rate of Auranofin which could result in a higher serum level.
DB01001
Lorazepam may decrease the excretion rate of Salbutamol which could result in a higher serum level.
DB01002
Lorazepam may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.
DB01010
Lorazepam may decrease the excretion rate of Edrophonium which could result in a higher serum level.
DB01020
Lorazepam may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
DB01022
Lorazepam may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
DB01024
Lorazepam may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
DB01043
Lorazepam may decrease the excretion rate of Memantine which could result in a higher serum level.
DB01046
Lorazepam may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
DB01048
Lorazepam may decrease the excretion rate of Abacavir which could result in a higher serum level.
DB01060
Lorazepam may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
DB01067
Lorazepam may decrease the excretion rate of Glipizide which could result in a higher serum level.
DB01099
Lorazepam may decrease the excretion rate of Flucytosine which could result in a higher serum level.
DB01101
Lorazepam may decrease the excretion rate of Capecitabine which could result in a higher serum level.
DB01124
Lorazepam may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
DB01133
Lorazepam may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
DB01137
Lorazepam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.
DB01157
Lorazepam may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
DB01166
Lorazepam may decrease the excretion rate of Cilostazol which could result in a higher serum level.
DB01169
Lorazepam may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.
DB01170
Lorazepam may decrease the excretion rate of Guanethidine which could result in a higher serum level.
DB01203
Lorazepam may decrease the excretion rate of Nadolol which could result in a higher serum level.
DB01213
Lorazepam may decrease the excretion rate of Fomepizole which could result in a higher serum level.
DB01240
Lorazepam may decrease the excretion rate of Epoprostenol which could result in a higher serum level.
DB01241
Lorazepam may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.
DB01249
Lorazepam may decrease the excretion rate of Iodixanol which could result in a higher serum level.
DB01261
Lorazepam may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
DB01273
Lorazepam may decrease the excretion rate of Varenicline which could result in a higher serum level.
DB01274
Lorazepam may decrease the excretion rate of Arformoterol which could result in a higher serum level.
DB01420
Lorazepam may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
DB01427
Lorazepam may decrease the excretion rate of Amrinone which could result in a higher serum level.
DB01428
Lorazepam may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
DB01550
Lorazepam may decrease the excretion rate of Fenproporex which could result in a higher serum level.
DB01638
Lorazepam may decrease the excretion rate of Sorbitol which could result in a higher serum level.
DB04895
Lorazepam may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
DB05018
Lorazepam may decrease the excretion rate of Migalastat which could result in a higher serum level.
DB06154
Lorazepam may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
DB06186
Lorazepam may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
DB06196
Lorazepam may decrease the excretion rate of Icatibant which could result in a higher serum level.
DB06203
Lorazepam may decrease the excretion rate of Alogliptin which could result in a higher serum level.
DB06209
Lorazepam may decrease the excretion rate of Prasugrel which could result in a higher serum level.
DB06211
Lorazepam may decrease the excretion rate of Doripenem which could result in a higher serum level.
DB06230
Lorazepam may decrease the excretion rate of Nalmefene which could result in a higher serum level.
DB06262
Lorazepam may decrease the excretion rate of Droxidopa which could result in a higher serum level.
DB06335
Lorazepam may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
DB06402
Lorazepam may decrease the excretion rate of Telavancin which could result in a higher serum level.
DB06623
Lorazepam may decrease the excretion rate of Flupirtine which could result in a higher serum level.
DB06637
Lorazepam may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
DB06695
Lorazepam may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
DB06705
Lorazepam may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
DB06710
Lorazepam may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
DB06767
Lorazepam may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
DB06782
Lorazepam may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
DB06796
Lorazepam may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
DB06800
Lorazepam may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
DB06809
Lorazepam may decrease the excretion rate of Plerixafor which could result in a higher serum level.
DB06813
Lorazepam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
DB06823
Lorazepam may decrease the excretion rate of Tiopronin which could result in a higher serum level.
DB06824
Lorazepam may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
DB08824
Lorazepam may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
DB08826
Lorazepam may decrease the excretion rate of Deferiprone which could result in a higher serum level.
DB08840
Lorazepam may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.
DB08893
Lorazepam may decrease the excretion rate of Mirabegron which could result in a higher serum level.
DB08894
Lorazepam may decrease the excretion rate of Peginesatide which could result in a higher serum level.
DB08932
Lorazepam may decrease the excretion rate of Macitentan which could result in a higher serum level.
DB08934
Lorazepam may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
DB09027
Lorazepam may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
DB09050
Lorazepam may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
DB09066
Lorazepam may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
DB09075
Lorazepam may decrease the excretion rate of Edoxaban which could result in a higher serum level.
DB09081
Lorazepam may decrease the excretion rate of Idebenone which could result in a higher serum level.
DB09082
Lorazepam may decrease the excretion rate of Vilanterol which could result in a higher serum level.
DB09091
Lorazepam may decrease the excretion rate of Tixocortol which could result in a higher serum level.
DB09103
Lorazepam may decrease the excretion rate of Ancestim which could result in a higher serum level.
DB09104
Lorazepam may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
DB09106
Lorazepam may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
DB09111
Lorazepam may decrease the excretion rate of Pentastarch which could result in a higher serum level.
DB09121
Lorazepam may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
DB09129
Lorazepam may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
DB09132
Lorazepam may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
DB09133
Lorazepam may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
DB09134
Lorazepam may decrease the excretion rate of Ioversol which could result in a higher serum level.
DB09135
Lorazepam may decrease the excretion rate of Ioxilan which could result in a higher serum level.
DB09136
Lorazepam may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
DB09137
Lorazepam may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
DB09139
Lorazepam may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
DB09148
Lorazepam may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
DB09149
Lorazepam may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
DB09156
Lorazepam may decrease the excretion rate of Iopromide which could result in a higher serum level.
DB09163
Lorazepam may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
DB09165
Lorazepam may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
DB09204
Lorazepam may decrease the excretion rate of Arotinolol which could result in a higher serum level.
DB09205
Lorazepam may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
DB09209
Lorazepam may decrease the excretion rate of Pholcodine which could result in a higher serum level.
DB09210
Lorazepam may decrease the excretion rate of Piracetam which could result in a higher serum level.
DB09219
Lorazepam may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
DB09220
Lorazepam may decrease the excretion rate of Nicorandil which could result in a higher serum level.
DB09255
Lorazepam may decrease the excretion rate of Dextran which could result in a higher serum level.
DB09256
Lorazepam may decrease the excretion rate of Tegafur which could result in a higher serum level.
DB09257
Lorazepam may decrease the excretion rate of Gimeracil which could result in a higher serum level.
DB09264
Lorazepam may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
DB09265
Lorazepam may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
DB09268
Lorazepam may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
DB09276
Lorazepam may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
DB09277
Lorazepam may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
DB09281
Lorazepam may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
DB09292
Lorazepam may decrease the excretion rate of Sacubitril which could result in a higher serum level.
DB09301
Lorazepam may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
DB09317
Lorazepam may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
DB09318
Lorazepam may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
DB09320
Lorazepam may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
DB09324
Lorazepam may decrease the excretion rate of Sulbactam which could result in a higher serum level.
DB09325
Lorazepam may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
DB09329
Lorazepam may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.
DB09344
Lorazepam may decrease the excretion rate of Invert sugar which could result in a higher serum level.
DB09357
Lorazepam may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
DB09394
Lorazepam may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
DB09395
Lorazepam may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
DB09407
Lorazepam may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
DB09418
Lorazepam may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
DB09472
Lorazepam may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
DB09477
Lorazepam may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
DB09481
Lorazepam may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
DB09488
Lorazepam may decrease the excretion rate of Acrivastine which could result in a higher serum level.
DB09496
Lorazepam may decrease the excretion rate of Octinoxate which could result in a higher serum level.
DB09502
Lorazepam may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
DB09546
Lorazepam may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
DB11077
Lorazepam may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
DB11090
Lorazepam may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
DB11098
Lorazepam may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
DB11102
Lorazepam may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
DB11114
Lorazepam may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
DB11127
Lorazepam may decrease the excretion rate of Selenious acid which could result in a higher serum level.
DB11135
Lorazepam may decrease the excretion rate of Selenium which could result in a higher serum level.
DB11136
Lorazepam may decrease the excretion rate of Chromium which could result in a higher serum level.
DB11145
Lorazepam may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
DB11164
Lorazepam may decrease the excretion rate of Bicisate which could result in a higher serum level.
DB11251
Lorazepam may decrease the excretion rate of Tocopherol which could result in a higher serum level.
DB11278
Lorazepam may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
DB11328
Lorazepam may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
DB11338
Lorazepam may decrease the excretion rate of Clove oil which could result in a higher serum level.
DB11364
Lorazepam may decrease the excretion rate of Pidotimod which could result in a higher serum level.
DB11577
Lorazepam may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
DB11587
Lorazepam may decrease the excretion rate of Etafedrine which could result in a higher serum level.
DB11598
Lorazepam may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
DB11691
Lorazepam may decrease the excretion rate of Naldemedine which could result in a higher serum level.
DB11915
Lorazepam may decrease the excretion rate of Valbenazine which could result in a higher serum level.
DB11943
Lorazepam may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
DB11989
Lorazepam may decrease the excretion rate of Benznidazole which could result in a higher serum level.
DB12007
Lorazepam may decrease the excretion rate of Isoflavone which could result in a higher serum level.
DB12107
Lorazepam may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
DB12783
Lorazepam may decrease the excretion rate of Benserazide which could result in a higher serum level.
DB13139
Lorazepam may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
DB13156
Lorazepam may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
DB13178
Lorazepam may decrease the excretion rate of Inositol which could result in a higher serum level.
DB13185
Lorazepam may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.
DB13191
Lorazepam may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.
DB13269
Lorazepam may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
DB13293
Lorazepam may decrease the excretion rate of Ipecac which could result in a higher serum level.
DB13595
Lorazepam may decrease the excretion rate of Almasilate which could result in a higher serum level.
DB13873
Lorazepam may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
DB13884
Lorazepam may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
DB13909
Lorazepam may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
DB13967
Lorazepam may decrease the excretion rate of Patent Blue which could result in a higher serum level.
DB14006
Lorazepam may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
DB14007
Lorazepam may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
DB14498
Lorazepam may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
DB14499
Lorazepam may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
DB14526
Lorazepam may decrease the excretion rate of Chromic citrate which could result in a higher serum level.
DB14527
Lorazepam may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
DB14528
Lorazepam may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
DB14529
Lorazepam may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
DB14530
Lorazepam may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
DB06815
Lorazepam may decrease the excretion rate of Pyrithione which could result in a higher serum level.
DB11121
Lorazepam may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
DB11085
Lorazepam may decrease the excretion rate of Resorcinol which could result in a higher serum level.
DB15593
Lorazepam may decrease the excretion rate of Golodirsen which could result in a higher serum level.
DB00490
Lorazepam may decrease the excretion rate of Buspirone which could result in a higher serum level.
DB00820
Lorazepam may decrease the excretion rate of Tadalafil which could result in a higher serum level.
DB00401
Lorazepam may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
DB00879
Lorazepam may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
DB06228
Lorazepam may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
DB14506
Lorazepam may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.
DB13987
Lorazepam may decrease the excretion rate of Strontium chloride which could result in a higher serum level.
DB04890
Lorazepam may decrease the excretion rate of Bepotastine which could result in a higher serum level.
DB00982
Lorazepam may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
DB04930
Lorazepam may decrease the excretion rate of Permethrin which could result in a higher serum level.
DB14509
Lorazepam may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
DB00479
Amikacin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00684
Tobramycin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00798
Gentamicin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00955
Netilmicin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00994
Neomycin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01082
Streptomycin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB01172
Kanamycin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB03615
Ribostamycin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB04729
Gentamicin C1a may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB06696
Arbekacin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB12604
Sisomicin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB13540
Isepamicin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00552
Lorazepam may decrease the excretion rate of Pentostatin which could result in a higher serum level.
DB13145
Lorazepam may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
DB00314
Lorazepam may decrease the excretion rate of Capreomycin which could result in a higher serum level.
DB00390
Lorazepam may decrease the excretion rate of Digoxin which could result in a higher serum level.
DB00512
Lorazepam may decrease the excretion rate of Vancomycin which could result in a higher serum level.
DB00515
Lorazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
DB00642
Lorazepam may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
DB01035
Lorazepam may decrease the excretion rate of Procainamide which could result in a higher serum level.
DB12615
Lorazepam may decrease the excretion rate of Plazomicin which could result in a higher serum level.
DB00803
Colistin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00524
Lorazepam may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.
DB00695
Lorazepam may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.
DB00808
Lorazepam may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00887
Lorazepam may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.
DB08907
Lorazepam may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
DB09338
Lorazepam may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.
DB00214
Torasemide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00232
Methyclothiazide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00310
Chlorthalidone may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00311
Ethoxzolamide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00421
Spironolactone may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00436
Bendroflumethiazide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00562
Benzthiazide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00594
Amiloride may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00606
Cyclothiazide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00774
Hydroflumethiazide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00880
Chlorothiazide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB01021
Trichlormethiazide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB01119
Diazoxide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB01144
Diclofenamide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB01324
Polythiazide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB01325
Quinethazone may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB02925
Piretanide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB04831
Tienilic acid may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB05034
Ularitide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB08961
Azosemide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB09015
Canrenoic acid may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB09125
Potassium citrate may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB11827
Ertugliflozin may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB12221
Canrenone may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB12670
Rolofylline may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB12704
Spiradoline may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB12766
Cicletanine may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB13284
Meticrane may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB13405
Mefruside may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB13430
Mebutizide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB13532
Cyclopenthiazide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB13617
Clorexolone may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB13663
Clofenamide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB13708
Fenquizone may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB13792
Clopamide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB13801
Muzolimine may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB13803
Xipamide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB13989
Epitizide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB14500
Potassium may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00703
Methazolamide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB06292
Dapagliflozin may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB00700
Eplerenone may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.
DB01345
Lorazepam may increase the excretion rate of Potassium cation which could result in a lower serum level and potentially a reduction in efficacy.
DB09046
The metabolism of Lorazepam can be increased when combined with Metreleptin.
DB08909
The metabolism of Glycerol phenylbutyrate can be increased when combined with Lorazepam.
DB11560
The metabolism of Lesinurad can be increased when combined with Lorazepam.
DB00615
The metabolism of Lorazepam can be increased when combined with Rifabutin.
DB01645
The metabolism of Lorazepam can be increased when combined with Genistein.
DB04911
The metabolism of Lorazepam can be increased when combined with Oritavancin.
DB06413
The metabolism of Lorazepam can be increased when combined with Armodafinil.
DB09078
The metabolism of Lorazepam can be increased when combined with Lenvatinib.
DB11586
The metabolism of Lorazepam can be increased when combined with Asunaprevir.
DB11767
The metabolism of Lorazepam can be increased when combined with Sarilumab.
DB00316
The metabolism of Acetaminophen can be increased when combined with Lorazepam.
DB00591
The metabolism of Fluocinolone acetonide can be increased when combined with Lorazepam.
DB00624
The metabolism of Testosterone can be increased when combined with Lorazepam.
DB01011
The metabolism of Metyrapone can be increased when combined with Lorazepam.
DB04920
The metabolism of Clevidipine can be increased when combined with Lorazepam.
DB08905
The metabolism of Formestane can be increased when combined with Lorazepam.
DB08911
The metabolism of Trametinib can be increased when combined with Lorazepam.
DB13943
The metabolism of Testosterone cypionate can be increased when combined with Lorazepam.
DB13946
The metabolism of Testosterone undecanoate can be increased when combined with Lorazepam.
DB13952
The metabolism of Estradiol acetate can be increased when combined with Lorazepam.
DB13955
The metabolism of Estradiol dienanthate can be increased when combined with Lorazepam.
DB00082
The metabolism of Lorazepam can be increased when combined with Pegvisomant.
DB00136
The metabolism of Lorazepam can be increased when combined with Calcitriol.
DB00180
The metabolism of Lorazepam can be increased when combined with Flunisolide.
DB00197
The metabolism of Lorazepam can be increased when combined with Troglitazone.
DB00301
The metabolism of Lorazepam can be increased when combined with Flucloxacillin.
DB00338
The metabolism of Lorazepam can be increased when combined with Omeprazole.
DB00357
The metabolism of Lorazepam can be increased when combined with Aminoglutethimide.
DB00394
The metabolism of Lorazepam can be increased when combined with Beclomethasone dipropionate.
DB00400
The metabolism of Lorazepam can be increased when combined with Griseofulvin.
DB00439
The metabolism of Lorazepam can be increased when combined with Cerivastatin.
DB00443
The metabolism of Lorazepam can be increased when combined with Betamethasone.
DB00448
The metabolism of Lorazepam can be increased when combined with Lansoprazole.
DB00485
The metabolism of Lorazepam can be increased when combined with Dicloxacillin.
DB00620
The metabolism of Lorazepam can be increased when combined with Triamcinolone.
DB00636
The metabolism of Lorazepam can be increased when combined with Clofibrate.
DB00741
The metabolism of Lorazepam can be increased when combined with Hydrocortisone.
DB00769
The metabolism of Lorazepam can be increased when combined with Hydrocortamate.
DB00857
The metabolism of Lorazepam can be increased when combined with Terbinafine.
DB00860
The metabolism of Lorazepam can be increased when combined with Prednisolone.
DB00959
The metabolism of Lorazepam can be increased when combined with Methylprednisolone.
DB01138
The metabolism of Lorazepam can be increased when combined with Sulfinpyrazone.
DB01201
The metabolism of Lorazepam can be increased when combined with Rifapentine.
DB01285
The metabolism of Lorazepam can be increased when combined with Corticotropin.
DB01380
The metabolism of Lorazepam can be increased when combined with Cortisone acetate.
DB01384
The metabolism of Lorazepam can be increased when combined with Paramethasone.
DB01609
The metabolism of Lorazepam can be increased when combined with Deferasirox.
DB04905
The metabolism of Lorazepam can be increased when combined with Tesmilifene.
DB06636
The metabolism of Lorazepam can be increased when combined with Isavuconazonium.
DB06708
The metabolism of Lorazepam can be increased when combined with Lumefantrine.
DB06739
The metabolism of Lorazepam can be increased when combined with Seratrodast.
DB08906
The metabolism of Lorazepam can be increased when combined with Fluticasone furoate.
DB08970
The metabolism of Lorazepam can be increased when combined with Fluprednidene.
DB09383
The metabolism of Lorazepam can be increased when combined with Meprednisone.
DB11487
The metabolism of Lorazepam can be increased when combined with Dexamethasone isonicotinate.
DB11921
The metabolism of Lorazepam can be increased when combined with Deflazacort.
DB13003
The metabolism of Lorazepam can be increased when combined with Cortivazol.
DB13208
The metabolism of Lorazepam can be increased when combined with Prednylidene.
DB13843
The metabolism of Lorazepam can be increased when combined with Cloprednol.
DB13867
The metabolism of Lorazepam can be increased when combined with Fluticasone.
DB14512
The metabolism of Lorazepam can be increased when combined with Mometasone furoate.
DB14539
The metabolism of Lorazepam can be increased when combined with Hydrocortisone acetate.
DB14545
The metabolism of Lorazepam can be increased when combined with Hydrocortisone succinate.
DB14631
The metabolism of Lorazepam can be increased when combined with Prednisolone phosphate.
DB14633
The metabolism of Lorazepam can be increased when combined with Prednisolone hemisuccinate.
DB14644
The metabolism of Lorazepam can be increased when combined with Methylprednisolone hemisuccinate.
DB14646
The metabolism of Lorazepam can be increased when combined with Prednisone acetate.
DB14652
The metabolism of Lorazepam can be increased when combined with Clocortolone acetate.
DB14659
The metabolism of Lorazepam can be increased when combined with Melengestrol acetate.
DB14669
The metabolism of Lorazepam can be increased when combined with Betamethasone phosphate.
DB14681
The metabolism of Lorazepam can be increased when combined with Cortisone.
DB00602
The metabolism of Lorazepam can be increased when combined with Ivermectin.
DB00163
The metabolism of Lorazepam can be increased when combined with Vitamin E.
DB00776
The metabolism of Lorazepam can be increased when combined with Oxcarbazepine.
DB01222
The metabolism of Lorazepam can be increased when combined with Budesonide.
DB01394
The metabolism of Lorazepam can be increased when combined with Colchicine.
DB06717
The metabolism of Lorazepam can be increased when combined with Fosaprepitant.
DB01115
The metabolism of Nifedipine can be increased when combined with Lorazepam.
DB01013
The metabolism of Lorazepam can be increased when combined with Clobetasol propionate.
DB01047
The metabolism of Lorazepam can be increased when combined with Fluocinonide.
DB14540
The metabolism of Lorazepam can be increased when combined with Hydrocortisone butyrate.
DB00764
The metabolism of Lorazepam can be increased when combined with Mometasone.
DB15822
The metabolism of Lorazepam can be increased when combined with Pralsetinib.
DB08971
The metabolism of Lorazepam can be increased when combined with Fluocortolone.
DB11750
The metabolism of Lorazepam can be increased when combined with Clobetasol.
DB15566
The metabolism of Lorazepam can be increased when combined with Prednisolone acetate.
DB09095
The metabolism of Difluocortolone can be increased when combined with Lorazepam.
DB01369
The metabolism of Lorazepam can be decreased when combined with Quinupristin.
DB01764
The metabolism of Lorazepam can be decreased when combined with Dalfopristin.
DB04894
The metabolism of Lorazepam can be decreased when combined with Vapreotide.
DB05928
The metabolism of Lorazepam can be decreased when combined with Dovitinib.
DB06663
The metabolism of Lorazepam can be decreased when combined with Pasireotide.
DB06791
The metabolism of Lorazepam can be decreased when combined with Lanreotide.
DB09099
The metabolism of Lorazepam can be decreased when combined with Somatostatin.
DB00778
The metabolism of Roxithromycin can be decreased when combined with Lorazepam.
DB01016
The metabolism of Glyburide can be decreased when combined with Lorazepam.
DB01259
The metabolism of Lapatinib can be decreased when combined with Lorazepam.
DB08820
The metabolism of Ivacaftor can be decreased when combined with Lorazepam.
DB09238
The metabolism of Manidipine can be decreased when combined with Lorazepam.
DB12332
The metabolism of Rucaparib can be decreased when combined with Lorazepam.
DB13941
The metabolism of Piperaquine can be decreased when combined with Lorazepam.
DB13879
The metabolism of Lorazepam can be decreased when combined with Glecaprevir.
DB11837
The metabolism of Lorazepam can be decreased when combined with Osilodrostat.
DB08864
The metabolism of Lorazepam can be decreased when combined with Rilpivirine.
DB04794
The metabolism of Lorazepam can be decreased when combined with Bifonazole.
DB00041
The metabolism of Lorazepam can be decreased when combined with Aldesleukin.
DB00254
The metabolism of Doxycycline can be decreased when combined with Lorazepam.
DB00435
The metabolism of Nitric Oxide can be decreased when combined with Lorazepam.
DB00759
The metabolism of Tetracycline can be decreased when combined with Lorazepam.
DB01015
The metabolism of Sulfamethoxazole can be decreased when combined with Lorazepam.
DB01093
The metabolism of Dimethyl sulfoxide can be decreased when combined with Lorazepam.
DB01129
The metabolism of Rabeprazole can be decreased when combined with Lorazepam.
DB01275
The metabolism of Hydralazine can be decreased when combined with Lorazepam.
DB01685
The metabolism of Topiroxostat can be decreased when combined with Lorazepam.
DB00317
The metabolism of Lorazepam can be decreased when combined with Gefitinib.
DB00353
The metabolism of Lorazepam can be decreased when combined with Methylergometrine.
DB00446
The metabolism of Lorazepam can be decreased when combined with Chloramphenicol.
DB00481
The metabolism of Lorazepam can be decreased when combined with Raloxifene.
DB00549
The metabolism of Lorazepam can be decreased when combined with Zafirlukast.
DB00627
The metabolism of Lorazepam can be decreased when combined with Niacin.
DB00668
The metabolism of Lorazepam can be decreased when combined with Epinephrine.
DB00678
The metabolism of Lorazepam can be decreased when combined with Losartan.
DB00845
The metabolism of Lorazepam can be decreased when combined with Clofazimine.
DB00954
The metabolism of Lorazepam can be decreased when combined with Dirithromycin.
DB01029
The metabolism of Lorazepam can be decreased when combined with Irbesartan.
DB01059
The metabolism of Lorazepam can be decreased when combined with Norfloxacin.
DB01062
The metabolism of Lorazepam can be decreased when combined with Oxybutynin.
DB01071
The metabolism of Lorazepam can be decreased when combined with Mequitazine.
DB01085
The metabolism of Lorazepam can be decreased when combined with Pilocarpine.
DB01152
The metabolism of Lorazepam can be decreased when combined with Candicidin.
DB01204
The metabolism of Lorazepam can be decreased when combined with Mitoxantrone.
DB01388
The metabolism of Lorazepam can be decreased when combined with Mibefradil.
DB01698
The metabolism of Lorazepam can be decreased when combined with Rutin.
DB01873
The metabolism of Lorazepam can be decreased when combined with Epothilone D.
DB02709
The metabolism of Lorazepam can be decreased when combined with Resveratrol.
DB03010
The metabolism of Lorazepam can be decreased when combined with Patupilone.
DB04070
The metabolism of Lorazepam can be decreased when combined with 6-Deoxyerythronolide B.
DB05482
The metabolism of Lorazepam can be decreased when combined with 7-ethyl-10-hydroxycamptothecin.
DB05814
The metabolism of Lorazepam can be decreased when combined with GPI-1485.
DB05903
The metabolism of Lorazepam can be decreased when combined with KOS-1584.
DB06174
The metabolism of Lorazepam can be decreased when combined with Noscapine.
DB06233
The metabolism of Lorazepam can be decreased when combined with Ridaforolimus.
DB06268
The metabolism of Lorazepam can be decreased when combined with Sitaxentan.
DB06318
The metabolism of Lorazepam can be decreased when combined with AVE9633.
DB06342
The metabolism of Lorazepam can be decreased when combined with Coltuximab ravtansine.
DB06370
The metabolism of Lorazepam can be decreased when combined with Indisulam.
DB06412
The metabolism of Lorazepam can be decreased when combined with Oxymetholone.
DB06419
The metabolism of Lorazepam can be decreased when combined with Cethromycin.
DB06469
The metabolism of Lorazepam can be decreased when combined with Lestaurtinib.
DB06587
The metabolism of Lorazepam can be decreased when combined with Mitemcinal.
DB06774
The metabolism of Lorazepam can be decreased when combined with Capsaicin.
DB07348
The metabolism of Lorazepam can be decreased when combined with Brefeldin A.
DB09235
The metabolism of Lorazepam can be decreased when combined with Efonidipine.
DB09308
The metabolism of Lorazepam can be decreased when combined with Solithromycin.
DB09309
The metabolism of Lorazepam can be decreased when combined with Kitasamycin.
DB11198
The metabolism of Lorazepam can be decreased when combined with Peppermint oil.
DB11383
The metabolism of Lorazepam can be decreased when combined with Carbomycin.
DB11405
The metabolism of Lorazepam can be decreased when combined with Eprinomectin.
DB11442
The metabolism of Lorazepam can be decreased when combined with Oleandomycin.
DB11459
The metabolism of Lorazepam can be decreased when combined with Selamectin.
DB11470
The metabolism of Lorazepam can be decreased when combined with Tildipirosin.
DB11471
The metabolism of Lorazepam can be decreased when combined with Tilmicosin.
DB11475
The metabolism of Lorazepam can be decreased when combined with Tylosin.
DB11554
The metabolism of Lorazepam can be decreased when combined with Tylvalosin.
DB11574
The metabolism of Lorazepam can be decreased when combined with Elbasvir.
DB11752
The metabolism of Lorazepam can be decreased when combined with Bryostatin 1.
DB11805
The metabolism of Lorazepam can be decreased when combined with Saracatinib.
DB12010
The metabolism of Lorazepam can be decreased when combined with Fostamatinib.
DB12070
The metabolism of Lorazepam can be decreased when combined with Letermovir.
DB12089
The metabolism of Lorazepam can be decreased when combined with Lorvotuzumab mertansine.
DB12245
The metabolism of Lorazepam can be decreased when combined with Triclabendazole.
DB12266
The metabolism of Lorazepam can be decreased when combined with Epofolate.
DB12391
The metabolism of Lorazepam can be decreased when combined with Sagopilone.
DB12489
The metabolism of Lorazepam can be decreased when combined with Mirvetuximab Soravtansine.
DB12532
The metabolism of Lorazepam can be decreased when combined with Oxetacaine.
DB13287
The metabolism of Lorazepam can be decreased when combined with Miocamycin.
DB13338
The metabolism of Lorazepam can be decreased when combined with Flurithromycin.
DB13409
The metabolism of Lorazepam can be decreased when combined with Rokitamycin.
DB13456
The metabolism of Lorazepam can be decreased when combined with Midecamycin.
DB13975
The metabolism of Lorazepam can be decreased when combined with Black cohosh.
DB14009
The metabolism of Medical Cannabis can be decreased when combined with Lorazepam.
DB01095
The metabolism of Lorazepam can be decreased when combined with Fluvastatin.
DB00701
The metabolism of Lorazepam can be decreased when combined with Amprenavir.
DB14635
The metabolism of Lorazepam can be decreased when combined with Curcumin sulfate.
DB01151
The metabolism of Lorazepam can be decreased when combined with Desipramine.
DB01023
The metabolism of Lorazepam can be decreased when combined with Felodipine.
DB08816
The metabolism of Lorazepam can be decreased when combined with Ticagrelor.
DB00104
The metabolism of Lorazepam can be decreased when combined with Octreotide.
DB00694
The metabolism of Lorazepam can be decreased when combined with Daunorubicin.
DB13633
The metabolism of Lorazepam can be decreased when combined with Mepartricin.
DB00619
The metabolism of Lorazepam can be decreased when combined with Imatinib.
DB00248
The metabolism of Cabergoline can be decreased when combined with Lorazepam.
DB08910
The metabolism of Pomalidomide can be decreased when combined with Lorazepam.
DB01100
The metabolism of Pimozide can be decreased when combined with Lorazepam.
DB09289
The metabolism of Tianeptine can be decreased when combined with Lorazepam.
DB00563
The metabolism of Lorazepam can be decreased when combined with Methotrexate.
DB00398
The metabolism of Sorafenib can be decreased when combined with Lorazepam.
DB01181
The metabolism of Ifosfamide can be decreased when combined with Lorazepam.
DB08877
The metabolism of Ruxolitinib can be decreased when combined with Lorazepam.
DB09570
The metabolism of Ixazomib can be decreased when combined with Lorazepam.
DB11817
The metabolism of Baricitinib can be decreased when combined with Lorazepam.
DB08912
The metabolism of Lorazepam can be decreased when combined with Dabrafenib.
DB08865
The metabolism of Lorazepam can be decreased when combined with Crizotinib.
DB11581
The metabolism of Lorazepam can be decreased when combined with Venetoclax.
DB12015
The metabolism of Lorazepam can be decreased when combined with Alpelisib.
DB00531
The metabolism of Lorazepam can be decreased when combined with Cyclophosphamide.
DB00570
The metabolism of Lorazepam can be decreased when combined with Vinblastine.
DB00675
The metabolism of Lorazepam can be decreased when combined with Tamoxifen.
DB00773
The metabolism of Lorazepam can be decreased when combined with Etoposide.
DB08881
The metabolism of Lorazepam can be decreased when combined with Vemurafenib.
DB09330
The metabolism of Lorazepam can be decreased when combined with Osimertinib.
DB12267
The metabolism of Lorazepam can be decreased when combined with Brigatinib.
DB13874
The metabolism of Lorazepam can be decreased when combined with Enasidenib.
DB14568
The metabolism of Lorazepam can be decreased when combined with Ivosidenib.
DB11703
The metabolism of Lorazepam can be decreased when combined with Acalabrutinib.
DB00444
The metabolism of Lorazepam can be decreased when combined with Teniposide.
DB00530
The metabolism of Lorazepam can be decreased when combined with Erlotinib.
DB00997
The metabolism of Lorazepam can be decreased when combined with Doxorubicin.
DB01248
The metabolism of Lorazepam can be decreased when combined with Docetaxel.
DB01268
The metabolism of Lorazepam can be decreased when combined with Sunitinib.
DB05773
The metabolism of Lorazepam can be decreased when combined with Trastuzumab emtansine.
DB06616
The metabolism of Lorazepam can be decreased when combined with Bosutinib.
DB08870
The metabolism of Lorazepam can be decreased when combined with Brentuximab vedotin.
DB08896
The metabolism of Lorazepam can be decreased when combined with Regorafenib.
DB00091
The metabolism of Cyclosporine can be decreased when combined with Lorazepam.
DB00204
The metabolism of Dofetilide can be decreased when combined with Lorazepam.
DB00277
The metabolism of Theophylline can be decreased when combined with Lorazepam.
DB00682
The metabolism of Warfarin can be decreased when combined with Lorazepam.
DB00864
The metabolism of Tacrolimus can be decreased when combined with Lorazepam.
DB00877
The metabolism of Sirolimus can be decreased when combined with Lorazepam.
DB00908
The metabolism of Quinidine can be decreased when combined with Lorazepam.
DB00946
The metabolism of Phenprocoumon can be decreased when combined with Lorazepam.
DB01008
The metabolism of Busulfan can be decreased when combined with Lorazepam.
DB01118
The metabolism of Amiodarone can be decreased when combined with Lorazepam.
DB01223
The metabolism of Aminophylline can be decreased when combined with Lorazepam.
DB01229
The metabolism of Paclitaxel can be decreased when combined with Lorazepam.
DB01254
The metabolism of Dasatinib can be decreased when combined with Lorazepam.
DB01396
The metabolism of Digitoxin can be decreased when combined with Lorazepam.
DB01418
The metabolism of Acenocoumarol can be decreased when combined with Lorazepam.
DB01590
The metabolism of Everolimus can be decreased when combined with Lorazepam.
DB04855
The metabolism of Dronedarone can be decreased when combined with Lorazepam.
DB06287
The metabolism of Temsirolimus can be decreased when combined with Lorazepam.
DB01128
The metabolism of Bicalutamide can be decreased when combined with Lorazepam.
DB05239
The metabolism of Cobimetinib can be decreased when combined with Lorazepam.
DB06589
The metabolism of Pazopanib can be decreased when combined with Lorazepam.
DB09063
The metabolism of Ceritinib can be decreased when combined with Lorazepam.
DB09073
The metabolism of Palbociclib can be decreased when combined with Lorazepam.
DB09074
The metabolism of Olaparib can be decreased when combined with Lorazepam.
DB11963
The metabolism of Dacomitinib can be decreased when combined with Lorazepam.
DB12371
The metabolism of Siponimod can be decreased when combined with Lorazepam.
DB00540
The metabolism of Nortriptyline can be decreased when combined with Lorazepam.
DB00320
The metabolism of Dihydroergotamine can be decreased when combined with Lorazepam.
DB01242
The metabolism of Clomipramine can be decreased when combined with Lorazepam.
DB06212
The metabolism of Lorazepam can be decreased when combined with Tolvaptan.
DB08827
The metabolism of Lorazepam can be decreased when combined with Lomitapide.
DB00637
The metabolism of Lorazepam can be decreased when combined with Astemizole.
DB00361
The metabolism of Vinorelbine can be decreased when combined with Lorazepam.
DB00541
The metabolism of Vincristine can be decreased when combined with Lorazepam.
DB04572
The metabolism of Thiotepa can be decreased when combined with Lorazepam.
DB05109
The metabolism of Trabectedin can be decreased when combined with Lorazepam.
DB05294
The metabolism of Vandetanib can be decreased when combined with Lorazepam.
DB11363
The metabolism of Alectinib can be decreased when combined with Lorazepam.
DB11641
The metabolism of Vinflunine can be decreased when combined with Lorazepam.
DB15035
The metabolism of Zanubrutinib can be decreased when combined with Lorazepam.
DB00188
The metabolism of Bortezomib can be decreased when combined with Lorazepam.
DB00309
The metabolism of Vindesine can be decreased when combined with Lorazepam.
DB04845
The metabolism of Ixabepilone can be decreased when combined with Lorazepam.
DB06603
The metabolism of Panobinostat can be decreased when combined with Lorazepam.
DB06626
The metabolism of Axitinib can be decreased when combined with Lorazepam.
DB08901
The metabolism of Ponatinib can be decreased when combined with Lorazepam.
DB09054
The metabolism of Idelalisib can be decreased when combined with Lorazepam.
DB09143
The metabolism of Sonidegib can be decreased when combined with Lorazepam.
DB11828
The metabolism of Neratinib can be decreased when combined with Lorazepam.
DB11986
The metabolism of Entrectinib can be decreased when combined with Lorazepam.
DB12147
The metabolism of Erdafitinib can be decreased when combined with Lorazepam.
DB12483
The metabolism of Copanlisib can be decreased when combined with Lorazepam.
DB12978
The metabolism of Pexidartinib can be decreased when combined with Lorazepam.
DB00762
The metabolism of Irinotecan can be decreased when combined with Lorazepam.
DB06176
The metabolism of Romidepsin can be decreased when combined with Lorazepam.
DB12001
The metabolism of Abemaciclib can be decreased when combined with Lorazepam.
DB06772
The metabolism of Cabazitaxel can be decreased when combined with Lorazepam.
DB00208
The metabolism of Ticlopidine can be decreased when combined with Lorazepam.
DB01039
The metabolism of Fenofibrate can be decreased when combined with Lorazepam.
DB01431
The metabolism of Allylestrenol can be decreased when combined with Lorazepam.
DB01656
The metabolism of Roflumilast can be decreased when combined with Lorazepam.
DB06480
The metabolism of Prucalopride can be decreased when combined with Lorazepam.
DB00191
The metabolism of Phentermine can be decreased when combined with Lorazepam.
DB00207
The metabolism of Azithromycin can be decreased when combined with Lorazepam.
DB00426
The metabolism of Famciclovir can be decreased when combined with Lorazepam.
DB00518
The metabolism of Albendazole can be decreased when combined with Lorazepam.
DB00590
The metabolism of Doxazosin can be decreased when combined with Lorazepam.
DB01098
The metabolism of Rosuvastatin can be decreased when combined with Lorazepam.
DB01411
The metabolism of Pranlukast can be decreased when combined with Lorazepam.
DB09030
The metabolism of Vorapaxar can be decreased when combined with Lorazepam.
DB09079
The metabolism of Nintedanib can be decreased when combined with Lorazepam.
DB11094
The metabolism of Vitamin D can be decreased when combined with Lorazepam.
DB11273
The metabolism of Dihydroergocornine can be decreased when combined with Lorazepam.
DB11952
The metabolism of Duvelisib can be decreased when combined with Lorazepam.
DB12141
The metabolism of Gilteritinib can be decreased when combined with Lorazepam.
DB12515
The metabolism of 9-aminocamptothecin can be decreased when combined with Lorazepam.
DB12952
The metabolism of Methylprednisone can be decreased when combined with Lorazepam.
DB13345
The metabolism of Dihydroergocristine can be decreased when combined with Lorazepam.
DB13385
The metabolism of Dihydroergocryptine can be decreased when combined with Lorazepam.
DB15444
The metabolism of Elexacaftor can be decreased when combined with Lorazepam.
DB12825
The metabolism of Lefamulin can be decreased when combined with Lorazepam.
DB12887
The metabolism of Tazemetostat can be decreased when combined with Lorazepam.
DB00247
The metabolism of Methysergide can be decreased when combined with Lorazepam.
DB11742
The metabolism of Ebastine can be decreased when combined with Lorazepam.
DB05077
The risk or severity of adverse effects can be increased when SLV319 is combined with Lorazepam.
DB06155
The risk or severity of adverse effects can be increased when Rimonabant is combined with Lorazepam.
DB06624
The risk or severity of adverse effects can be increased when Taranabant is combined with Lorazepam.
DB09061
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Lorazepam.
DB11903
The risk or severity of adverse effects can be increased when GW842166 is combined with Lorazepam.
DB12193
The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Lorazepam.
DB12649
The risk or severity of adverse effects can be increased when Ibipinabant is combined with Lorazepam.
DB13070
The risk or severity of adverse effects can be increased when Surinabant is combined with Lorazepam.
DB13950
The risk or severity of adverse effects can be increased when WIN 55212-2 is combined with Lorazepam.
DB14011
The risk or severity of adverse effects can be increased when Nabiximols is combined with Lorazepam.
DB14043
The risk or severity of adverse effects can be increased when Palmidrol is combined with Lorazepam.
DB14737
The risk or severity of adverse effects can be increased when Cannabinol is combined with Lorazepam.
DB00182
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Amphetamine.
DB00422
The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Lorazepam.
DB00608
The therapeutic efficacy of Chloroquine can be decreased when used in combination with Lorazepam.
DB00951
The therapeutic efficacy of Isoniazid can be decreased when used in combination with Lorazepam.
DB01004
The therapeutic efficacy of Ganciclovir can be decreased when used in combination with Lorazepam.
DB01367
The therapeutic efficacy of Rasagiline can be decreased when used in combination with Lorazepam.
DB01610
The therapeutic efficacy of Valganciclovir can be decreased when used in combination with Lorazepam.
DB11358
The therapeutic efficacy of Evening primrose oil can be decreased when used in combination with Lorazepam.
DB00291
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Chlorambucil.
DB00397
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Phenylpropanolamine.
DB00779
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Nalidixic acid.
DB00902
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Methdilazine.
DB01061
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Azlocillin.
DB01598
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Imipenem.
DB02136
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Cephalosporin analog.
DB03313
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Cephalosporin C.
DB03938
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Deacetoxycephalosporin C.
DB09449
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Sodium phosphate, monobasic.
DB11199
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Sage oil.
DB11238
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Borage oil.
DB11447
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Phenothiazine.
DB13679
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Dexchlorpheniramine.
DB13854
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Gamolenic acid.
DB14071
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Desmethylsertraline.
DB00719
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Azatadine.
DB01362
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Iohexol.
DB00281
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Lidocaine.
DB00297
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Bupivacaine.
DB01218
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Halofantrine.
DB09555
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Dexchlorpheniramine maleate.
DB14256
The therapeutic efficacy of Lorazepam can be decreased when used in combination with Centella asiatica.
DB00005
The metabolism of Lorazepam can be increased when combined with Etanercept.
DB00026
The metabolism of Lorazepam can be increased when combined with Anakinra.
DB00051
The metabolism of Lorazepam can be increased when combined with Adalimumab.
DB00065
The metabolism of Lorazepam can be increased when combined with Infliximab.
DB01281
The metabolism of Lorazepam can be increased when combined with Abatacept.
DB04956
The metabolism of Lorazepam can be increased when combined with Afelimomab.
DB05676
The metabolism of Lorazepam can be increased when combined with Apremilast.
DB06168
The metabolism of Lorazepam can be increased when combined with Canakinumab.
DB06273
The metabolism of Lorazepam can be increased when combined with Tocilizumab.
DB06372
The metabolism of Lorazepam can be increased when combined with Rilonacept.
DB06674
The metabolism of Lorazepam can be increased when combined with Golimumab.
DB08904
The metabolism of Lorazepam can be increased when combined with Certolizumab pegol.
DB09029
The metabolism of Lorazepam can be increased when combined with Secukinumab.
DB09036
The metabolism of Lorazepam can be increased when combined with Siltuximab.
DB14724
The metabolism of Lorazepam can be increased when combined with Emapalumab.
DB00295
The risk or severity of adverse effects can be increased when Morphine is combined with Lorazepam.
DB00318
The risk or severity of adverse effects can be increased when Codeine is combined with Lorazepam.
DB00327
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lorazepam.
DB00454
The risk or severity of adverse effects can be increased when Meperidine is combined with Lorazepam.
DB00497
The risk or severity of adverse effects can be increased when Oxycodone is combined with Lorazepam.
DB00611
The risk or severity of adverse effects can be increased when Butorphanol is combined with Lorazepam.
DB00652
The risk or severity of adverse effects can be increased when Pentazocine is combined with Lorazepam.
DB00704
The risk or severity of adverse effects can be increased when Naltrexone is combined with Lorazepam.
DB00708
The risk or severity of adverse effects can be increased when Sufentanil is combined with Lorazepam.
DB00802
The risk or severity of adverse effects can be increased when Alfentanil is combined with Lorazepam.
DB00813
The risk or severity of adverse effects can be increased when Fentanyl is combined with Lorazepam.
DB00844
The risk or severity of adverse effects can be increased when Nalbuphine is combined with Lorazepam.
DB00854
The risk or severity of adverse effects can be increased when Levorphanol is combined with Lorazepam.
DB00899
The risk or severity of adverse effects can be increased when Remifentanil is combined with Lorazepam.
DB01081
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lorazepam.
DB01192
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Lorazepam.
DB01209
The risk or severity of adverse effects can be increased when Dezocine is combined with Lorazepam.
DB01227
The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Lorazepam.
DB01433
The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Lorazepam.
DB01450
The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Lorazepam.
DB01452
The risk or severity of adverse effects can be increased when Diamorphine is combined with Lorazepam.
DB01459
The risk or severity of adverse effects can be increased when Bezitramide is combined with Lorazepam.
DB01466
The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Lorazepam.
DB01497
The risk or severity of adverse effects can be increased when Etorphine is combined with Lorazepam.
DB01529
The risk or severity of adverse effects can be increased when Dextromoramide is combined with Lorazepam.
DB01531
The risk or severity of adverse effects can be increased when Desomorphine is combined with Lorazepam.
DB01535
The risk or severity of adverse effects can be increased when Carfentanil is combined with Lorazepam.
DB01551
The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lorazepam.
DB01555
The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Lorazepam.
DB01565
The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lorazepam.
DB06738
The risk or severity of adverse effects can be increased when Ketobemidone is combined with Lorazepam.
DB08861
The risk or severity of adverse effects can be increased when DPDPE is combined with Lorazepam.
DB09174
The risk or severity of adverse effects can be increased when Lofentanil is combined with Lorazepam.
DB09272
The risk or severity of adverse effects can be increased when Eluxadoline is combined with Lorazepam.
DB11130
The risk or severity of adverse effects can be increased when Opium is combined with Lorazepam.
DB11609
The risk or severity of adverse effects can be increased when Normethadone is combined with Lorazepam.
DB12492
The risk or severity of adverse effects can be increased when Piritramide is combined with Lorazepam.
DB13160
The risk or severity of adverse effects can be increased when Alphaprodine is combined with Lorazepam.
DB13454
The risk or severity of adverse effects can be increased when Nicomorphine is combined with Lorazepam.
DB13478
The risk or severity of adverse effects can be increased when Meptazinol is combined with Lorazepam.
DB13605
The risk or severity of adverse effects can be increased when Phenoperidine is combined with Lorazepam.
DB13606
The risk or severity of adverse effects can be increased when Phenazocine is combined with Lorazepam.
DB13787
The risk or severity of adverse effects can be increased when Tilidine is combined with Lorazepam.
DB15360
The risk or severity of adverse effects can be increased when Carfentanil, C-11 is combined with Lorazepam.
DB15465
The risk or severity of adverse effects can be increased when Benzhydrocodone is combined with Lorazepam.
DB11823
The risk or severity of adverse effects can be increased when Lorazepam is combined with Esketamine.
DB00230
The risk or severity of adverse effects can be increased when Pregabalin is combined with Lorazepam.
DB00395
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Lorazepam.
DB06711
The risk or severity of CNS depression can be increased when Naphazoline is combined with Lorazepam.
DB00402
The risk or severity of CNS depression can be increased when Lorazepam is combined with Eszopiclone.
DB00564
Lorazepam may increase the Change in thyroid function activities of Carbamazepine.
DB00575
The risk or severity of sedation can be increased when Clonidine is combined with Lorazepam.
DB00294
The metabolism of Etonogestrel can be increased when combined with Lorazepam.
DB00351
The metabolism of Megestrol acetate can be increased when combined with Lorazepam.
DB00603
The metabolism of Medroxyprogesterone acetate can be increased when combined with Lorazepam.
DB00783
The metabolism of Estradiol can be increased when combined with Lorazepam.
DB04574
The metabolism of Estrone sulfate can be increased when combined with Lorazepam.
DB09123
The metabolism of Dienogest can be increased when combined with Lorazepam.
DB13944
The metabolism of Testosterone enanthate can be increased when combined with Lorazepam.
DB13954
The metabolism of Estradiol cypionate can be increased when combined with Lorazepam.
DB13956
The metabolism of Estradiol valerate can be increased when combined with Lorazepam.
DB09401
The metabolism of Lorazepam can be increased when combined with Isosorbide.
DB00396
The metabolism of Lorazepam can be increased when combined with Progesterone.
DB00834
The metabolism of Lorazepam can be increased when combined with Mifepristone.
DB00957
The metabolism of Lorazepam can be increased when combined with Norgestimate.
DB13953
The metabolism of Lorazepam can be increased when combined with Estradiol benzoate.
DB00255
The metabolism of Lorazepam can be increased when combined with Diethylstilbestrol.
DB00304
The metabolism of Desogestrel can be increased when combined with Lorazepam.
DB00367
The metabolism of Levonorgestrel can be increased when combined with Lorazepam.
DB00717
The metabolism of Norethisterone can be increased when combined with Lorazepam.
DB00823
The metabolism of Ethynodiol diacetate can be increased when combined with Lorazepam.
DB00977
The metabolism of Ethinylestradiol can be increased when combined with Lorazepam.
DB01357
The metabolism of Mestranol can be increased when combined with Lorazepam.
DB04839
The metabolism of Cyproterone acetate can be increased when combined with Lorazepam.
DB06713
The metabolism of Norelgestromin can be increased when combined with Lorazepam.
DB06730
The metabolism of Gestodene can be increased when combined with Lorazepam.
DB06789
The metabolism of Hydroxyprogesterone caproate can be increased when combined with Lorazepam.
DB08867
The metabolism of Ulipristal can be increased when combined with Lorazepam.
DB09371
The metabolism of Norethynodrel can be increased when combined with Lorazepam.
DB09389
The metabolism of Norgestrel can be increased when combined with Lorazepam.
DB11619
The metabolism of Gestrinone can be increased when combined with Lorazepam.
DB11636
The metabolism of Nomegestrol can be increased when combined with Lorazepam.
DB12474
The metabolism of Lynestrenol can be increased when combined with Lorazepam.
DB13528
The metabolism of Chlormadinone can be increased when combined with Lorazepam.
DB13685
The metabolism of Quingestanol can be increased when combined with Lorazepam.
DB13857
The metabolism of Demegestone can be increased when combined with Lorazepam.
DB13866
The metabolism of Etynodiol can be increased when combined with Lorazepam.
DB13981
The metabolism of Nomegestrol acetate can be increased when combined with Lorazepam.
DB01395
The metabolism of Drospirenone can be increased when combined with Lorazepam.
DB04066
The metabolism of p-Coumaric acid can be increased when combined with Lorazepam.
DB04682
The metabolism of Octylphenoxy polyethoxyethanol can be increased when combined with Lorazepam.
DB05830
The metabolism of Trestolone can be increased when combined with Lorazepam.
DB06266
The metabolism of Lonidamine can be increased when combined with Lorazepam.
DB06804
The metabolism of Nonoxynol-9 can be increased when combined with Lorazepam.
DB11507
The metabolism of Cloprostenol can be increased when combined with Lorazepam.
DB12025
The metabolism of Triptolide can be increased when combined with Lorazepam.
DB13044
The metabolism of Gossypol can be increased when combined with Lorazepam.
DB13310
The metabolism of Ormeloxifene can be increased when combined with Lorazepam.
DB13563
The metabolism of Norgestrienone can be increased when combined with Lorazepam.
DB14583
The metabolism of Segesterone acetate can be increased when combined with Lorazepam.
DB14678
The metabolism of Norethindrone enanthate can be increased when combined with Lorazepam.
DB01611
The therapeutic efficacy of Hydroxychloroquine can be decreased when used in combination with Lorazepam.
DB00924
The risk or severity of CNS depression can be increased when Lorazepam is combined with Cyclobenzaprine.
DB01233
The risk or severity of sedation can be increased when Lorazepam is combined with Metoclopramide.
DB01224
The serum concentration of Quetiapine can be increased when it is combined with Lorazepam.
DB11732
The risk or severity of adverse effects can be increased when Lorazepam is combined with Lasmiditan.
DB00388
The risk or severity of hypertension can be decreased when Lorazepam is combined with Phenylephrine.
DB06119
The serum concentration of Lorazepam can be decreased when it is combined with Cenobamate.
DB00193
The risk or severity of CNS depression can be increased when Tramadol is combined with Lorazepam.
DB00246
The risk or severity of adverse effects can be increased when Lorazepam is combined with Ziprasidone.
DB00503
The serum concentration of Lorazepam can be increased when it is combined with Ritonavir.
DB00502
The risk or severity of CNS depression can be increased when Lorazepam is combined with Haloperidol.
DB11652
The metabolism of Tucatinib can be decreased when combined with Lorazepam.
DB06283
The risk or severity of CNS depression can be increased when Lorazepam is combined with Ziconotide.
DB00472
The serum concentration of Fluoxetine can be increased when it is combined with Lorazepam.
DB12404
The risk or severity of sedation can be increased when Lorazepam is combined with Remimazolam.
DB11932
The serum concentration of Lorazepam can be increased when it is combined with Abametapir.
DB14881
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Lorazepam is combined with Oliceridine.
DB15762
The serum concentration of Lorazepam can be decreased when it is combined with Satralizumab.
序列
实验性质
Water Solubility
80 mg/L
MERCK INDEX (1996)
Melting Point
192-194
British Patent 1,022,642.
Boiling Point
533.8 ºC at 760 mm Hg
Chemspider
logP
2.39
HANSCH,C ET AL. (1995)
logS
-3.6
ADME Research, USCD
caco2 Permeability
200
Li C., Liu T., Ciu X., Uss A. and Cheng K. (2007). Society of Biomolecular Science.
pKa
13
MERCK INDEX (1996); pK1
外部标识符
resource:Drugs Product Database (DPD)
identifier:2300
resource:ChEBI
identifier:6539
resource:PubChem Compound
identifier:3958
resource:PubChem Substance
identifier:46508468
resource:KEGG Drug
identifier:D00365
resource:ChemSpider
identifier:3821
resource:BindingDB
identifier:50292627
resource:PharmGKB
identifier:PA450267
resource:Therapeutic Targets Database
identifier:DAP000237
resource:Wikipedia
identifier:Lorazepam
resource:ChEMBL
identifier:CHEMBL580
resource:RxCUI
identifier:6470
外部链接
RxList
http://www.rxlist.com/cgi/generic/loraz.htm
Drugs.com
http://www.drugs.com/lorazepam.html
路径
目标
id:BE0004797
name:GABA(A) Receptor
organism:Humans
action:positive allosteric modulator
Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31.
Sigel E, Steinmann ME: Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012 Nov 23;287(48):40224-31. doi: 10.1074/jbc.R112.386664. Epub 2012 Oct 4.
Zhu S, Noviello CM, Teng J, Walsh RM Jr, Kim JJ, Hibbs RE: Structure of a human synaptic GABAA receptor. Nature. 2018 Jul;559(7712):67-72. doi: 10.1038/s41586-018-0255-3. Epub 2018 Jun 27.
known-action:yes
name:Gamma-aminobutyric acid receptor subunit alpha-1
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
gene-name:GABRA1
locus:5q34-q35
cellular-location:Cell junction
transmembrane-regions:252-273 279-300 313-334 422-443
signal-regions:1-27
theoretical-pi:9.61
molecular-weight:51801.395
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4075GenAtlasGABRA1GenBank Gene DatabaseX13584GenBank Protein Database31631IUPHAR404Guide to Pharmacology404UniProtKBP14867UniProt AccessionGBRA1_HUMAN
synonyms:GABA(A) receptor subunit alpha-1
amino-acid-sequence:>lcl|BSEQ0010561|Gamma-aminobutyric acid receptor subunit alpha-1 MRKSPGLSDCLWAWILLLSTLTGRSYGQPSLQDELKDNTTVFTRILDRLLDGYDNRLRPG LGERVTEVKTDIFVTSFGPVSDHDMEYTIDVFFRQSWKDERLKFKGPMTVLRLNNLMASK IWTPDTFFHNGKKSVAHNMTMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAHAC PLKFGSYAYTRAEVVYEWTREPARSVVVAEDGSRLNQYDLLGQTVDSGIVQSSTGEYVVM TTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISA RNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGYAWDGKSVVPEKPKKVKDP LIKKNNTYAPTATSYTPNLARGDPGLATIAKSATIEPKEVKPETKPPEPKKTFNSVSKID RLSRIAFPLLFGIFNLVYWATYLNREPQLKAPTPHQ
gene-sequence:>lcl|BSEQ0010562|Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1) ATGAGGAAAAGTCCAGGTCTGTCTGACTGTCTTTGGGCCTGGATCCTCCTTCTGAGCACA CTGACTGGAAGAAGCTATGGACAGCCGTCATTACAAGATGAACTTAAAGACAATACCACT GTCTTCACCAGGATTTTGGACAGACTCCTAGATGGTTATGACAATCGCCTGAGACCAGGA TTGGGAGAGCGTGTAACCGAAGTGAAGACTGATATCTTCGTCACCAGTTTCGGACCCGTT TCAGACCATGATATGGAATATACAATAGATGTATTTTTCCGTCAAAGCTGGAAGGATGAA AGGTTAAAATTTAAAGGACCTATGACAGTCCTCCGGTTAAATAACCTAATGGCAAGTAAA ATCTGGACTCCGGACACATTTTTCCACAATGGAAAGAAGTCAGTGGCCCACAACATGACC ATGCCCAACAAACTCCTGCGGATCACAGAGGATGGCACCTTGCTGTACACCATGAGGCTG ACAGTGAGAGCTGAATGTCCGATGCATTTGGAGGACTTCCCTATGGATGCCCATGCTTGC CCACTAAAATTTGGAAGTTATGCTTATACAAGAGCAGAAGTTGTTTATGAATGGACCAGA GAGCCAGCACGCTCAGTGGTTGTAGCAGAAGATGGATCACGTCTAAACCAGTATGACCTT CTTGGACAAACAGTAGACTCTGGAATTGTCCAGTCAAGTACAGGAGAATATGTTGTTATG ACCACTCATTTCCACTTGAAGAGAAAGATTGGCTACTTTGTTATTCAAACATACCTGCCA TGCATAATGACAGTGATTCTCTCACAAGTCTCCTTCTGGCTCAACAGAGAGTCTGTACCA GCAAGAACTGTCTTTGGAGTAACAACTGTGCTCACCATGACAACATTGAGCATCAGTGCC AGAAACTCCCTCCCTAAGGTGGCTTATGCAACAGCTATGGATTGGTTTATTGCCGTGTGC TATGCCTTTGTGTTCTCAGCTCTGATTGAGTTTGCCACAGTAAACTATTTCACTAAGAGA GGTTATGCATGGGATGGCAAAAGTGTGGTTCCAGAAAAGCCAAAGAAAGTAAAGGATCCT CTTATTAAGAAAAACAACACTTACGCTCCAACAGCAACCAGCTACACCCCTAATTTGGCC AGGGGCGACCCGGGCTTAGCCACCATTGCTAAAAGTGCAACCATAGAACCTAAAGAGGTC AAGCCCGAAACAAAACCACCAGAACCCAAGAAAACCTTTAACAGTGTCAGCAAAATTGAC CGACTGTCAAGAATAGCCTTCCCGCTGCTATTTGGAATCTTTAACTTAGTCTACTGGGCT ACGTATTTAAACAGAGAGCCTCAGCTAAAAGCCCCCACACCACATCAATAG
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA receptor complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctiondrug bindingfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesscellular response to histamineprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmissionprocesssynaptic transmission, GABAergicprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit alpha-2
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRA2
locus:4p12
cellular-location:Cell junction
transmembrane-regions:252-273 279-300 313-334 420-441
signal-regions:1-28
theoretical-pi:9.41
molecular-weight:51325.85
chromosome-location:4
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4076GenAtlasGABRA2GenBank Gene DatabaseS62907GenBank Protein Database386422IUPHAR405Guide to Pharmacology405UniProtKBP47869UniProt AccessionGBRA2_HUMAN
synonyms:GABA(A) receptor subunit alpha-2
amino-acid-sequence:>lcl|BSEQ0037005|Gamma-aminobutyric acid receptor subunit alpha-2 MKTKLNIYNMQFLLFVFLVWDPARLVLANIQEDEAKNNITIFTRILDRLLDGYDNRLRPG LGDSITEVFTNIYVTSFGPVSDTDMEYTIDVFFRQKWKDERLKFKGPMNILRLNNLMASK IWTPDTFFHNGKKSVAHNMTMPNKLLRIQDDGTLLYTMRLTVQAECPMHLEDFPMDAHSC PLKFGSYAYTTSEVTYIWTYNASDSVQVAPDGSRLNQYDLLGQSIGKETIKSSTGEYTVM TAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISA RNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKSVVNDKKKEKASV MIQNNAYAVAVANYAPNLSKDPVLSTISKSATTPEPNKKPENKPAEAKKTFNSVSKIDRM SRIVFPVLFGTFNLVYWATYLNREPVLGVSP
gene-sequence:>lcl|BSEQ0010268|Gamma-aminobutyric acid receptor subunit alpha-2 (GABRA2) ATGAAGACAAAATTGAACATCTACAACATGCAGTTCCTGCTTTTTGTTTTCTTGGTGTGG GACCCTGCCAGGTTGGTGCTGGCTAACATCCAAGAAGATGAGGCTAAAAATAACATTACC ATCTTTACGAGAATTCTTGACAGACTTCTGGATGGTTACGATAATCGGCTTAGACCAGGA CTGGGAGACAGTATTACTGAAGTCTTCACTAACATCTACGTGACCAGTTTTGGCCCTGTC TCAGATACAGATATGGAATATACAATTGATGTTTTCTTTCGACAAAAATGGAAAGATGAA CGTTTAAAATTTAAAGGTCCTATGAATATCCTTCGACTAAACAATTTAATGGCTAGCAAA ATCTGGACTCCAGATACCTTTTTTCACAATGGGAAAAAATCAGTAGCTCATAATATGACA ATGCCAAATAAGTTGCTTCGAATTCAGGATGATGGGACTCTGCTGTATACCATGAGGCTT ACAGTTCAAGCTGAATGCCCAATGCACTTGGAGGATTTCCCAATGGATGCTCATTCATGT CCTCTGAAATTTGGCAGCTATGCATATACAACTTCAGAGGTCACTTATATTTGGACTTAC AATGCATCTGATTCAGTACAGGTTGCTCCTGATGGCTCTAGGTTAAATCAATATGACCTG CTGGGCCAATCAATCGGAAAGGAGACAATTAAATCCAGTACAGGTGAATATACTGTAATG ACAGCTCATTTCCACCTGAAAAGAAAAATTGGGTATTTTGTGATTCAAACCTATCTGCCT TGCATCATGACTGTCATTCTCTCCCAAGTTTCATTCTGGCTTAACAGAGAATCTGTGCCT GCAAGAACTGTGTTTGGAGTAACAACTGTCCTAACAATGACAACTCTAAGCATCAGTGCT CGGAATTCTCTCCCCAAAGTGGCTTATGCAACTGCCATGGACTGGTTTATTGCTGTTTGT TATGCATTTGTGTTCTCTGCCCTAATTGAATTTGCAACTGTTAATTACTTCACCAAAAGA GGATGGGCTTGGGATGGGAAGAGTGTAGTAAATGACAAGAAAAAAGAAAAGGCTTCCGTT ATGATACAGAACAACGCTTATGCAGTGGCTGTTGCCAATTATGCCCCGAATCTTTCAAAA GATCCAGTTCTCTCCACCATCTCCAAGAGTGCAACCACGCCAGAACCCAACAAGAAGCCA GAAAACAAGCCAGCTGAAGCAAAGAAAACTTTCAACAGTGTTAGCAAAATTGACAGAATG TCCAGAATAGTTTTTCCAGTTTTGTTTGGTACCTTTAATTTAGTTTACTGGGCTACATAT TTAAACAGAGAACCTGTATTAGGGGTCAGTCCTTGA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentaxoncomponentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentintegral component of synaptic vesicle membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranefunctionbenzodiazepine receptor activityfunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessneurotransmitter transportprocessregulation of membrane potentialprocessregulation of neurotransmitter levelsprocessresponse to drugprocesssynaptic transmissionprocesstransmembrane transport
name:Gamma-aminobutyric acid receptor subunit alpha-3
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRA3
locus:Xq28
cellular-location:Cell junction
transmembrane-regions:277-298 304-325 338-359 458-479
signal-regions:1-28
theoretical-pi:8.93
molecular-weight:55164.055
chromosome-location:X
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4077GenAtlasGABRA3GenBank Gene DatabaseS62908GenBank Protein Database386424IUPHAR406Guide to Pharmacology406UniProtKBP34903UniProt AccessionGBRA3_HUMAN
synonyms:GABA(A) receptor subunit alpha-3
amino-acid-sequence:>lcl|BSEQ0016119|Gamma-aminobutyric acid receptor subunit alpha-3 MIITQTSHCYMTSLGILFLINILPGTTGQGESRRQEPGDFVKQDIGGLSPKHAPDIPDDS TDNITIFTRILDRLLDGYDNRLRPGLGDAVTEVKTDIYVTSFGPVSDTDMEYTIDVFFRQ TWHDERLKFDGPMKILPLNNLLASKIWTPDTFFHNGKKSVAHNMTTPNKLLRLVDNGTLL YTMRLTIHAECPMHLEDFPMDVHACPLKFGSYAYTTAEVVYSWTLGKNKSVEVAQDGSRL NQYDLLGHVVGTEIIRSSTGEYVVMTTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLN RESVPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVN YFTKRSWAWEGKKVPEALEMKKKTPAAPAKKTSTTFNIVGTTYPINLAKDTEFSTISKGA APSASSTPTIIASPKATYVQDSPTETKTYNSVSKVDKISRIIFPVLFAIFNLVYWATYVN RESAIKGMIRKQ
gene-sequence:>lcl|BSEQ0016120|Gamma-aminobutyric acid receptor subunit alpha-3 (GABRA3) ATGATAATCACACAAACAAGTCACTGTTACATGACCAGCCTTGGGATTCTTTTCCTGATT AATATTCTCCCTGGAACCACTGGTCAAGGGGAATCAAGACGACAAGAACCCGGGGACTTT GTGAAGCAGGACATTGGCGGGCTGTCTCCTAAGCATGCCCCAGATATTCCTGATGACAGC ACTGACAACATCACTATCTTCACCAGAATCTTGGATCGTCTTCTGGACGGCTATGACAAC CGGCTGCGACCTGGGCTTGGAGATGCAGTGACTGAAGTGAAGACTGACATCTACGTGACC AGTTTTGGCCCTGTGTCAGACACTGACATGGAGTACACTATTGATGTATTTTTTCGGCAG ACATGGCATGATGAAAGACTGAAATTTGATGGCCCCATGAAGATCCTTCCACTGAACAAT CTCCTGGCTAGTAAGATCTGGACACCGGACACCTTCTTCCACAATGGCAAGAAATCAGTG GCTCATAACATGACCACGCCCAACAAGCTGCTCAGATTGGTGGACAACGGAACCCTCCTC TATACAATGAGGTTAACAATTCATGCTGAGTGTCCCATGCATTTGGAAGATTTTCCCATG GATGTGCATGCCTGCCCACTGAAGTTTGGAAGCTATGCCTATACAACAGCTGAAGTGGTT TATTCTTGGACTCTCGGAAAGAACAAATCCGTGGAAGTGGCACAGGATGGTTCTCGCTTG AACCAGTATGACCTTTTGGGCCATGTTGTTGGGACAGAGATAATCCGGTCTAGTACAGGA GAATATGTCGTCATGACAACCCACTTCCATCTCAAGCGAAAAATTGGCTACTTTGTGATC CAGACCTACTTGCCATGTATCATGACTGTCATTCTGTCACAAGTGTCGTTCTGGCTCAAC AGAGAGTCTGTTCCTGCCCGTACAGTCTTTGGTGTCACCACTGTGCTTACCATGACCACC TTGAGTATCAGTGCCAGAAATTCCTTACCTAAAGTGGCATATGCGACGGCCATGGACTGG TTCATAGCCGTCTGTTATGCCTTTGTATTTTCTGCACTGATTGAATTTGCCACTGTCAAC TATTTCACCAAGCGGAGTTGGGCTTGGGAAGGCAAGAAGGTGCCAGAGGCCCTGGAGATG AAGAAGAAAACACCAGCAGCCCCAGCAAAGAAAACCAGCACTACCTTCAACATCGTGGGG ACCACCTATCCCATCAACCTGGCCAAGGACACTGAATTTTCCACCATCTCCAAGGGCGCT GCTCCCAGTGCCTCCTCAACCCCAACAATCATTGCTTCACCCAAGGCCACCTACGTGCAG GACAGCCCGACTGAGACCAAGACCTACAACAGTGTCAGCAAGGTTGACAAAATTTCCCGC ATCATCTTTCCTGTGCTCTTTGCCATATTCAATCTGGTCTATTGGGCCACATATGTCAAC CGGGAGTCAGCTATCAAGGGCATGATCCGCAAACAGTAG
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionbenzodiazepine receptor activityfunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmissionprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit alpha-4
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRA4
locus:4p12
cellular-location:Cell junction
transmembrane-regions:259-280 285-306 318-340 524-543
signal-regions:1-35
theoretical-pi:10.0
molecular-weight:61622.645
chromosome-location:4
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4078GenAtlasGABRA4GenBank Gene DatabaseU30461GenBank Protein Database905393IUPHAR407UniProtKBP48169UniProt AccessionGBRA4_HUMAN
synonyms:GABA(A) receptor subunit alpha-4
amino-acid-sequence:>lcl|BSEQ0018959|Gamma-aminobutyric acid receptor subunit alpha-4 MVSAKKVPAIALSAGVSFALLRFLCLAVCLNESPGQNQKEEKLCTENFTRILDSLLDGYD NRLRPGFGGPVTEVKTDIYVTSFGPVSDVEMEYTMDVFFRQTWIDKRLKYDGPIEILRLN NMMVTKVWTPDTFFRNGKKSVSHNMTAPNKLFRIMRNGTILYTMRLTISAECPMRLVDFP MDGHACPLKFGSYAYPKSEMIYTWTKGPEKSVEVPKESSSLVQYDLIGQTVSSETIKSIT GEYIVMTVYFHLRRKMGYFMIQTYIPCIMTVILSQVSFWINKESVPARTVFGITTVLTMT TLSISARHSLPKVSYATAMDWFIAVCFAFVFSALIEFAAVNYFTNIQMEKAKRKTSKPPQ EVPAAPVQREKHPEAPLQNTNANLNMRKRTNALVHSESDVGNRTEVGNHSSKSSTVVQES SKGTPRSYLASSPNPFSRANAAETISAARALPSASPTSIRTGYMPRKASVGSASTRHVFG SRLQRIKTTVNTIGATGKLSATPPPSAPPPSGSGTSKIDKYARILFPVTFGAFNMVYWVV YLSKDTMEKSESLM
gene-sequence:>lcl|BSEQ0018960|Gamma-aminobutyric acid receptor subunit alpha-4 (GABRA4) ATGGTTTCTGCCAAGAAGGTACCCGCGATCGCTCTGTCCGCCGGGGTCAGTTTCGCCCTC CTGCGCTTCCTGTGCCTGGCGGTTTGTTTAAACGAATCCCCAGGACAGAACCAAAAGGAG GAGAAATTGTGCACAGAAAATTTCACCCGCATCCTGGACAGTTTGCTCGATGGTTATGAC AACAGGCTGCGTCCTGGATTTGGGGGTCCTGTTACAGAAGTGAAAACTGACATATATGTC ACCAGCTTTGGACCTGTTTCTGATGTTGAAATGGAATACACAATGGATGTGTTCTTCAGG CAGACATGGATTGACAAAAGATTAAAATATGACGGCCCCATTGAAATTTTGAGATTGAAC AATATGATGGTAACGAAAGTGTGGACCCCTGATACTTTCTTCAGGAATGGAAAGAAATCT GTCTCACATAATATGACAGCTCCAAATAAGCTTTTTAGAATTATGAGAAATGGTACTATT TTATACACAATGAGACTCACCATAAGTGCGGAGTGTCCCATGAGATTGGTGGATTTTCCC ATGGATGGTCATGCATGCCCTTTGAAATTCGGGAGTTATGCCTATCCAAAGAGTGAGATG ATCTATACCTGGACAAAAGGTCCTGAGAAATCAGTTGAAGTTCCGAAGGAGTCTTCCAGC TTAGTTCAATATGATTTGATTGGGCAAACCGTATCAAGTGAAACCATCAAATCAATTACG GGTGAATATATTGTTATGACGGTTTACTTCCACCTCAGACGGAAGATGGGTTATTTTATG ATTCAGACCTATATTCCGTGCATTATGACAGTGATTCTTTCTCAAGTTTCATTTTGGATA AATAAAGAATCAGTTCCCGCTAGGACTGTATTTGGAATAACAACTGTCCTCACCATGACC ACACTAAGCATCAGTGCACGACATTCTTTGCCCAAAGTGTCCTATGCTACCGCCATGGAC TGGTTCATAGCTGTCTGCTTTGCTTTTGTATTTTCGGCCCTTATCGAGTTTGCTGCTGTC AACTATTTCACCAATATTCAAATGGAAAAAGCCAAAAGGAAGACATCAAAGCCCCCTCAG GAAGTTCCCGCTGCTCCAGTGCAGAGAGAGAAGCATCCTGAAGCCCCTCTGCAGAATACA AATGCCAATTTGAACATGAGAAAAAGAACAAATGCTTTGGTTCACTCTGAATCTGATGTT GGCAACAGAACTGAGGTGGGAAACCATTCAAGCAAATCTTCCACAGTTGTTCAAGAATCT TCTAAAGGCACACCTCGGTCTTACTTAGCTTCCAGTCCAAACCCATTCAGCCGTGCAAAT GCAGCTGAAACCATATCTGCAGCAAGAGCACTTCCATCTGCTTCTCCTACTTCTATCCGA ACTGGATATATGCCTCGAAAGGCTTCAGTTGGATCTGCTTCTACTCGTCACGTGTTTGGA TCAAGACTGCAGAGGATAAAGACCACAGTTAATACCATAGGGGCTACTGGGAAGTTGTCA GCTACTCCTCCTCCATCGGCTCCACCACCTTCTGGATCTGGCACAAGTAAAATAGACAAA TATGCCCGTATTCTCTTTCCAGTCACATTTGGGGCATTTAACATGGTTTATTGGGTTGTT TATTTATCTAAGGACACTATGGAGAAATCAGAAAGTCTAATGTAA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionbenzodiazepine receptor activityfunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesscentral nervous system developmentprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocessregulation of response to drugprocessresponse to drugprocesssynaptic transmissionprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit alpha-5
general-function:Transporter activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRA5
locus:15q11.2-q12
cellular-location:Cell junction
transmembrane-regions:260-281 286-307 319-341 428-449
signal-regions:1-31
theoretical-pi:9.56
molecular-weight:52145.645
chromosome-location:15
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4079GenAtlasGABRA5GenBank Gene DatabaseL08485GenBank Protein Database182916IUPHAR408Guide to Pharmacology408UniProtKBP31644UniProt AccessionGBRA5_HUMAN
synonyms:GABA(A) receptor subunit alpha-5
amino-acid-sequence:>lcl|BSEQ0010331|Gamma-aminobutyric acid receptor subunit alpha-5 MDNGMFSGFIMIKNLLLFCISMNLSSHFGFSQMPTSSVKDETNDNITIFTRILDGLLDGY DNRLRPGLGERITQVRTDIYVTSFGPVSDTEMEYTIDVFFRQSWKDERLRFKGPMQRLPL NNLLASKIWTPDTFFHNGKKSIAHNMTTPNKLLRLEDDGTLLYTMRLTISAECPMQLEDF PMDAHACPLKFGSYAYPNSEVVYVWTNGSTKSVVVAEDGSRLNQYHLMGQTVGTENISTS TGEYTIMTAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTM TTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKKALEAA KIKKKREVILNKSTNAFTTGKMSHPPNIPKEQTPAGTSNTTSVSVKPSEEKTSESKKTYN SISKIDKMSRIVFPVLFGTFNLVYWATYLNREPVIKGAASPK
gene-sequence:>lcl|BSEQ0010332|Gamma-aminobutyric acid receptor subunit alpha-5 (GABRA5) ATGGACAATGGAATGTTCTCTGGTTTTATCATGATCAAAAACCTCCTTCTCTTTTGTATT TCCATGAACTTATCCAGTCACTTTGGCTTTTCACAGATGCCAACCAGTTCAGTGAAAGAT GAGACCAATGACAACATCACGATATTTACCAGGATCTTGGATGGGCTCTTGGATGGCTAC GACAACAGACTTCGGCCCGGGCTGGGAGAGCGCATCACTCAGGTGAGGACCGACATCTAC GTCACCAGCTTCGGCCCGGTGTCCGACACGGAAATGGAGTACACCATAGACGTGTTTTTC CGACAAAGCTGGAAAGATGAAAGGCTTCGGTTTAAGGGGCCCATGCAGCGCCTCCCTCTC AACAACCTCCTTGCCAGCAAGATCTGGACCCCAGACACGTTCTTCCACAACGGGAAGAAG TCCATCGCTCACAACATGACCACGCCCAACAAGCTGCTGCGGCTGGAGGACGACGGCACC CTGCTCTACACCATGCGCTTGACCATCTCTGCAGAGTGCCCCATGCAGCTTGAGGACTTC CCGATGGATGCGCACGCTTGCCCTCTGAAATTTGGCAGCTATGCGTACCCTAATTCTGAA GTCGTTTACGTCTGGACCAACGGCTCCACCAAGTCGGTGGTGGTGGCGGAAGATGGCTCC AGACTGAACCAGTACCACCTGATGGGGCAGACGGTGGGCACTGAGAACATCAGCACCAGC ACAGGCGAATACACAATCATGACAGCTCACTTCCACCTGAAAAGGAAGATTGGCTACTTT GTCATCCAGACCTACCTTCCCTGCATAATGACCGTGATCTTATCACAGGTGTCCTTTTGG CTGAACCGGGAATCAGTCCCAGCCAGGACAGTTTTTGGGGTCACCACGGTGCTGACCATG ACGACCCTCAGCATCAGCGCCAGGAACTCTCTGCCCAAAGTGGCCTACGCCACCGCCATG GACTGGTTCATAGCCGTGTGCTATGCCTTCGTCTTCTCGGCGCTGATAGAGTTTGCCACG GTCAATTACTTTACCAAGAGAGGCTGGGCCTGGGATGGCAAAAAAGCCTTGGAAGCAGCC AAGATCAAGAAAAAGCGTGAAGTCATACTAAATAAGTCAACAAACGCTTTTACAACTGGG AAGATGTCTCACCCCCCAAACATTCCGAAGGAACAGACCCCAGCAGGGACGTCGAATACA ACCTCAGTCTCAGTAAAACCCTCTGAAGAGAAGACTTCTGAAAGCAAAAAGACTTACAAC AGTATCAGCAAAATTGACAAAATGTCCCGAATCGTATTCCCAGTCTTGTTCGGCACTTTC AACTTAGTTTACTGGGCAACGTATTTGAATAGGGAGCCGGTGATAAAAGGAGCCGCCTCT CCAAAATAA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentdendritecomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentneuronal cell body membranecomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityfunctionreceptor activityfunctiontransporter activityprocessassociative learningprocessbehavioral fear responseprocessbrain developmentprocesschloride transmembrane transportprocesscochlea developmentprocessgamma-aminobutyric acid signaling pathwayprocessinner ear receptor cell developmentprocessinnervationprocession transmembrane transportprocessmitophagy in response to mitochondrial depolarizationprocessnegative regulation of neuron apoptotic processprocessneurological system processprocesspositive regulation of defense response to virus by hostprocessregulation of membrane potentialprocessresponse to drugprocesssensory perception of soundprocesssignal transductionprocesssynaptic transmissionprocesstransmembrane transportprocesstransportprocessxenophagy
name:Gamma-aminobutyric acid receptor subunit alpha-6
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRA6
locus:5q34
cellular-location:Cell junction
transmembrane-regions:243-264 269-290 301-324 420-441
signal-regions:1-19
theoretical-pi:8.4
molecular-weight:51023.69
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4080GenAtlasGABRA6GenBank Gene DatabaseS81944GenBank Protein Database1470364IUPHAR409Guide to Pharmacology409UniProtKBQ16445UniProt AccessionGBRA6_HUMAN
synonyms:GABA(A) receptor subunit alpha-6
amino-acid-sequence:>lcl|BSEQ0010540|Gamma-aminobutyric acid receptor subunit alpha-6 MASSLPWLCIILWLENALGKLEVEGNFYSENVSRILDNLLEGYDNRLRPGFGGAVTEVKT DIYVTSFGPVSDVEMEYTMDVFFRQTWTDERLKFGGPTEILSLNNLMVSKIWTPDTFFRN GKKSIAHNMTTPNKLFRIMQNGTILYTMRLTINADCPMRLVNFPMDGHACPLKFGSYAYP KSEIIYTWKKGPLYSVEVPEESSSLLQYDLIGQTVSSETIKSNTGEYVIMTVYFHLQRKM GYFMIQIYTPCIMTVILSQVSFWINKESVPARTVFGITTVLTMTTLSISARHSLPKVSYA TAMDWFIAVCFAFVFSALIEFAAVNYFTNLQTQKAKRKAQFAAPPTVTISKATEPLEAEI VLHPDSKYHLKKRITSLSLPIVSSSEANKVLTRAPILQSTPVTPPPLSPAFGGTSKIDQY SRILFPVAFAGFNLVYWVVYLSKDTMEVSSSVE
gene-sequence:>lcl|BSEQ0010541|Gamma-aminobutyric acid receptor subunit alpha-6 (GABRA6) ATGGCGTCGTCTCTGCCCTGGCTGTGCATTATTCTGTGGCTAGAAAATGCCCTAGGGAAA CTCGAAGTTGAAGGCAACTTCTACTCAGAAAACGTCAGTCGGATCCTGGACAACTTGCTT GAAGGCTATGACAATCGGCTGCGGCCGGGATTTGGAGGTGCTGTCACTGAAGTCAAAACA GACATTTATGTGACCAGTTTTGGGCCCGTGTCAGATGTGGAGATGGAGTATACGATGGAT GTTTTTTTCCGCCAGACCTGGACTGATGAGAGGTTGAAGTTTGGGGGGCCAACTGAGATT CTGAGTCTGAATAATTTGATGGTCAGTAAAATCTGGACGCCTGACACCTTTTTCAGAAAT GGTAAAAAGTCCATTGCTCACAACATGACAACTCCTAATAAACTCTTCAGAATAATGCAG AATGGAACCATTTTATACACCATGAGGCTTACCATCAATGCTGACTGTCCCATGAGGCTG GTTAACTTTCCTATGGATGGGCATGCTTGTCCACTCAAGTTTGGGAGCTATGCTTATCCC AAAAGTGAAATCATATATACGTGGAAAAAAGGACCACTTTACTCAGTAGAAGTCCCAGAA GAATCTTCAAGCCTTCTCCAGTATGATCTGATTGGACAAACAGTATCTAGTGAGACAATT AAATCTAACACAGGTGAATACGTTATAATGACAGTTTACTTCCACTTGCAAAGGAAGATG GGCTACTTCATGATACAGATATACACTCCTTGCATTATGACAGTCATTCTTTCCCAGGTG TCTTTCTGGATTAATAAGGAGTCCGTCCCAGCAAGAACTGTTTTTGGGATCACCACTGTT TTAACTATGACCACTTTGAGCATCAGTGCCCGGCACTCTTTGCCAAAAGTGTCATATGCC ACTGCCATGGATTGGTTCATAGCTGTTTGCTTTGCATTCGTCTTCTCTGCGCTTATCGAG TTCGCAGCTGTCAACTACTTTACCAATCTTCAGACACAGAAGGCCAAAAGGAAGGCACAG TTTGCAGCCCCACCCACAGTGACAATATCAAAAGCTACTGAACCTTTGGAAGCTGAGATT GTTTTGCATCCTGACTCCAAATATCATCTGAAGAAAAGGATCACTTCTCTGTCTTTGCCA ATAGTTTCATCTTCCGAGGCCAATAAAGTGCTCACGAGAGCGCCCATCTTACAATCAACA CCTGTCACACCCCCACCACTCTCGCCAGCCTTTGGAGGCACCAGTAAAATAGACCAGTAT TCTCGAATTCTCTTCCCAGTTGCATTTGCAGGATTCAACCTTGTGTACTGGGTAGTTTAT CTTTCCAAAGATACAATGGAAGTCAGTAGCAGTGTTGAATAG
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionbenzodiazepine receptor activityfunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssignal transductionprocesssynaptic transmissionprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit beta-1
general-function:Ligand-gated ion channel activity
specific-function:Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
gene-name:GABRB1
locus:4p12
cellular-location:Cell junction
transmembrane-regions:246-267 271-293 305-327 452-473
signal-regions:1-25
theoretical-pi:9.01
molecular-weight:54234.085
chromosome-location:4
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4081GenAtlasGABRB1GenBank Gene DatabaseX14767GenBank Protein Database31635IUPHAR410UniProtKBP18505UniProt AccessionGBRB1_HUMAN
synonyms:GABA(A) receptor subunit beta-1
amino-acid-sequence:>lcl|BSEQ0004603|Gamma-aminobutyric acid receptor subunit beta-1 MWTVQNRESLGLLSFPVMITMVCCAHSTNEPSNMSYVKETVDRLLKGYDIRLRPDFGGPP VDVGMRIDVASIDMVSEVNMDYTLTMYFQQSWKDKRLSYSGIPLNLTLDNRVADQLWVPD TYFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIE SYGYTTDDIEFYWNGGEGAVTGVNKIELPQFSIVDYKMVSKKVEFTTGAYPRLSLSFRLK RNIGYFILQTYMPSTLITILSWVSFWINYDASAARVALGITTVLTMTTISTHLRETLPKI PYVKAIDIYLMGCFVFVFLALLEYAFVNYIFFGKGPQKKGASKQDQSANEKNKLEMNKVQ VDAHGNILLSTLEIRNETSGSEVLTSVSDPKATMYSYDSASIQYRKPLSSREAYGRALDR HGVPSKGRIRRRASQLKVKIPDLTDVNSIDKWSRMFFPITFSLFNVVYWLYYVH
gene-sequence:>lcl|BSEQ0020610|Gamma-aminobutyric acid receptor subunit beta-1 (GABRB1) ATGTGGACAGTACAAAATCGAGAGAGTCTGGGGCTTCTCTCTTTCCCTGTGATGATTACC ATGGTCTGTTGTGCACACAGCACCAATGAACCCAGCAACATGTCATACGTGAAAGAGACA GTGGACAGATTGCTCAAAGGATATGACATTCGCTTGCGGCCGGACTTCGGAGGGCCCCCC GTCGACGTTGGGATGCGGATCGATGTCGCCAGCATAGACATGGTCTCCGAAGTGAATATG GATTATACACTCACCATGTATTTCCAGCAGTCTTGGAAAGACAAAAGGCTTTCTTATTCT GGAATCCCACTGAACCTCACCCTAGACAATAGGGTAGCTGACCAACTCTGGGTACCAGAC ACCTACTTTCTGAATGACAAGAAATCATTTGTGCATGGGGTCACAGTGAAAAATCGAATG ATTCGACTGCATCCTGATGGAACAGTTCTCTATGGACTCCGAATCACAACCACAGCTGCA TGTATGATGGATCTTCGAAGATATCCACTGGATGAGCAGAACTGCACCCTGGAGATCGAA AGTTATGGCTATACCACTGATGACATTGAATTTTACTGGAATGGAGGAGAAGGGGCAGTC ACTGGTGTTAATAAAATCGAACTTCCTCAATTTTCAATTGTTGACTACAAGATGGTGTCT AAGAAGGTGGAGTTCACAACAGGAGCGTATCCACGACTGTCACTAAGTTTTCGTCTAAAG AGAAACATTGGTTACTTCATTTTGCAAACCTACATGCCTTCTACACTGATTACAATTCTG TCCTGGGTGTCTTTTTGGATCAACTATGATGCATCTGCAGCCAGAGTCGCACTAGGAATC ACGACAGTGCTTACAATGACAACCATCAGCACCCACCTCAGGGAGACCCTGCCAAAGATC CCTTATGTCAAAGCGATTGATATTTATCTGATGGGTTGCTTTGTGTTTGTGTTCCTGGCT CTGCTGGAGTATGCCTTTGTAAATTACATCTTCTTTGGGAAAGGCCCTCAGAAAAAGGGA GCTAGCAAACAAGACCAGAGTGCCAATGAGAAGAATAAACTGGAGATGAATAAAGTCCAG GTCGACGCCCACGGTAACATTCTCCTCAGCACCCTGGAAATCCGGAATGAGACGAGTGGC TCGGAAGTGCTCACGAGCGTGAGCGACCCCAAGGCCACCATGTACTCCTATGACAGCGCC AGCATCCAGTACCGCAAGCCCCTGAGCAGCCGCGAGGCCTACGGGCGCGCCCTGGACCGG CACGGGGTACCCAGCAAGGGGCGCATCCGCAGGCGTGCCTCCCAGCTCAAAGTCAAGATC CCCGACTTGACTGATGTGAATTCCATAGACAAGTGGTCCCGAATGTTTTTCCCCATCACC TTTTCTCTTTTTAATGTCGTCTATTGGCTTTACTATGTACACTGA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentcytoplasmcomponentdendritecomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentnuclear envelopecomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionextracellular ligand-gated ion channel activityfunctionGABA-A receptor activityfunctionligand-gated ion channel activityprocesscellular response to histamineprocesscentral nervous system neuron developmentprocesschloride transmembrane transportprocession transmembrane transportprocession transportprocessneurological system processprocessovulation cycleprocessregulation of membrane potentialprocessresponse to progesteroneprocessresponse to toxic substanceprocesssignal transductionprocesssynaptic transmissionprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit beta-2
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
gene-name:GABRB2
locus:5q34
cellular-location:Cell junction
transmembrane-regions:245-266 270-292 304-326 490-511
signal-regions:1-25
theoretical-pi:9.66
molecular-weight:59149.895
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4082GenAtlasGABRB2GenBank Gene DatabaseS67368GenBank Protein Database455946IUPHAR411UniProtKBP47870UniProt AccessionGBRB2_HUMAN
synonyms:GABA(A) receptor subunit beta-2
amino-acid-sequence:>lcl|BSEQ0037195|Gamma-aminobutyric acid receptor subunit beta-2 MWRVRKRGYFGIWSFPLIIAAVCAQSVNDPSNMSLVKETVDRLLKGYDIRLRPDFGGPPV AVGMNIDIASIDMVSEVNMDYTLTMYFQQAWRDKRLSYNVIPLNLTLDNRVADQLWVPDT YFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIES YGYTTDDIEFYWRGDDNAVTGVTKIELPQFSIVDYKLITKKVVFSTGSYPRLSLSFKLKR NIGYFILQTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLPKIP YVKAIDMYLMGCFVFVFMALLEYALVNYIFFGRGPQRQKKAAEKAASANNEKMRLDVNKI FYKDIKQNGTQYRSLWDPTGNLSPTRRTTNYDFSLYTMDPHENILLSTLEIKNEMATSEA VMGLGDPRSTMLAYDASSIQYRKAGLPRHSFGRNALERHVAQKKSRLRRRASQLKITIPD LTDVNAIDRWSRIFFPVVFSFFNIVYWLYYVN
gene-sequence:>lcl|BSEQ0011685|Gamma-aminobutyric acid receptor subunit beta-2 (GABRB2) ATGTGGAGAGTGCGGAAAAGGGGCTACTTTGGGATTTGGTCCTTCCCCTTAATAATCGCC GCTGTCTGTGCGCAGAGTGTCAATGACCCTAGTAATATGTCGCTGGTTAAAGAGACGGTG GATAGACTCCTGAAAGGCTATGACATTCGTCTGAGACCAGATTTTGGAGGTCCCCCCGTG GCTGTGGGGATGAACATTGACATTGCCAGCATCGATATGGTTTCTGAAGTCAATATGGAT TATACCTTGACAATGTACTTTCAACAAGCCTGGAGAGATAAGAGGCTGTCCTATAATGTA ATACCTTTAAACTTGACTCTGGACAACAGAGTGGCAGACCAGCTCTGGGTGCCTGATACC TATTTCCTGAACGATAAGAAGTCATTTGTGCACGGAGTGACTGTTAAGAACCGCATGATT CGCCTGCATCCTGATGGCACCGTCCTTTATGGACTCAGAATCACAACCACAGCTGCCTGC ATGATGGACCTAAGGAGGTACCCACTGGATGAACAAAACTGCACCTTGGAAATTGAGAGC TATGGATACACAACTGATGACATTGAGTTTTACTGGCGTGGCGATGATAATGCAGTAACA GGAGTAACGAAAATTGAACTTCCACAGTTCTCTATTGTAGATTACAAACTTATCACCAAG AAGGTTGTTTTTTCCACAGGTTCCTATCCCAGGTTATCCCTCAGCTTTAAGCTTAAGAGA AACATTGGCTACTTTATCCTGCAAACATACATGCCTTCCATCCTGATTACCATCCTCTCC TGGGTCTCCTTCTGGATTAATTACGATGCTTCAGCTGCAAGGGTGGCATTAGGAATCACA ACTGTCCTCACAATGACCACAATCAACACCCACCTCCGGGAAACTCTCCCTAAAATCCCC TATGTGAAGGCCATTGACATGTACCTGATGGGGTGCTTTGTCTTCGTTTTCATGGCCCTT CTGGAATATGCCCTAGTCAACTACATCTTCTTTGGGAGGGGGCCCCAACGCCAAAAGAAA GCAGCTGAGAAGGCTGCCAGTGCCAACAATGAGAAGATGCGCCTGGATGTCAACAAGATG GACCCCCATGAGAACATCTTACTGAGCACTCTCGAGATAAAAAATGAAATGGCCACATCT GAGGCTGTGATGGGACTTGGAGACCCCAGAAGCACAATGCTAGCCTATGATGCCTCCAGC ATCCAGTATCGGAAAGCTGGGTTGCCCAGGCATAGTTTTGGCCGAAATGCTCTGGAACGA CATGTGGCGCAAAAGAAAAGTCGCCTGAGGAGACGCGCCTCCCAACTGAAAATCACCATC CCTGACTTGACTGATGTGAATGCCATAGATCGGTGGTCCCGCATATTCTTCCCAGTGGTT TTTTCCTTCTTCAACATCGTCTATTGGCTTTATTATGTGAACTAA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentcytosolcomponentextracellular exosomecomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesscellular response to histamineprocesschloride transmembrane transportprocesscochlea developmentprocessgamma-aminobutyric acid signaling pathwayprocessinner ear receptor cell developmentprocessinnervationprocession transmembrane transportprocessnegative regulation of neuron apoptotic processprocessneurological system processprocessregulation of membrane potentialprocesssensory perception of soundprocesssynaptic transmissionprocesssynaptic transmission, GABAergicprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit beta-3
general-function:Gaba-gated chloride ion channel activity
specific-function:Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
gene-name:GABRB3
locus:15q11.2-q12
cellular-location:Cell junction
transmembrane-regions:246-267 271-293 305-327 451-472
signal-regions:1-25
theoretical-pi:9.41
molecular-weight:54115.04
chromosome-location:15
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4083GenAtlasGABRB3GenBank Gene DatabaseM82919GenBank Protein Database182925IUPHAR412Guide to Pharmacology412UniProtKBP28472UniProt AccessionGBRB3_HUMAN
synonyms:GABA(A) receptor subunit beta-3
amino-acid-sequence:>lcl|BSEQ0004605|Gamma-aminobutyric acid receptor subunit beta-3 MWGLAGGRLFGIFSAPVLVAVVCCAQSVNDPGNMSFVKETVDKLLKGYDIRLRPDFGGPP VCVGMNIDIASIDMVSEVNMDYTLTMYFQQYWRDKRLAYSGIPLNLTLDNRVADQLWVPD TYFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIE SYGYTTDDIEFYWRGGDKAVTGVERIELPQFSIVEHRLVSRNVVFATGAYPRLSLSFRLK RNIGYFILQTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLPKI PYVKAIDMYLMGCFVFVFLALLEYAFVNYIFFGRGPQRQKKLAEKTAKAKNDRSKSESNR VDAHGNILLTSLEVHNEMNEVSGGIGDTRNSAISFDNSGIQYRKQSMPREGHGRFLGDRS LPHKKTHLRRRSSQLKIKIPDLTDVNAIDRWSRIVFPFTFSLFNLVYWLYYVN
gene-sequence:>lcl|BSEQ0016761|Gamma-aminobutyric acid receptor subunit beta-3 (GABRB3) ATGTGGGGCCTTGCGGGAGGAAGGCTTTTCGGCATCTTCTCGGCCCCGGTGCTGGTGGCT GTGGTGTGCTGCGCCCAGAGTGTGAACGATCCCGGGAACATGTCCTTTGTGAAGGAGACG GTGGACAAGCTGTTGAAAGGCTACGACATTCGCCTAAGACCCGACTTCGGGGGTCCCCCG GTCTGCGTGGGGATGAACATCGACATCGCCAGCATCGACATGGTTTCCGAAGTCAACATG GATTATACCTTAACCATGTATTTTCAACAATATTGGAGAGATAAAAGGCTCGCCTATTCT GGGATCCCTCTCAACCTCACGCTTGACAATCGAGTGGCTGACCAGCTATGGGTGCCCGAC ACATATTTCTTAAATGACAAAAAGTCATTTGTGCATGGAGTGACAGTGAAAAACCGCATG ATCCGTCTTCACCCTGATGGGACAGTGCTGTATGGGCTCAGAATCACCACGACAGCAGCA TGCATGATGGACCTCAGGAGATACCCCCTGGACGAGCAGAACTGCACTCTGGAAATTGAA AGCTATGGCTACACCACGGATGACATTGAGTTTTACTGGCGAGGCGGGGACAAGGCTGTT ACCGGAGTGGAAAGGATTGAGCTCCCGCAGTTCTCCATCGTGGAGCACCGTCTGGTCTCG AGGAATGTTGTCTTCGCCACAGGTGCCTATCCTCGACTGTCACTGAGCTTTCGGTTGAAG AGGAACATTGGATACTTCATTCTTCAGACTTATATGCCCTCTATACTGATAACGATTCTG TCGTGGGTGTCCTTCTGGATCAATTATGATGCATCTGCTGCTAGAGTTGCCCTCGGGATC ACAACTGTGCTGACAATGACAACCATCAACACCCACCTTCGGGAGACCTTGCCCAAAATC CCCTATGTCAAAGCCATTGACATGTACCTTATGGGCTGCTTCGTCTTTGTGTTCCTGGCC CTTCTGGAGTATGCCTTTGTCAACTACATTTTCTTTGGAAGAGGCCCTCAAAGGCAGAAG AAGCTTGCAGAAAAGACAGCCAAGGCAAAGAATGACCGTTCAAAGAGCGAAAGCAACCGG GTGGATGCTCATGGAAATATTCTGTTGACATCGCTGGAAGTTCACAATGAAATGAATGAG GTCTCAGGCGGCATTGGCGATACCAGGAATTCAGCAATATCCTTTGACAACTCAGGAATC CAGTACAGGAAACAGAGCATGCCTCGAGAAGGGCATGGGCGATTCCTGGGGGACAGAAGC CTCCCGCACAAGAAGACCCATCTACGGAGGAGGTCTTCACAGCTCAAAATTAAAATACCT GATCTAACCGATGTGAATGCCATAGACAGATGGTCCAGGATCGTGTTTCCATTCACTTTT TCTCTTTTCAACTTAGTTTACTGGCTGTACTATGTTAACTGA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionextracellular ligand-gated ion channel activityfunctionGABA-A receptor activityfunctionGABA-gated chloride ion channel activityprocesscellular response to histamineprocesschloride transmembrane transportprocesscochlea developmentprocessinhibitory postsynaptic potentialprocessinner ear receptor cell developmentprocessinnervationprocession transmembrane transportprocessnegative regulation of neuron apoptotic processprocessneurological system processprocesspalate developmentprocessregulation of membrane potentialprocesssensory perception of soundprocesssignal transductionprocesssynaptic transmissionprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit delta
general-function:Gaba-a receptor activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRD
locus:1p|1p36.3
cellular-location:Cell junction
transmembrane-regions:249-271 275-297 309-331 430-452
signal-regions:1-16
theoretical-pi:8.73
molecular-weight:50707.835
chromosome-location:1
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4084GenBank Gene DatabaseAF016917GenBank Protein Database2388693UniProtKBO14764UniProt AccessionGBRD_HUMAN
synonyms:GABA(A) receptor subunit delta
amino-acid-sequence:>lcl|BSEQ0012501|Gamma-aminobutyric acid receptor subunit delta MDAPARLLAPLLLLCAQQLRGTRAMNDIGDYVGSNLEISWLPNLDGLIAGYARNFRPGIG GPPVNVALALEVASIDHISEANMEYTMTVFLHQSWRDSRLSYNHTNETLGLDSRFVDKLW LPDTFIVNAKSAWFHDVTVENKLIRLQPDGVILYSIRITSTVACDMDLAKYPMDEQECML DLESYGYSSEDIVYYWSESQEHIHGLDKLQLAQFTITSYRFTTELMNFKSAGQFPRLSLH FHLRRNRGVYIIQSYMPSVLLVAMSWVSFWISQAAVPARVSLGITTVLTMTTLMVSARSS LPRASAIKALDVYFWICYVFVFAALVEYAFAHFNADYRKKQKAKVKVSRPRAEMDVRNAI VLFSLSAAGVTQELAISRRQRRVPGNLMGSYRSVGVETGETKKEGAARSGGQGGIRARLR PIDADTIDIYARAVFPAAFAAVNVIYWAAYAM
gene-sequence:>lcl|BSEQ0012502|Gamma-aminobutyric acid receptor subunit delta (GABRD) ATGGACGCGCCCGCCCGGCTGCTGGCCCCGCTCCTGCTCCTCTGCGCGCAGCAGCTCCGC GGCACCAGAGCGATGAATGACATCGGCGACTACGTGGGCTCCAACCTGGAGATCTCCTGG CTCCCCAACCTGGACGGGCTGATAGCCGGCTACGCCCGCAACTTCCGGCCTGGCATCGGA GGCCCCCCCGTGAATGTGGCCCTTGCCCTGGAGGTGGCCAGCATCGACCACATCTCAGAG GCCAACATGGAGTACACCATGACGGTGTTCCTGCACCAGAGCTGGCGGGACAGCAGGCTC TCCTACAACCACACCAACGAGACCCTGGGTCTGGACAGCCGCTTCGTGGACAAGCTGTGG CTGCCCGACACCTTCATCGTGAACGCCAAGTCGGCCTGGTTCCACGACGTGACGGTGGAG AACAAGCTCATCCGGCTGCAGCCCGACGGCGTGATCCTGTACAGCATCCGAATCACCTCC ACTGTGGCCTGCGACATGGACCTGGCCAAATACCCCATGGACGAGCAGGAGTGCATGCTG GACCTGGAGAGCTACGGTTACTCATCGGAGGACATCGTCTACTACTGGTCGGAGAGCCAG GAGCACATCCACGGGCTGGACAAGCTGCAGCTGGCGCAGTTCACCATCACCAGCTACCGC TTCACCACGGAGCTGATGAACTTCAAGTCCGCTGGCCAGTTCCCACGGCTCAGCCTGCAC TTCCACCTGCGGAGGAACCGCGGCGTGTACATCATCCAATCCTACATGCCCTCCGTCCTG CTGGTCGCCATGTCCTGGGTCTCCTTCTGGATCAGCCAGGCGGCGGTGCCCGCCAGGGTG TCTCTAGGCATCACCACGGTGCTGACGATGACCACGCTCATGGTCAGTGCCCGCTCCTCC CTGCCACGGGCATCAGCCATCAAGGCACTGGACGTCTACTTCTGGATCTGCTATGTCTTC GTGTTTGCCGCCCTGGTGGAGTACGCCTTTGCTCATTTCAACGCCGACTACAGGAAGAAG CAGAAGGCCAAGGTCAAGGTCTCCAGGCCGAGGGCAGAGATGGACGTGAGGAACGCCATT GTCCTCTTCTCCCTCTCTGCTGCCGGCGTCACGCAGGAGCTGGCCATCTCCCGCCGGCAG CGCCGCGTCCCGGGGAACCTGATGGGCTCCTACAGGTCGGTGGGGGTGGAGACAGGGGAG ACGAAGAAGGAGGGGGCAGCCCGCTCAGGAGGCCAGGGGGGCATCCGTGCCCGGCTCAGG CCCATCGACGCAGACACCATTGACATTTACGCCCGCGCTGTGTTCCCTGCGGCGTTTGCG GCCGTCAATGTCATCTACTGGGCGGCATACGCCATGTGA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionextracellular ligand-gated ion channel activityfunctionGABA-A receptor activityprocesschloride transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocesssignal transductionprocesssynaptic transmissionprocesstransport
name:Gamma-aminobutyric acid receptor subunit epsilon
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRE
locus:
cellular-location:Cell junction
transmembrane-regions:254-274 281-301 344-364 486-506
signal-regions:1-22
theoretical-pi:8.09
molecular-weight:57971.175
chromosome-location:X
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4085GenBank Gene DatabaseU66661GenBank Protein Database1857126UniProtKBP78334UniProt AccessionGBRE_HUMAN
synonyms:GABA(A) receptor subunit epsilon
amino-acid-sequence:>lcl|BSEQ0006923|Gamma-aminobutyric acid receptor subunit epsilon MLSKVLPVLLGILLILQSRVEGPQTESKNEASSRDVVYGPQPQPLENQLLSEETKSTETE TGSRVGKLPEASRILNTILSNYDHKLRPGIGEKPTVVTVEISVNSLGPLSILDMEYTIDI IFSQTWYDERLCYNDTFESLVLNGNVVSQLWIPDTFFRNSKRTHEHEITMPNQMVRIYKD GKVLYTIRMTIDAGCSLHMLRFPMDSHSCPLSFSSFSYPENEMIYKWENFKLEINEKNSW KLFQFDFTGVSNKTEIITTPVGDFMVMTIFFNVSRRFGYVAFQNYVPSSVTTMLSWVSFW IKTESAPARTSLGITSVLTMTTLGTFSRKNFPRVSYITALDFYIAICFVFCFCALLEFAV LNFLIYNQTKAHASPKLRHPRINSRAHARTRARSRACARQHQEAFVCQIVTTEGSDGEER PSCSAQQPPSPGSPEGPRSLCSKLACCEWCKRFKKYFCMVPDCEGSTWQQGRLCIHVYRL DNYSRVVFPVTFFFFNVLYWLVCLNL
gene-sequence:>lcl|BSEQ0020703|Gamma-aminobutyric acid receptor subunit epsilon (GABRE) ATGTTGTCCAAAGTTCTTCCAGTCCTCCTAGGCATCTTATTGATCCTCCAGTCGAGGGTC GAGGGACCTCAGACTGAATCAAAGAATGAAGCCTCTTCCCGTGATGTTGTCTATGGCCCC CAGCCCCAGCCTCTGGAAAATCAGCTCCTCTCTGAGGAAACAAAGTCAACTGAGACTGAG ACTGGGAGCAGAGTTGGCAAACTGCCAGAAGCCTCTCGCATCCTGAACACTATCCTGAGT AATTATGACCACAAACTGCGCCCTGGCATTGGAGAGAAGCCCACTGTGGTCACTGTTGAG ATCTCCGTCAACAGCCTTGGTCCTCTCTCTATCCTAGACATGGAATACACCATTGACATC ATCTTCTCCCAGACCTGGTACGACGAACGCCTCTGTTACAACGACACCTTTGAGTCTCTT GTTCTGAATGGCAATGTGGTGAGCCAGCTATGGATCCCGGACACCTTTTTTAGGAATTCT AAGAGGACCCACGAGCATGAGATCACCATGCCCAACCAGATGGTCCGCATCTACAAGGAT GGCAAGGTGTTGTACACAATTAGGATGACCATTGATGCCGGATGCTCACTCCACATGCTC AGATTTCCAATGGATTCTCACTCTTGCCCTCTATCTTTCTCTAGCTTTTCCTATCCTGAG AATGAGATGATCTACAAGTGGGAAAATTTCAAGCTTGAAATCAATGAGAAGAACTCCTGG AAGCTCTTCCAGTTTGATTTTACAGGAGTGAGCAACAAAACTGAAATAATCACAACCCCA GTTGGTGACTTCATGGTCATGACGATTTTCTTCAATGTGAGCAGGCGGTTTGGCTATGTT GCCTTTCAAAACTATGTCCCTTCTTCCGTGACCACGATGCTCTCCTGGGTTTCCTTTTGG ATCAAGACAGAGTCTGCTCCAGCCCGGACCTCTCTAGGGATCACCTCTGTTCTGACCATG ACCACGTTGGGCACCTTTTCTCGTAAGAATTTCCCGCGTGTCTCCTATATCACAGCCTTG GATTTCTATATCGCCATCTGCTTCGTCTTCTGCTTCTGCGCTCTGTTGGAGTTTGCTGTG CTCAACTTCCTGATCTACAACCAGACAAAAGCCCATGCTTCTCCTAAACTCCGCCATCCT CGTATCAATAGCCGTGCCCATGCCCGTACCCGTGCACGTTCCCGAGCCTGTGCCCGCCAA CATCAGGAAGCTTTTGTGTGCCAGATTGTCACCACTGAGGGAAGTGATGGAGAGGAGCGC CCGTCTTGCTCAGCCCAGCAGCCCCCTAGCCCAGGTAGCCCTGAGGGTCCCCGCAGCCTC TGCTCCAAGCTGGCCTGCTGTGAGTGGTGCAAGCGTTTTAAGAAGTACTTCTGCATGGTC CCCGATTGTGAGGGCAGTACCTGGCAGCAGGGCCGCCTCTGCATCCATGTCTACCGCCTG GATAACTACTCGAGAGTTGTTTTCCCAGTGACTTTCTTCTTCTTCAATGTGCTCTACTGG CTTGTTTGCCTTAACTTGTAG
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmissionprocesstransport
name:Gamma-aminobutyric acid receptor subunit gamma-1
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRG1
locus:4p12
cellular-location:Cell junction
transmembrane-regions:273-294 299-320 332-354 445-465
signal-regions:1-35
theoretical-pi:8.23
molecular-weight:53594.49
chromosome-location:4
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4086GenBank Gene DatabaseAK122845GenBank Protein Database193783776UniProtKBQ8N1C3UniProt AccessionGBRG1_HUMAN
synonyms:GABA(A) receptor subunit gamma-1
amino-acid-sequence:>lcl|BSEQ0012496|Gamma-aminobutyric acid receptor subunit gamma-1 MGPLKAFLFSPFLLRSQSRGVRLVFLLLTLHLGNCVDKADDEDDEDLTVNKTWVLAPKIH EGDITQILNSLLQGYDNKLRPDIGVRPTVIETDVYVNSIGPVDPINMEYTIDIIFAQTWF DSRLKFNSTMKVLMLNSNMVGKIWIPDTFFRNSRKSDAHWITTPNRLLRIWNDGRVLYTL RLTINAECYLQLHNFPMDEHSCPLEFSSYGYPKNEIEYKWKKPSVEVADPKYWRLYQFAF VGLRNSTEITHTISGDYVIMTIFFDLSRRMGYFTIQTYIPCILTVVLSWVSFWINKDAVP ARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCFIFVFAALMEYGTLHYFTSN QKGKTATKDRKLKNKASMTPGLHPGSTLIPMNNISVPQEDDYGYQCLEGKDCASFFCCFE DCRTGSWREGRIHIRIAKIDSYSRIFFPTAFALFNLVYWVGYLYL
gene-sequence:>lcl|BSEQ0012497|Gamma-aminobutyric acid receptor subunit gamma-1 (GABRG1) ATGGGTCCTTTGAAAGCTTTTCTCTTCTCCCCTTTTCTTCTGCGGAGTCAAAGTAGAGGG GTGAGGTTGGTCTTCTTGTTACTGACCCTGCATTTGGGAAACTGTGTTGATAAGGCAGAT GATGAAGATGATGAGGATTTAACGGTGAACAAAACCTGGGTCTTGGCCCCAAAAATTCAT GAAGGAGATATCACACAAATTCTGAATTCATTGCTTCAAGGCTATGACAATAAACTTCGT CCAGATATAGGAGTGAGGCCCACAGTAATTGAAACTGATGTTTATGTAAACAGCATTGGA CCAGTTGATCCAATTAATATGGAATATACAATAGATATAATTTTTGCCCAAACCTGGTTT GACAGTCGTTTAAAATTCAATAGTACCATGAAAGTGCTTATGCTTAACAGTAATATGGTT GGAAAAATTTGGATTCCTGACACTTTCTTCAGAAACTCAAGAAAATCTGATGCTCACTGG ATAACAACTCCTAATCGTCTGCTTCGAATTTGGAATGATGGACGAGTTCTGTATACTCTA AGATTGACAATTAATGCAGAATGTTATCTTCAGCTTCATAACTTTCCCATGGATGAACAT TCCTGTCCACTGGAATTTTCAAGCTATGGATACCCTAAAAATGAAATTGAGTATAAGTGG AAAAAGCCCTCCGTAGAAGTGGCTGATCCTAAATACTGGAGATTATATCAGTTTGCATTT GTAGGGTTACGGAACTCAACTGAAATCACTCACACGATCTCTGGGGATTATGTTATCATG ACAATTTTTTTTGACCTGAGCAGAAGAATGGGATATTTCACTATTCAGACCTACATTCCA TGCATTCTGACAGTTGTTCTTTCTTGGGTGTCTTTTTGGATCAATAAAGATGCAGTGCCT GCAAGAACATCGTTGGGTATCACTACAGTTCTGACTATGACAACCCTGAGTACAATTGCC AGGAAGTCTTTACCTAAGGTTTCTTATGTGACTGCGATGGATCTCTTTGTTTCTGTTTGT TTCATTTTTGTTTTTGCAGCCTTGATGGAATATGGAACCTTGCATTATTTTACCAGCAAC CAAAAAGGAAAGACTGCTACTAAAGACAGAAAGCTAAAAAATAAAGCCTCGATGACTCCT GGTCTCCATCCTGGATCCACTCTGATTCCAATGAATAATATTTCTGTGCCGCAAGAAGAT GATTATGGGTATCAGTGTTTGGAGGGCAAAGATTGTGCCAGCTTCTTCTGTTGCTTTGAA GACTGCAGAACAGGATCTTGGAGGGAAGGAAGGATACACATACGCATTGCCAAAATTGAC TCTTATTCTAGAATATTTTTCCCAACCGCTTTTGCCCTGTTCAACTTGGTTTATTGGGTT GGCTATCTTTACTTATAA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmission
name:Gamma-aminobutyric acid receptor subunit gamma-2
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
gene-name:GABRG2
locus:5q31.1-q33.1
cellular-location:Cell junction
transmembrane-regions:274-296 300-322 334-356 444-466
signal-regions:1-39
theoretical-pi:8.6
molecular-weight:54161.78
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4087GenBank Gene DatabaseX15376GenBank Protein Database31637UniProtKBP18507UniProt AccessionGBRG2_HUMAN
synonyms:GABA(A) receptor subunit gamma-2
amino-acid-sequence:>lcl|BSEQ0006917|Gamma-aminobutyric acid receptor subunit gamma-2 MSSPNIWSTGSSVYSTPVFSQKMTVWILLLLSLYPGFTSQKSDDDYEDYASNKTWVLTPK VPEGDVTVILNNLLEGYDNKLRPDIGVKPTLIHTDMYVNSIGPVNAINMEYTIDIFFAQT WYDRRLKFNSTIKVLRLNSNMVGKIWIPDTFFRNSKKADAHWITTPNRMLRIWNDGRVLY TLRLTIDAECQLQLHNFPMDEHSCPLEFSSYGYPREEIVYQWKRSSVEVGDTRSWRLYQF SFVGLRNTTEVVKTTSGDYVVMSVYFDLSRRMGYFTIQTYIPCTLIVVLSWVSFWINKDA VPARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCFIFVFSALVEYGTLHYFV SNRKPSKDKDKKKKNPAPTIDIRPRSATIQMNNATHLQERDEEYGYECLDGKDCASFFCC FEDCRTGAWRHGRIHIRIAKMDSYARIFFPTAFCLFNLVYWVSYLYL
gene-sequence:>lcl|BSEQ0019445|Gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2) ATGAGTTCGCCAAATATATGGAGCACAGGAAGCTCAGTCTACTCGACTCCTGTATTTTCA CAGAAAATGACGGTGTGGATTCTGCTCCTGCTGTCGCTCTACCCTGGCTTCACTAGCCAG AAATCTGATGATGACTATGAAGATTATGCTTCTAACAAAACATGGGTCTTGACTCCAAAA GTTCCTGAGGGTGATGTCACTGTCATCTTAAACAACCTGCTGGAAGGATATGACAATAAA CTTCGGCCTGATATAGGAGTGAAGCCAACGTTAATTCACACAGACATGTATGTGAATAGC ATTGGTCCAGTGAACGCTATCAATATGGAATACACTATTGATATATTTTTTGCGCAAACG TGGTATGACAGACGTTTGAAATTTAACAGCACCATTAAAGTCCTCCGATTGAACAGCAAC ATGGTGGGGAAAATCTGGATTCCAGACACTTTCTTCAGAAATTCCAAAAAAGCTGATGCA CACTGGATCACCACCCCCAACAGGATGCTGAGAATTTGGAATGATGGTCGAGTGCTCTAC ACCCTAAGGTTGACAATTGATGCTGAGTGCCAATTACAATTGCACAACTTTCCAATGGAT GAACACTCCTGCCCCTTGGAGTTCTCCAGTTATGGCTATCCACGTGAAGAAATTGTTTAT CAATGGAAGCGAAGTTCTGTTGAAGTGGGCGACACAAGATCCTGGAGGCTTTATCAATTC TCATTTGTTGGTCTAAGAAATACCACCGAAGTAGTGAAGACAACTTCCGGAGATTATGTG GTCATGTCTGTCTACTTTGATCTGAGCAGAAGAATGGGATACTTTACCATCCAGACCTAT ATCCCCTGCACACTCATTGTCGTCCTATCCTGGGTGTCTTTCTGGATCAATAAGGATGCT GTTCCAGCCAGAACATCTTTAGGTATCACCACTGTCCTGACAATGACCACCCTCAGCACC ATTGCCCGGAAATCGCTCCCCAAGGTCTCCTATGTCACAGCGATGGATCTCTTTGTATCT GTTTGTTTCATCTTTGTCTTCTCTGCTCTGGTGGAGTATGGCACCTTGCATTATTTTGTC AGCAACCGGAAACCAAGCAAGGACAAAGATAAAAAGAAGAAAAACCCTGCCCCTACCATT GATATCCGCCCAAGATCAGCAACCATTCAAATGAATAATGCTACACACCTTCAAGAGAGA GATGAAGAGTACGGCTATGAGTGTCTGGACGGCAAGGACTGTGCCAGTTTTTTCTGCTGT TTTGAAGATTGTCGAACAGGAGCTTGGAGACATGGGAGGATACATATCCGCATTGCCAAA ATGGACTCCTATGCTCGGATCTTCTTCCCCACTGCCTTCTGCCTGTTTAATCTGGTCTAT TGGGTCTCCTACCTCTACCTGTGA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentaxoncomponentcell junctioncomponentchloride channel complexcomponentdendrite membranecomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionbenzodiazepine receptor activityfunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocessadult behaviorprocesscellular response to histamineprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocesspost-embryonic developmentprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmissionprocesssynaptic transmission, GABAergicprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit gamma-3
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRG3
locus:15q12
cellular-location:Cell junction
transmembrane-regions:255-277 281-303 315-337 444-467
signal-regions:1-17
theoretical-pi:7.58
molecular-weight:54288.16
chromosome-location:15
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4088GenBank Gene DatabaseS82769GenBank Protein Database1754749UniProtKBQ99928UniProt AccessionGBRG3_HUMAN
synonyms:GABA(A) receptor subunit gamma-3
amino-acid-sequence:>lcl|BSEQ0006921|Gamma-aminobutyric acid receptor subunit gamma-3 MAPKLLLLLCLFSGLHARSRKVEEDEYEDSSSNQKWVLAPKSQDTDVTLILNKLLREYDK KLRPDIGIKPTVIDVDIYVNSIGPVSSINMEYQIDIFFAQTWTDSRLRFNSTMKILTLNS NMVGLIWIPDTIFRNSKTAEAHWITTPNQLLRIWNDGKILYTLRLTINAECQLQLHNFPM DEHSCPLIFSSYGYPKEEMIYRWRKNSVEAADQKSWRLYQFDFMGLRNTTEIVTTSAGDY VVMTIYFELSRRMGYFTIQTYIPCILTVVLSWVSFWIKKDATPARTALGITTVLTMTTLS TIARKSLPRVSYVTAMDLFVTVCFLFVFAALMEYATLNYYSSCRKPTTTKKTTSLLHPDS SRWIPERISLQAPSNYSLLDMRPPPTAMITLNNSVYWQEFEDTCVYECLDGKDCQSFFCC YEECKSGSWRKGRIHIDILELDSYSRVFFPTSFLLFNLVYWVGYLYL
gene-sequence:>lcl|BSEQ0012498|Gamma-aminobutyric acid receptor subunit gamma-3 (GABRG3) ATGGCCCCGAAGCTGCTGCTCCTCCTCTGCCTGTTCTCGGGCTTGCACGCGCGGTCCAGA AAGGTGGAAGAGGATGAATATGAAGATTCATCATCAAACCAAAAGTGGGTCTTGGCTCCA AAATCCCAAGACACCGACGTGACTCTTATTCTCAACAAGTTGCTAAGAGAATATGATAAA AAGCTGAGGCCAGATATTGGAATAAAACCGACCGTAATTGACGTTGACATTTATGTTAAC AGCATTGGTCCTGTGTCATCAATAAACATGGAATACCAAATTGACATATTTTTTGCTCAG ACCTGGACAGATAGTCGCCTTCGATTCAACAGCACAATGAAAATTCTTACTCTGAACAGC AACATGGTGGGGTTAATCTGGATCCCAGACACCATCTTCCGCAATTCTAAAACCGCAGAG GCTCACTGGATCACCACACCCAATCAGCTCCTCCGGATTTGGAATGACGGGAAAATCCTT TACACTTTGAGGCTCACCATCAATGCTGAGTGCCAGCTGCAGCTGCACAACTTCCCCATG GACGAACACTCCTGCCCGCTGATTTTCTCCAGCTATGGCTATCCCAAAGAAGAAATGATT TATAGATGGAGAAAAAATTCAGTGGAGGCAGCTGACCAGAAATCATGGCGGCTTTATCAG TTTGACTTCATGGGCCTCAGAAACACCACAGAAATCGTGACAACGTCTGCAGGTAGGAAT TTACTGAAAGAGGCACAGCTCTCAAAAGCCAGAGAGGCCTAA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmissionprocesstransmembrane transport
name:Gamma-aminobutyric acid receptor subunit pi
general-function:Gaba-a receptor activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to modulatory agents such as pregnanolone.
gene-name:GABRP
locus:5q33-q34
cellular-location:Cell junction
transmembrane-regions:243-266 270-292 305-327 417-438
signal-regions:1-16
theoretical-pi:6.99
molecular-weight:50639.735
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4089GenBank Gene DatabaseU95367GenBank Protein Database2197001UniProtKBO00591UniProt AccessionGBRP_HUMAN
synonyms:GABA(A) receptor subunit pi
amino-acid-sequence:>lcl|BSEQ0017152|Gamma-aminobutyric acid receptor subunit pi MNYSLHLAFVCLSLFTERMCIQGSQFNVEVGRSDKLSLPGFENLTAGYNKFLRPNFGGEP VQIALTLDIASISSISESNMDYTATIYLRQRWMDQRLVFEGNKSFTLDARLVEFLWVPDT YIVESKKSFLHEVTVGNRLIRLFSNGTVLYALRITTTVACNMDLSKYPMDTQTCKLQLES WGYDGNDVEFTWLRGNDSVRGLEHLRLAQYTIERYFTLVTRSQQETGNYTRLVLQFELRR NVLYFILETYVPSTFLVVLSWVSFWISLDSVPARTCIGVTTVLSMTTLMIGSRTSLPNTN CFIKAIDVYLGICFSFVFGALLEYAVAHYSSLQQMAAKDRGTTKEVEEVSITNIINSSIS SFKRKISFASIEISSDNVDYSDLTMKTSDKFKFVFREKMGRIVDYFTIQNPSNVDHYSKL LFPLIFMLANVFYWAYYMYF
gene-sequence:>lcl|BSEQ0017153|Gamma-aminobutyric acid receptor subunit pi (GABRP) ATGAACTACAGCCTCCACTTGGCCTTCGTGTGTCTGAGTCTCTTCACTGAGAGGATGTGC ATCCAGGGGAGTCAGTTCAACGTCGAGGTCGGCAGAAGTGACAAGCTTTCCCTGCCTGGC TTTGAGAACCTCACAGCAGGATATAACAAATTTCTCAGGCCCAATTTTGGTGGAGAACCC GTACAGATAGCGCTGACTCTGGACATTGCAAGTATCTCTAGCATTTCAGAGAGTAACATG GACTACACAGCCACCATATACCTCCGACAGCGCTGGATGGACCAGCGGCTGGTGTTTGAA GGCAACAAGAGCTTCACTCTGGATGCCCGCCTCGTGGAGTTCCTCTGGGTGCCAGATACT TACATTGTGGAGTCCAAGAAGTCCTTCCTCCATGAAGTCACTGTGGGAAACAGGCTCATC CGCCTCTTCTCCAATGGCACGGTCCTGTATGCCCTCAGAATCACGACAACTGTTGCATGT AACATGGATCTGTCTAAATACCCCATGGACACACAGACATGCAAGTTGCAGCTGGAAAGC TGGGGCTATGATGGAAATGATGTGGAGTTCACCTGGCTGAGAGGGAACGACTCTGTGCGT GGACTGGAACACCTGCGGCTTGCTCAGTACACCATAGAGCGGTATTTCACCTTAGTCACC AGATCGCAGCAGGAGACAGGAAATTACACTAGATTGGTCTTACAGTTTGAGCTTCGGAGG AATGTTCTGTATTTCATTTTGGAAACCTACGTTCCTTCCACTTTCCTGGTGGTGTTGTCC TGGGTTTCATTTTGGATCTCTCTCGATTCAGTCCCTGCAAGAACCTGCATTGGGGACAAC AAAGGAAGTAGAAGAAGTCAGTATTACTAA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionextracellular ligand-gated ion channel activityfunctionGABA-A receptor activityprocesschloride transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocesssignal transductionprocesssynaptic transmission
name:Gamma-aminobutyric acid receptor subunit theta
general-function:Transmembrane signaling receptor activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRQ
locus:
cellular-location:Cell junction
transmembrane-regions:269-289 327-347 612-632
signal-regions:1-21
theoretical-pi:5.76
molecular-weight:72020.875
chromosome-location:X
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:14454GenBank Gene DatabaseAF189259GenBank Protein Database7861736UniProtKBQ9UN88UniProt AccessionGBRT_HUMAN
synonyms:GABA(A) receptor subunit theta
amino-acid-sequence:>lcl|BSEQ0012499|Gamma-aminobutyric acid receptor subunit theta MGIRGMLRAAVILLLIRTWLAEGNYPSPIPKFHFEFSSAVPEVVLNLFNCKNCANEAVVQ KILDRVLSRYDVRLRPNFGGAPVPVRISIYVTSIEQISEMNMDYTITMFFHQTWKDSRLA YYETTLNLTLDYRMHEKLWVPDCYFLNSKDAFVHDVTVENRVFQLHPDGTVRYGIRLTTT AACSLDLHKFPMDKQACNLVVESYGYTVEDIILFWDDNGNAIHMTEELHIPQFTFLGRTI TSKEVYFYTGSYIRLILKFQVQREVNSYLVQVYWPTVLTTITSWISFWMNYDSSAARVTI GLTSMLILTTIDSHLRDKLPNISCIKAIDIYILVCLFFVFLSLLEYVYINYLFYSRGPRR QPRRHRRPRRVIARYRYQQVVVGNVQDGLINVEDGVSSLPITPAQAPLASPESLGSLTST SEQAQLATSESLSPLTSLSGQAPLATGESLSDLPSTSEQARHSYGVRFNGFQADDSIFPT EIRNRVEAHGHGVTHDHEDSNESLSSDERHGHGPSGKPMLHHGEKGVQEAGWDLDDNNDK SDCLAIKEQFKCDTNSTWGLNDDELMAHGQEKDSSSESEDSCPPSPGCSFTEGFSFDLFN PDYVPKVDKWSRFLFPLAFGLFNIVYWVYHMY
gene-sequence:>lcl|BSEQ0012500|Gamma-aminobutyric acid receptor subunit theta (GABRQ) ATGGGCATCCGAGGCATGCTGCGAGCCGCAGTGATCCTGCTGCTCATCAGGACCTGGCTC GCGGAGGGCAACTACCCCAGTCCCATCCCGAAATTCCACTTCGAGTTCTCCTCTGCTGTG CCCGAAGTCGTCCTGAACCTCTTCAACTGCAAAAATTGTGCAAATGAAGCTGTGGTTCAA AAGATTTTGGACAGGGTGCTGTCAAGATACGATGTCCGCCTGAGACCGAATTTTGGAGGT GCCCCTGTGCCTGTGAGAATATCTATTTATGTCACGAGCATTGAACAGATCTCAGAAATG AATATGGACTACACGATCACGATGTTTTTTCATCAGACTTGGAAAGATTCACGCTTAGCA TACTATGAGACCACCCTGAACTTGACCCTGGACTATCGGATGCATGAGAAGTTGTGGGTC CCTGACTGCTACTTTCTGAACAGCAAGGATGCTTTCGTGCATGATGTGACTGTGGAGAAT CGCGTGTTTCAGCTTCACCCAGATGGAACGGTGCGGTACGGCATCCGACTCACCACTACA GCAGCTTGTTCCCTGGATCTGCATAAATTCCCTATGGACAAGCAGGCCTGCAACCTGGTG GTAGAGAGCTATGGTTACACGGTTGAAGACATCATATTATTCTGGGATGACAATGGGAAC GCCATCCACATGACTGAGGAGCTGCATATCCCTCAGTTCACTTTCCTGGGAAGGACGATT ACTAGCAAGGAGGTGTATTTCTACACAGGTTCCTACATACGCCTGATACTGAAGTTCCAG GTTCAGAGGGAAGTTAACAGCTACCTTGTGCAAGTCTACTGGCCTACTGTCCTCACCACT ATTACCTCTTGGATATCGTTTTGGATGAACTATGATTCCTCTGCAGCCAGGGTGACAATT GGCTTAACTTCAATGCTCATCCTGACCACCATCGACTCACATCTGCGGGATAAGCTCCCC AACATTTCCTGTATCAAGGCCATTGATATCTATATCCTCGTGTGCTTGTTCTTTGTGTTC CTGTCCTTGCTGGAGTATGTCTACATCAACTATCTTTTCTACAGTCGAGGACCTCGGCGC CAGCCTAGGCGACACAGGAGACCCCGAAGAGTCATTGCCCGCTACCGCTACCAGCAAGTG GTGGTAGGAAACGTGCAGGATGGCCTGATTAACGTGGAAGACGGAGTCAGCTCTCTCCCC ATCACCCCAGCGCAGGCCCCCCTGGCAAGCCCGGAAAGCCTCGGTTCTTTGACGTCCACC TCCGAGCAGGCCCAGCTGGCCACCTCGGAAAGCCTCAGCCCACTCACTTCTCTCTCAGGC CAGGCCCCCCTGGCCACTGGAGAAAGCCTGAGCGATCTCCCCTCCACCTCAGAGCAGGCC CGGCACAGCTATGGTGTTCGCTTTAATGGTTTCCAGGCTGATGACAGTATTATTCCTACC GAAATCCGCAACCGTGTCGAAGCCCATGGCCATGGTGTTACCCATGACCATGAAGATTCC AATGAGAGCTTGAGCTCGGATGAGCGCCATGGCCATGGCCCCAGTGGGAAGCCCATGCTT CACCATGGCGAGAAGGGTGTGCAAGAAGCAGGCTGGGACCTTGATGACAACAATGACAAG AGCGACTGCCTTGCCATTAAGGAGCAATTCAAGTGTGATACTAACAGTACCTGGGGCCTT AATGATGATGAGCTCATGGCCCATGGCCAAGAGAAGGACAGTAGCTCAGAGTCTGAGGAT AGTTGCCCCCCAAGCCCTGGGTGCTCCTTCACTGAAGGGTTCTCCTTCGATCTCTTTAAT CCTGACTACGTCCCAAAGGTCGACAAGTGGTCCCGGTTCCTCTTCCCTCTGGCCTTTGGG TTGTTCAACATTGTTTACTGGGTATACCATATGTATTAG
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentreceptor complexcomponentsynapsefunctionchloride channel activityfunctionextracellular ligand-gated ion channel activityfunctionGABA-A receptor activityfunctionneurotransmitter transporter activityfunctiontransmembrane signaling receptor activityprocesschloride transmembrane transportprocession transmembrane transportprocessneurological system processprocessneurotransmitter transportprocessregulation of membrane potentialprocesssignal transductionprocesssynaptic transmissionprocesstransmembrane transport
id:BE0008668
name:GABA(A) Receptor Benzodiazepine Binding Site
organism:Humans
action:ligand
Zhu S, Noviello CM, Teng J, Walsh RM Jr, Kim JJ, Hibbs RE: Structure of a human synaptic GABAA receptor. Nature. 2018 Jul;559(7712):67-72. doi: 10.1038/s41586-018-0255-3. Epub 2018 Jun 27.
Sigel E, Steinmann ME: Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012 Nov 23;287(48):40224-31. doi: 10.1074/jbc.R112.386664. Epub 2012 Oct 4.
known-action:yes
name:Gamma-aminobutyric acid receptor subunit alpha-1
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
gene-name:GABRA1
locus:5q34-q35
cellular-location:Cell junction
transmembrane-regions:252-273 279-300 313-334 422-443
signal-regions:1-27
theoretical-pi:9.61
molecular-weight:51801.395
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4075GenAtlasGABRA1GenBank Gene DatabaseX13584GenBank Protein Database31631IUPHAR404Guide to Pharmacology404UniProtKBP14867UniProt AccessionGBRA1_HUMAN
synonyms:GABA(A) receptor subunit alpha-1
amino-acid-sequence:>lcl|BSEQ0010561|Gamma-aminobutyric acid receptor subunit alpha-1 MRKSPGLSDCLWAWILLLSTLTGRSYGQPSLQDELKDNTTVFTRILDRLLDGYDNRLRPG LGERVTEVKTDIFVTSFGPVSDHDMEYTIDVFFRQSWKDERLKFKGPMTVLRLNNLMASK IWTPDTFFHNGKKSVAHNMTMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAHAC PLKFGSYAYTRAEVVYEWTREPARSVVVAEDGSRLNQYDLLGQTVDSGIVQSSTGEYVVM TTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISA RNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGYAWDGKSVVPEKPKKVKDP LIKKNNTYAPTATSYTPNLARGDPGLATIAKSATIEPKEVKPETKPPEPKKTFNSVSKID RLSRIAFPLLFGIFNLVYWATYLNREPQLKAPTPHQ
gene-sequence:>lcl|BSEQ0010562|Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1) ATGAGGAAAAGTCCAGGTCTGTCTGACTGTCTTTGGGCCTGGATCCTCCTTCTGAGCACA CTGACTGGAAGAAGCTATGGACAGCCGTCATTACAAGATGAACTTAAAGACAATACCACT GTCTTCACCAGGATTTTGGACAGACTCCTAGATGGTTATGACAATCGCCTGAGACCAGGA TTGGGAGAGCGTGTAACCGAAGTGAAGACTGATATCTTCGTCACCAGTTTCGGACCCGTT TCAGACCATGATATGGAATATACAATAGATGTATTTTTCCGTCAAAGCTGGAAGGATGAA AGGTTAAAATTTAAAGGACCTATGACAGTCCTCCGGTTAAATAACCTAATGGCAAGTAAA ATCTGGACTCCGGACACATTTTTCCACAATGGAAAGAAGTCAGTGGCCCACAACATGACC ATGCCCAACAAACTCCTGCGGATCACAGAGGATGGCACCTTGCTGTACACCATGAGGCTG ACAGTGAGAGCTGAATGTCCGATGCATTTGGAGGACTTCCCTATGGATGCCCATGCTTGC CCACTAAAATTTGGAAGTTATGCTTATACAAGAGCAGAAGTTGTTTATGAATGGACCAGA GAGCCAGCACGCTCAGTGGTTGTAGCAGAAGATGGATCACGTCTAAACCAGTATGACCTT CTTGGACAAACAGTAGACTCTGGAATTGTCCAGTCAAGTACAGGAGAATATGTTGTTATG ACCACTCATTTCCACTTGAAGAGAAAGATTGGCTACTTTGTTATTCAAACATACCTGCCA TGCATAATGACAGTGATTCTCTCACAAGTCTCCTTCTGGCTCAACAGAGAGTCTGTACCA GCAAGAACTGTCTTTGGAGTAACAACTGTGCTCACCATGACAACATTGAGCATCAGTGCC AGAAACTCCCTCCCTAAGGTGGCTTATGCAACAGCTATGGATTGGTTTATTGCCGTGTGC TATGCCTTTGTGTTCTCAGCTCTGATTGAGTTTGCCACAGTAAACTATTTCACTAAGAGA GGTTATGCATGGGATGGCAAAAGTGTGGTTCCAGAAAAGCCAAAGAAAGTAAAGGATCCT CTTATTAAGAAAAACAACACTTACGCTCCAACAGCAACCAGCTACACCCCTAATTTGGCC AGGGGCGACCCGGGCTTAGCCACCATTGCTAAAAGTGCAACCATAGAACCTAAAGAGGTC AAGCCCGAAACAAAACCACCAGAACCCAAGAAAACCTTTAACAGTGTCAGCAAAATTGAC CGACTGTCAAGAATAGCCTTCCCGCTGCTATTTGGAATCTTTAACTTAGTCTACTGGGCT ACGTATTTAAACAGAGAGCCTCAGCTAAAAGCCCCCACACCACATCAATAG
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA receptor complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctiondrug bindingfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesscellular response to histamineprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmissionprocesssynaptic transmission, GABAergicprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit alpha-2
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRA2
locus:4p12
cellular-location:Cell junction
transmembrane-regions:252-273 279-300 313-334 420-441
signal-regions:1-28
theoretical-pi:9.41
molecular-weight:51325.85
chromosome-location:4
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4076GenAtlasGABRA2GenBank Gene DatabaseS62907GenBank Protein Database386422IUPHAR405Guide to Pharmacology405UniProtKBP47869UniProt AccessionGBRA2_HUMAN
synonyms:GABA(A) receptor subunit alpha-2
amino-acid-sequence:>lcl|BSEQ0037005|Gamma-aminobutyric acid receptor subunit alpha-2 MKTKLNIYNMQFLLFVFLVWDPARLVLANIQEDEAKNNITIFTRILDRLLDGYDNRLRPG LGDSITEVFTNIYVTSFGPVSDTDMEYTIDVFFRQKWKDERLKFKGPMNILRLNNLMASK IWTPDTFFHNGKKSVAHNMTMPNKLLRIQDDGTLLYTMRLTVQAECPMHLEDFPMDAHSC PLKFGSYAYTTSEVTYIWTYNASDSVQVAPDGSRLNQYDLLGQSIGKETIKSSTGEYTVM TAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISA RNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKSVVNDKKKEKASV MIQNNAYAVAVANYAPNLSKDPVLSTISKSATTPEPNKKPENKPAEAKKTFNSVSKIDRM SRIVFPVLFGTFNLVYWATYLNREPVLGVSP
gene-sequence:>lcl|BSEQ0010268|Gamma-aminobutyric acid receptor subunit alpha-2 (GABRA2) ATGAAGACAAAATTGAACATCTACAACATGCAGTTCCTGCTTTTTGTTTTCTTGGTGTGG GACCCTGCCAGGTTGGTGCTGGCTAACATCCAAGAAGATGAGGCTAAAAATAACATTACC ATCTTTACGAGAATTCTTGACAGACTTCTGGATGGTTACGATAATCGGCTTAGACCAGGA CTGGGAGACAGTATTACTGAAGTCTTCACTAACATCTACGTGACCAGTTTTGGCCCTGTC TCAGATACAGATATGGAATATACAATTGATGTTTTCTTTCGACAAAAATGGAAAGATGAA CGTTTAAAATTTAAAGGTCCTATGAATATCCTTCGACTAAACAATTTAATGGCTAGCAAA ATCTGGACTCCAGATACCTTTTTTCACAATGGGAAAAAATCAGTAGCTCATAATATGACA ATGCCAAATAAGTTGCTTCGAATTCAGGATGATGGGACTCTGCTGTATACCATGAGGCTT ACAGTTCAAGCTGAATGCCCAATGCACTTGGAGGATTTCCCAATGGATGCTCATTCATGT CCTCTGAAATTTGGCAGCTATGCATATACAACTTCAGAGGTCACTTATATTTGGACTTAC AATGCATCTGATTCAGTACAGGTTGCTCCTGATGGCTCTAGGTTAAATCAATATGACCTG CTGGGCCAATCAATCGGAAAGGAGACAATTAAATCCAGTACAGGTGAATATACTGTAATG ACAGCTCATTTCCACCTGAAAAGAAAAATTGGGTATTTTGTGATTCAAACCTATCTGCCT TGCATCATGACTGTCATTCTCTCCCAAGTTTCATTCTGGCTTAACAGAGAATCTGTGCCT GCAAGAACTGTGTTTGGAGTAACAACTGTCCTAACAATGACAACTCTAAGCATCAGTGCT CGGAATTCTCTCCCCAAAGTGGCTTATGCAACTGCCATGGACTGGTTTATTGCTGTTTGT TATGCATTTGTGTTCTCTGCCCTAATTGAATTTGCAACTGTTAATTACTTCACCAAAAGA GGATGGGCTTGGGATGGGAAGAGTGTAGTAAATGACAAGAAAAAAGAAAAGGCTTCCGTT ATGATACAGAACAACGCTTATGCAGTGGCTGTTGCCAATTATGCCCCGAATCTTTCAAAA GATCCAGTTCTCTCCACCATCTCCAAGAGTGCAACCACGCCAGAACCCAACAAGAAGCCA GAAAACAAGCCAGCTGAAGCAAAGAAAACTTTCAACAGTGTTAGCAAAATTGACAGAATG TCCAGAATAGTTTTTCCAGTTTTGTTTGGTACCTTTAATTTAGTTTACTGGGCTACATAT TTAAACAGAGAACCTGTATTAGGGGTCAGTCCTTGA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentaxoncomponentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentintegral component of synaptic vesicle membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranefunctionbenzodiazepine receptor activityfunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessneurotransmitter transportprocessregulation of membrane potentialprocessregulation of neurotransmitter levelsprocessresponse to drugprocesssynaptic transmissionprocesstransmembrane transport
name:Gamma-aminobutyric acid receptor subunit alpha-3
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRA3
locus:Xq28
cellular-location:Cell junction
transmembrane-regions:277-298 304-325 338-359 458-479
signal-regions:1-28
theoretical-pi:8.93
molecular-weight:55164.055
chromosome-location:X
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4077GenAtlasGABRA3GenBank Gene DatabaseS62908GenBank Protein Database386424IUPHAR406Guide to Pharmacology406UniProtKBP34903UniProt AccessionGBRA3_HUMAN
synonyms:GABA(A) receptor subunit alpha-3
amino-acid-sequence:>lcl|BSEQ0016119|Gamma-aminobutyric acid receptor subunit alpha-3 MIITQTSHCYMTSLGILFLINILPGTTGQGESRRQEPGDFVKQDIGGLSPKHAPDIPDDS TDNITIFTRILDRLLDGYDNRLRPGLGDAVTEVKTDIYVTSFGPVSDTDMEYTIDVFFRQ TWHDERLKFDGPMKILPLNNLLASKIWTPDTFFHNGKKSVAHNMTTPNKLLRLVDNGTLL YTMRLTIHAECPMHLEDFPMDVHACPLKFGSYAYTTAEVVYSWTLGKNKSVEVAQDGSRL NQYDLLGHVVGTEIIRSSTGEYVVMTTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLN RESVPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVN YFTKRSWAWEGKKVPEALEMKKKTPAAPAKKTSTTFNIVGTTYPINLAKDTEFSTISKGA APSASSTPTIIASPKATYVQDSPTETKTYNSVSKVDKISRIIFPVLFAIFNLVYWATYVN RESAIKGMIRKQ
gene-sequence:>lcl|BSEQ0016120|Gamma-aminobutyric acid receptor subunit alpha-3 (GABRA3) ATGATAATCACACAAACAAGTCACTGTTACATGACCAGCCTTGGGATTCTTTTCCTGATT AATATTCTCCCTGGAACCACTGGTCAAGGGGAATCAAGACGACAAGAACCCGGGGACTTT GTGAAGCAGGACATTGGCGGGCTGTCTCCTAAGCATGCCCCAGATATTCCTGATGACAGC ACTGACAACATCACTATCTTCACCAGAATCTTGGATCGTCTTCTGGACGGCTATGACAAC CGGCTGCGACCTGGGCTTGGAGATGCAGTGACTGAAGTGAAGACTGACATCTACGTGACC AGTTTTGGCCCTGTGTCAGACACTGACATGGAGTACACTATTGATGTATTTTTTCGGCAG ACATGGCATGATGAAAGACTGAAATTTGATGGCCCCATGAAGATCCTTCCACTGAACAAT CTCCTGGCTAGTAAGATCTGGACACCGGACACCTTCTTCCACAATGGCAAGAAATCAGTG GCTCATAACATGACCACGCCCAACAAGCTGCTCAGATTGGTGGACAACGGAACCCTCCTC TATACAATGAGGTTAACAATTCATGCTGAGTGTCCCATGCATTTGGAAGATTTTCCCATG GATGTGCATGCCTGCCCACTGAAGTTTGGAAGCTATGCCTATACAACAGCTGAAGTGGTT TATTCTTGGACTCTCGGAAAGAACAAATCCGTGGAAGTGGCACAGGATGGTTCTCGCTTG AACCAGTATGACCTTTTGGGCCATGTTGTTGGGACAGAGATAATCCGGTCTAGTACAGGA GAATATGTCGTCATGACAACCCACTTCCATCTCAAGCGAAAAATTGGCTACTTTGTGATC CAGACCTACTTGCCATGTATCATGACTGTCATTCTGTCACAAGTGTCGTTCTGGCTCAAC AGAGAGTCTGTTCCTGCCCGTACAGTCTTTGGTGTCACCACTGTGCTTACCATGACCACC TTGAGTATCAGTGCCAGAAATTCCTTACCTAAAGTGGCATATGCGACGGCCATGGACTGG TTCATAGCCGTCTGTTATGCCTTTGTATTTTCTGCACTGATTGAATTTGCCACTGTCAAC TATTTCACCAAGCGGAGTTGGGCTTGGGAAGGCAAGAAGGTGCCAGAGGCCCTGGAGATG AAGAAGAAAACACCAGCAGCCCCAGCAAAGAAAACCAGCACTACCTTCAACATCGTGGGG ACCACCTATCCCATCAACCTGGCCAAGGACACTGAATTTTCCACCATCTCCAAGGGCGCT GCTCCCAGTGCCTCCTCAACCCCAACAATCATTGCTTCACCCAAGGCCACCTACGTGCAG GACAGCCCGACTGAGACCAAGACCTACAACAGTGTCAGCAAGGTTGACAAAATTTCCCGC ATCATCTTTCCTGTGCTCTTTGCCATATTCAATCTGGTCTATTGGGCCACATATGTCAAC CGGGAGTCAGCTATCAAGGGCATGATCCGCAAACAGTAG
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionbenzodiazepine receptor activityfunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmissionprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit alpha-5
general-function:Transporter activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRA5
locus:15q11.2-q12
cellular-location:Cell junction
transmembrane-regions:260-281 286-307 319-341 428-449
signal-regions:1-31
theoretical-pi:9.56
molecular-weight:52145.645
chromosome-location:15
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4079GenAtlasGABRA5GenBank Gene DatabaseL08485GenBank Protein Database182916IUPHAR408Guide to Pharmacology408UniProtKBP31644UniProt AccessionGBRA5_HUMAN
synonyms:GABA(A) receptor subunit alpha-5
amino-acid-sequence:>lcl|BSEQ0010331|Gamma-aminobutyric acid receptor subunit alpha-5 MDNGMFSGFIMIKNLLLFCISMNLSSHFGFSQMPTSSVKDETNDNITIFTRILDGLLDGY DNRLRPGLGERITQVRTDIYVTSFGPVSDTEMEYTIDVFFRQSWKDERLRFKGPMQRLPL NNLLASKIWTPDTFFHNGKKSIAHNMTTPNKLLRLEDDGTLLYTMRLTISAECPMQLEDF PMDAHACPLKFGSYAYPNSEVVYVWTNGSTKSVVVAEDGSRLNQYHLMGQTVGTENISTS TGEYTIMTAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTM TTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKKALEAA KIKKKREVILNKSTNAFTTGKMSHPPNIPKEQTPAGTSNTTSVSVKPSEEKTSESKKTYN SISKIDKMSRIVFPVLFGTFNLVYWATYLNREPVIKGAASPK
gene-sequence:>lcl|BSEQ0010332|Gamma-aminobutyric acid receptor subunit alpha-5 (GABRA5) ATGGACAATGGAATGTTCTCTGGTTTTATCATGATCAAAAACCTCCTTCTCTTTTGTATT TCCATGAACTTATCCAGTCACTTTGGCTTTTCACAGATGCCAACCAGTTCAGTGAAAGAT GAGACCAATGACAACATCACGATATTTACCAGGATCTTGGATGGGCTCTTGGATGGCTAC GACAACAGACTTCGGCCCGGGCTGGGAGAGCGCATCACTCAGGTGAGGACCGACATCTAC GTCACCAGCTTCGGCCCGGTGTCCGACACGGAAATGGAGTACACCATAGACGTGTTTTTC CGACAAAGCTGGAAAGATGAAAGGCTTCGGTTTAAGGGGCCCATGCAGCGCCTCCCTCTC AACAACCTCCTTGCCAGCAAGATCTGGACCCCAGACACGTTCTTCCACAACGGGAAGAAG TCCATCGCTCACAACATGACCACGCCCAACAAGCTGCTGCGGCTGGAGGACGACGGCACC CTGCTCTACACCATGCGCTTGACCATCTCTGCAGAGTGCCCCATGCAGCTTGAGGACTTC CCGATGGATGCGCACGCTTGCCCTCTGAAATTTGGCAGCTATGCGTACCCTAATTCTGAA GTCGTTTACGTCTGGACCAACGGCTCCACCAAGTCGGTGGTGGTGGCGGAAGATGGCTCC AGACTGAACCAGTACCACCTGATGGGGCAGACGGTGGGCACTGAGAACATCAGCACCAGC ACAGGCGAATACACAATCATGACAGCTCACTTCCACCTGAAAAGGAAGATTGGCTACTTT GTCATCCAGACCTACCTTCCCTGCATAATGACCGTGATCTTATCACAGGTGTCCTTTTGG CTGAACCGGGAATCAGTCCCAGCCAGGACAGTTTTTGGGGTCACCACGGTGCTGACCATG ACGACCCTCAGCATCAGCGCCAGGAACTCTCTGCCCAAAGTGGCCTACGCCACCGCCATG GACTGGTTCATAGCCGTGTGCTATGCCTTCGTCTTCTCGGCGCTGATAGAGTTTGCCACG GTCAATTACTTTACCAAGAGAGGCTGGGCCTGGGATGGCAAAAAAGCCTTGGAAGCAGCC AAGATCAAGAAAAAGCGTGAAGTCATACTAAATAAGTCAACAAACGCTTTTACAACTGGG AAGATGTCTCACCCCCCAAACATTCCGAAGGAACAGACCCCAGCAGGGACGTCGAATACA ACCTCAGTCTCAGTAAAACCCTCTGAAGAGAAGACTTCTGAAAGCAAAAAGACTTACAAC AGTATCAGCAAAATTGACAAAATGTCCCGAATCGTATTCCCAGTCTTGTTCGGCACTTTC AACTTAGTTTACTGGGCAACGTATTTGAATAGGGAGCCGGTGATAAAAGGAGCCGCCTCT CCAAAATAA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentdendritecomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentneuronal cell body membranecomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityfunctionreceptor activityfunctiontransporter activityprocessassociative learningprocessbehavioral fear responseprocessbrain developmentprocesschloride transmembrane transportprocesscochlea developmentprocessgamma-aminobutyric acid signaling pathwayprocessinner ear receptor cell developmentprocessinnervationprocession transmembrane transportprocessmitophagy in response to mitochondrial depolarizationprocessnegative regulation of neuron apoptotic processprocessneurological system processprocesspositive regulation of defense response to virus by hostprocessregulation of membrane potentialprocessresponse to drugprocesssensory perception of soundprocesssignal transductionprocesssynaptic transmissionprocesstransmembrane transportprocesstransportprocessxenophagy
name:Gamma-aminobutyric acid receptor subunit gamma-1
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRG1
locus:4p12
cellular-location:Cell junction
transmembrane-regions:273-294 299-320 332-354 445-465
signal-regions:1-35
theoretical-pi:8.23
molecular-weight:53594.49
chromosome-location:4
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4086GenBank Gene DatabaseAK122845GenBank Protein Database193783776UniProtKBQ8N1C3UniProt AccessionGBRG1_HUMAN
synonyms:GABA(A) receptor subunit gamma-1
amino-acid-sequence:>lcl|BSEQ0012496|Gamma-aminobutyric acid receptor subunit gamma-1 MGPLKAFLFSPFLLRSQSRGVRLVFLLLTLHLGNCVDKADDEDDEDLTVNKTWVLAPKIH EGDITQILNSLLQGYDNKLRPDIGVRPTVIETDVYVNSIGPVDPINMEYTIDIIFAQTWF DSRLKFNSTMKVLMLNSNMVGKIWIPDTFFRNSRKSDAHWITTPNRLLRIWNDGRVLYTL RLTINAECYLQLHNFPMDEHSCPLEFSSYGYPKNEIEYKWKKPSVEVADPKYWRLYQFAF VGLRNSTEITHTISGDYVIMTIFFDLSRRMGYFTIQTYIPCILTVVLSWVSFWINKDAVP ARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCFIFVFAALMEYGTLHYFTSN QKGKTATKDRKLKNKASMTPGLHPGSTLIPMNNISVPQEDDYGYQCLEGKDCASFFCCFE DCRTGSWREGRIHIRIAKIDSYSRIFFPTAFALFNLVYWVGYLYL
gene-sequence:>lcl|BSEQ0012497|Gamma-aminobutyric acid receptor subunit gamma-1 (GABRG1) ATGGGTCCTTTGAAAGCTTTTCTCTTCTCCCCTTTTCTTCTGCGGAGTCAAAGTAGAGGG GTGAGGTTGGTCTTCTTGTTACTGACCCTGCATTTGGGAAACTGTGTTGATAAGGCAGAT GATGAAGATGATGAGGATTTAACGGTGAACAAAACCTGGGTCTTGGCCCCAAAAATTCAT GAAGGAGATATCACACAAATTCTGAATTCATTGCTTCAAGGCTATGACAATAAACTTCGT CCAGATATAGGAGTGAGGCCCACAGTAATTGAAACTGATGTTTATGTAAACAGCATTGGA CCAGTTGATCCAATTAATATGGAATATACAATAGATATAATTTTTGCCCAAACCTGGTTT GACAGTCGTTTAAAATTCAATAGTACCATGAAAGTGCTTATGCTTAACAGTAATATGGTT GGAAAAATTTGGATTCCTGACACTTTCTTCAGAAACTCAAGAAAATCTGATGCTCACTGG ATAACAACTCCTAATCGTCTGCTTCGAATTTGGAATGATGGACGAGTTCTGTATACTCTA AGATTGACAATTAATGCAGAATGTTATCTTCAGCTTCATAACTTTCCCATGGATGAACAT TCCTGTCCACTGGAATTTTCAAGCTATGGATACCCTAAAAATGAAATTGAGTATAAGTGG AAAAAGCCCTCCGTAGAAGTGGCTGATCCTAAATACTGGAGATTATATCAGTTTGCATTT GTAGGGTTACGGAACTCAACTGAAATCACTCACACGATCTCTGGGGATTATGTTATCATG ACAATTTTTTTTGACCTGAGCAGAAGAATGGGATATTTCACTATTCAGACCTACATTCCA TGCATTCTGACAGTTGTTCTTTCTTGGGTGTCTTTTTGGATCAATAAAGATGCAGTGCCT GCAAGAACATCGTTGGGTATCACTACAGTTCTGACTATGACAACCCTGAGTACAATTGCC AGGAAGTCTTTACCTAAGGTTTCTTATGTGACTGCGATGGATCTCTTTGTTTCTGTTTGT TTCATTTTTGTTTTTGCAGCCTTGATGGAATATGGAACCTTGCATTATTTTACCAGCAAC CAAAAAGGAAAGACTGCTACTAAAGACAGAAAGCTAAAAAATAAAGCCTCGATGACTCCT GGTCTCCATCCTGGATCCACTCTGATTCCAATGAATAATATTTCTGTGCCGCAAGAAGAT GATTATGGGTATCAGTGTTTGGAGGGCAAAGATTGTGCCAGCTTCTTCTGTTGCTTTGAA GACTGCAGAACAGGATCTTGGAGGGAAGGAAGGATACACATACGCATTGCCAAAATTGAC TCTTATTCTAGAATATTTTTCCCAACCGCTTTTGCCCTGTTCAACTTGGTTTATTGGGTT GGCTATCTTTACTTATAA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmission
name:Gamma-aminobutyric acid receptor subunit gamma-2
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
gene-name:GABRG2
locus:5q31.1-q33.1
cellular-location:Cell junction
transmembrane-regions:274-296 300-322 334-356 444-466
signal-regions:1-39
theoretical-pi:8.6
molecular-weight:54161.78
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4087GenBank Gene DatabaseX15376GenBank Protein Database31637UniProtKBP18507UniProt AccessionGBRG2_HUMAN
synonyms:GABA(A) receptor subunit gamma-2
amino-acid-sequence:>lcl|BSEQ0006917|Gamma-aminobutyric acid receptor subunit gamma-2 MSSPNIWSTGSSVYSTPVFSQKMTVWILLLLSLYPGFTSQKSDDDYEDYASNKTWVLTPK VPEGDVTVILNNLLEGYDNKLRPDIGVKPTLIHTDMYVNSIGPVNAINMEYTIDIFFAQT WYDRRLKFNSTIKVLRLNSNMVGKIWIPDTFFRNSKKADAHWITTPNRMLRIWNDGRVLY TLRLTIDAECQLQLHNFPMDEHSCPLEFSSYGYPREEIVYQWKRSSVEVGDTRSWRLYQF SFVGLRNTTEVVKTTSGDYVVMSVYFDLSRRMGYFTIQTYIPCTLIVVLSWVSFWINKDA VPARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCFIFVFSALVEYGTLHYFV SNRKPSKDKDKKKKNPAPTIDIRPRSATIQMNNATHLQERDEEYGYECLDGKDCASFFCC FEDCRTGAWRHGRIHIRIAKMDSYARIFFPTAFCLFNLVYWVSYLYL
gene-sequence:>lcl|BSEQ0019445|Gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2) ATGAGTTCGCCAAATATATGGAGCACAGGAAGCTCAGTCTACTCGACTCCTGTATTTTCA CAGAAAATGACGGTGTGGATTCTGCTCCTGCTGTCGCTCTACCCTGGCTTCACTAGCCAG AAATCTGATGATGACTATGAAGATTATGCTTCTAACAAAACATGGGTCTTGACTCCAAAA GTTCCTGAGGGTGATGTCACTGTCATCTTAAACAACCTGCTGGAAGGATATGACAATAAA CTTCGGCCTGATATAGGAGTGAAGCCAACGTTAATTCACACAGACATGTATGTGAATAGC ATTGGTCCAGTGAACGCTATCAATATGGAATACACTATTGATATATTTTTTGCGCAAACG TGGTATGACAGACGTTTGAAATTTAACAGCACCATTAAAGTCCTCCGATTGAACAGCAAC ATGGTGGGGAAAATCTGGATTCCAGACACTTTCTTCAGAAATTCCAAAAAAGCTGATGCA CACTGGATCACCACCCCCAACAGGATGCTGAGAATTTGGAATGATGGTCGAGTGCTCTAC ACCCTAAGGTTGACAATTGATGCTGAGTGCCAATTACAATTGCACAACTTTCCAATGGAT GAACACTCCTGCCCCTTGGAGTTCTCCAGTTATGGCTATCCACGTGAAGAAATTGTTTAT CAATGGAAGCGAAGTTCTGTTGAAGTGGGCGACACAAGATCCTGGAGGCTTTATCAATTC TCATTTGTTGGTCTAAGAAATACCACCGAAGTAGTGAAGACAACTTCCGGAGATTATGTG GTCATGTCTGTCTACTTTGATCTGAGCAGAAGAATGGGATACTTTACCATCCAGACCTAT ATCCCCTGCACACTCATTGTCGTCCTATCCTGGGTGTCTTTCTGGATCAATAAGGATGCT GTTCCAGCCAGAACATCTTTAGGTATCACCACTGTCCTGACAATGACCACCCTCAGCACC ATTGCCCGGAAATCGCTCCCCAAGGTCTCCTATGTCACAGCGATGGATCTCTTTGTATCT GTTTGTTTCATCTTTGTCTTCTCTGCTCTGGTGGAGTATGGCACCTTGCATTATTTTGTC AGCAACCGGAAACCAAGCAAGGACAAAGATAAAAAGAAGAAAAACCCTGCCCCTACCATT GATATCCGCCCAAGATCAGCAACCATTCAAATGAATAATGCTACACACCTTCAAGAGAGA GATGAAGAGTACGGCTATGAGTGTCTGGACGGCAAGGACTGTGCCAGTTTTTTCTGCTGT TTTGAAGATTGTCGAACAGGAGCTTGGAGACATGGGAGGATACATATCCGCATTGCCAAA ATGGACTCCTATGCTCGGATCTTCTTCCCCACTGCCTTCTGCCTGTTTAATCTGGTCTAT TGGGTCTCCTACCTCTACCTGTGA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentaxoncomponentcell junctioncomponentchloride channel complexcomponentdendrite membranecomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionbenzodiazepine receptor activityfunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocessadult behaviorprocesscellular response to histamineprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocesspost-embryonic developmentprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmissionprocesssynaptic transmission, GABAergicprocesstransmembrane transportprocesstransport
name:Gamma-aminobutyric acid receptor subunit gamma-3
general-function:Inhibitory extracellular ligand-gated ion channel activity
specific-function:GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
gene-name:GABRG3
locus:15q12
cellular-location:Cell junction
transmembrane-regions:255-277 281-303 315-337 444-467
signal-regions:1-17
theoretical-pi:7.58
molecular-weight:54288.16
chromosome-location:15
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4088GenBank Gene DatabaseS82769GenBank Protein Database1754749UniProtKBQ99928UniProt AccessionGBRG3_HUMAN
synonyms:GABA(A) receptor subunit gamma-3
amino-acid-sequence:>lcl|BSEQ0006921|Gamma-aminobutyric acid receptor subunit gamma-3 MAPKLLLLLCLFSGLHARSRKVEEDEYEDSSSNQKWVLAPKSQDTDVTLILNKLLREYDK KLRPDIGIKPTVIDVDIYVNSIGPVSSINMEYQIDIFFAQTWTDSRLRFNSTMKILTLNS NMVGLIWIPDTIFRNSKTAEAHWITTPNQLLRIWNDGKILYTLRLTINAECQLQLHNFPM DEHSCPLIFSSYGYPKEEMIYRWRKNSVEAADQKSWRLYQFDFMGLRNTTEIVTTSAGDY VVMTIYFELSRRMGYFTIQTYIPCILTVVLSWVSFWIKKDATPARTALGITTVLTMTTLS TIARKSLPRVSYVTAMDLFVTVCFLFVFAALMEYATLNYYSSCRKPTTTKKTTSLLHPDS SRWIPERISLQAPSNYSLLDMRPPPTAMITLNNSVYWQEFEDTCVYECLDGKDCQSFFCC YEECKSGSWRKGRIHIDILELDSYSRVFFPTSFLLFNLVYWVGYLYL
gene-sequence:>lcl|BSEQ0012498|Gamma-aminobutyric acid receptor subunit gamma-3 (GABRG3) ATGGCCCCGAAGCTGCTGCTCCTCCTCTGCCTGTTCTCGGGCTTGCACGCGCGGTCCAGA AAGGTGGAAGAGGATGAATATGAAGATTCATCATCAAACCAAAAGTGGGTCTTGGCTCCA AAATCCCAAGACACCGACGTGACTCTTATTCTCAACAAGTTGCTAAGAGAATATGATAAA AAGCTGAGGCCAGATATTGGAATAAAACCGACCGTAATTGACGTTGACATTTATGTTAAC AGCATTGGTCCTGTGTCATCAATAAACATGGAATACCAAATTGACATATTTTTTGCTCAG ACCTGGACAGATAGTCGCCTTCGATTCAACAGCACAATGAAAATTCTTACTCTGAACAGC AACATGGTGGGGTTAATCTGGATCCCAGACACCATCTTCCGCAATTCTAAAACCGCAGAG GCTCACTGGATCACCACACCCAATCAGCTCCTCCGGATTTGGAATGACGGGAAAATCCTT TACACTTTGAGGCTCACCATCAATGCTGAGTGCCAGCTGCAGCTGCACAACTTCCCCATG GACGAACACTCCTGCCCGCTGATTTTCTCCAGCTATGGCTATCCCAAAGAAGAAATGATT TATAGATGGAGAAAAAATTCAGTGGAGGCAGCTGACCAGAAATCATGGCGGCTTTATCAG TTTGACTTCATGGGCCTCAGAAACACCACAGAAATCGTGACAACGTCTGCAGGTAGGAAT TTACTGAAAGAGGCACAGCTCTCAAAAGCCAGAGAGGCCTAA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentcell junctioncomponentchloride channel complexcomponentGABA-A receptor complexcomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionchloride channel activityfunctionGABA-A receptor activityfunctioninhibitory extracellular ligand-gated ion channel activityprocesschloride transmembrane transportprocessgamma-aminobutyric acid signaling pathwayprocession transmembrane transportprocessneurological system processprocessregulation of membrane potentialprocessresponse to drugprocesssynaptic transmissionprocesstransmembrane transport
BE0004696UDP-glucuronosyltransferase 2B15HumanssubstrateA1802015961980Chung JY, Cho JY, Yu KS, Kim JR, Jung HR, Lim KS, Jang IJ, Shin SG: Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005 Jun;77(6):486-94.unknownUDP-glucuronosyltransferase 2B15Glucuronosyltransferase activityUDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme displays activity toward several classes of xenobiotic substrates, including simple phenolic compounds, 7-hydroxylated coumarins, flavonoids, anthraquinones, and certain drugs and their hydroxylated metabolites. It also catalyzes the glucuronidation of endogenous estrogens and androgens.UGT2B15Microsome membrane495-5151-2361035.8154HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:12546UniProtKBP54855UniProt AccessionUDB15_HUMAN2.4.1.17HLUG4UDP-glucuronosyltransferase 2B8UDPGT 2B15UDPGT 2B8UDPGTh-3UGT2B8>lcl|BSEQ0017513|UDP-glucuronosyltransferase 2B15 MSLKWTSVFLLIQLSCYFSSGSCGKVLVWPTEYSHWINMKTILEELVQRGHEVTVLTSSA STLVNASKSSAIKLEVYPTSLTKNYLEDSLLKILDRWIYGVSKNTFWSYFSQLQELCWEY YDYSNKLCKDAVLNKKLMMKLQESKFDVILADALNPCGELLAELFNIPFLYSLRFSVGYT FEKNGGGFLFPPSYVPVVMSELSDQMIFMERIKNMIHMLYFDFWFQIYDLKKWDQFYSEV LGRPTTLFETMGKAEMWLIRTYWDFEFPRPFLPNVDFVGGLHCKPAKPLPKEMEEFVQSS GENGIVVFSLGSMISNMSEESANMIASALAQIPQKVLWRFDGKKPNTLGSNTRLYKWLPQ NDLLGHPKTKAFITHGGTNGIYEAIYHGIPMVGIPLFADQHDNIAHMKAKGAALSVDIRT MSSRDLLNALKSVINDPVYKENVMKLSRIHHDQPMKPLDRAVFWIEFVMRHKGAKHLRVA AHNLTWIQYHSLDVIAFLLACVATVIFIITKFCLFCFRKLAKKGKKKKRD>lcl|BSEQ0017514|UDP-glucuronosyltransferase 2B15 (UGT2B15) ATGTCTCTGAAATGGACGTCAGTCTTTCTGCTGATACAGCTCAGTTGTTACTTTAGCTCT GGAAGCTGTGGAAAGGTGCTAGTGTGGCCCACAGAATACAGCCATTGGATAAATATGAAG ACAATCCTGGAAGAGCTTGTTCAGAGGGGTCATGAGGTGACTGTGTTGACATCTTCGGCT TCTACTCTTGTCAATGCCAGTAAATCATCTGCTATTAAATTAGAAGTTTATCCTACATCT TTAACTAAAAATTATTTGGAAGATTCTCTTCTGAAAATTCTCGATAGATGGATATATGGT GTTTCAAAAAATACATTTTGGTCATATTTTTCACAATTACAAGAATTGTGTTGGGAATAT TATGACTACAGTAACAAGCTCTGTAAAGATGCAGTTTTGAATAAGAAACTTATGATGAAA CTACAAGAGTCAAAGTTTGATGTCATTCTGGCAGATGCCCTTAATCCCTGTGGTGAGCTA CTGGCTGAACTATTTAACATACCCTTTCTGTACAGTCTTCGATTCTCTGTTGGCTACACA TTTGAGAAGAATGGTGGAGGATTTCTGTTCCCTCCTTCCTATGTACCTGTTGTTATGTCA GAATTAAGTGATCAAATGATTTTCATGGAGAGGATAAAAAATATGATACATATGCTTTAT TTTGACTTTTGGTTTCAAATTTATGATCTGAAGAAGTGGGACCAGTTTTATAGTGAAGTT CTAGGAAGACCCACTACATTATTTGAGACAATGGGGAAAGCTGAAATGTGGCTCATTCGA ACCTATTGGGATTTTGAATTTCCTCGCCCATTCTTACCAAATGTTGATTTTGTTGGAGGA CTTCACTGTAAACCAGCCAAACCCCTGCCTAAGGAAATGGAAGAGTTTGTGCAGAGCTCT GGAGAAAATGGTATTGTGGTGTTTTCTCTGGGGTCGATGATCAGTAACATGTCAGAAGAA AGTGCCAACATGATTGCATCAGCCCTTGCCCAGATCCCACAAAAGGTTCTATGGAGATTT GATGGCAAGAAGCCAAATACTTTAGGTTCCAATACTCGACTGTACAAGTGGTTACCCCAG AATGACCTTCTTGGTCATCCCAAAACCAAAGCTTTTATAACTCATGGTGGAACCAATGGC ATCTATGAGGCGATCTACCATGGGATCCCTATGGTGGGCATTCCCTTGTTTGCGGATCAA CATGATAACATTGCTCACATGAAAGCCAAGGGAGCAGCCCTCAGTGTGGACATCAGGACC ATGTCAAGTAGAGATTTGCTCAATGCATTGAAGTCAGTCATTAATGACCCTGTCTATAAA GAGAATGTCATGAAATTATCAAGAATTCATCATGACCAACCAATGAAGCCCCTGGATCGA GCAGTCTTCTGGATTGAGTTTGTCATGCGCCACAAAGGAGCCAAGCACCTTCGAGTCGCA GCTCACAACCTCACCTGGATCCAGTACCACTCTTTGGATGTGATAGCATTCCTGCTGGCC TGCGTGGCAACTGTGATATTTATCATCACAAAATTTTGCCTGTTTTGTTTCCGAAAGCTT GCCAAAAAAGGAAAGAAGAAGAAAAGAGATTAGPF00201UDPGTcomponentendoplasmic reticulum membranecomponentintegral component of membranecomponentintracellular membrane-bounded organellefunctionglucuronosyltransferase activityprocesscellular glucuronidationprocesscellular response to hormone stimulusprocessflavonoid biosynthetic processprocessflavonoid glucuronidationprocesssteroid metabolic processprocessxenobiotic metabolic processBE0002638Cytochrome P450 3A4HumanssubstrateA399049387087Gregor KJ, Way K, Young CH, James SP: Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does it really happen? J Affect Disord. 1997 Oct;46(1):59-67.A209918175099Olkkola KT, Ahonen J: Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;(182):335-60. doi: 10.1007/978-3-540-74806-9_16.L4784Benzodiazepine metabolism and pharmacokinetichttp://paindr.com/wp-content/uploads/2015/10/Revised-BZD_-9-30.pdfnoCytochrome P450 3A4Vitamin d3 25-hydroxylase activityCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).CYP3A47q21.1Endoplasmic reticulum membrane2-228.2557342.677HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2637GenAtlasCYP3A4GenBank Gene DatabaseM18907Guide to Pharmacology1337UniProtKBP08684UniProt AccessionCP3A4_HUMAN1,8-cineole 2-exo-monooxygenase1.14.13.-Albendazole monooxygenaseAlbendazole sulfoxidaseCholesterol 25-hydroxylaseCYP3A3CYPIIIA3CYPIIIA4Cytochrome P450 3A3Cytochrome P450 HLpCytochrome P450 NF-25Cytochrome P450-PCN1Nifedipine oxidaseQuinine 3-monooxygenaseTaurochenodeoxycholate 6-alpha-hydroxylase>lcl|BSEQ0021936|Cytochrome P450 3A4 MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG GLLQPEKPVVLKVESRDGTVSGA>lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4) ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT GGAGCCTGAPF00067p450componentcytoplasmcomponentendoplasmic reticulum membranecomponentintegral component of membranecomponentintracellular membrane-bounded organellefunctionalbendazole monooxygenase activityfunctionaromatase activityfunctioncaffeine oxidase activityfunctionenzyme bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxygen bindingfunctionquinine 3-monooxygenase activityfunctionsteroid bindingfunctionsteroid hydroxylase activityfunctiontaurochenodeoxycholate 6alpha-hydroxylase activityfunctiontestosterone 6-beta-hydroxylase activityfunctionvitamin D 24-hydroxylase activityfunctionvitamin D3 25-hydroxylase activityprocessalkaloid catabolic processprocessandrogen metabolic processprocesscalcitriol biosynthetic process from calciolprocessdrug catabolic processprocessdrug metabolic processprocessexogenous drug catabolic processprocessheterocycle metabolic processprocesslipid metabolic processprocessmonoterpenoid metabolic processprocessoxidation-reduction processprocessoxidative demethylationprocesssmall molecule metabolic processprocesssteroid catabolic processprocesssteroid metabolic processprocessvitamin D metabolic processprocessxenobiotic metabolic process
载体
运输工具
药物反应
reactions:1
left-element--drugbank-id:DB00186
left-element--name:Lorazepam
right-element--drugbank-id:DBMET00648
right-element--name:Lorazepam glucuronide
效应
不良反应